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The Adaptor Protein 1 Complex (AP-1) at the Heart of
Post-Golgi Trafficking in a Corticotrope Tumor Cell Line
Mathilde L. Bonnemaison, PhD
University of Connecticut, 2014
Peptides act as chemical messengers to regulate physiological functions. First synthesized
as inactive precursors, peptides undergo a set of post-translational modifications to gain
bioactivity en route through the secretory pathway. Peptides exit the Golgi apparatus in
secretory granules (SGs) that are stored until a stimulus triggers their exocytosis. The
adaptor protein 1A (AP-1A) is required for SG maturation in neuroendocrine cells and for the
formation of specialized SGs such as the glue granules in Drosophila, Weibel-Palade bodies
in endothelial cells and rhoptries in Toxoplasma gondii. AP-1A is a heterotetrameric complex
(γ/β1/µ1A/σ1) that interacts with cargo proteins and clathrin to transport proteins between
the trans-Golgi network (TGN) and endosomes. Lack of any AP-1A subunit is sufficient to
impair AP-1A function.
A decrease in expression of the µ1A subunit in AtT-20 cells, a corticotrope tumor cell
line (sh-µ1A), resulted in vacuolization of the TGN, formation of non-condensing SGs and
impaired responsiveness to secretagogue. Impaired AP-1A function in AtT-20 cells also
dramatically altered the endocytic pathway. Early and recycling endosomes accumulated
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above the Golgi complex instead of peripherally and endosome maturation was altered in
sh-µ1A cells.
Clinically, patients with MEDNIK syndrome, a rare genetic disorder caused by lack of
expression of σ1A, exhibit clinical and biochemical signs of impaired copper homeostasis.
Peptidylglycine α-amidating monooxygenase 1 (PAM-1), a SG membrane protein that cat-
alyzes peptide amidation, requires copper for activity. Atp7a brings copper from the cytosol to
the lumen of the secretory pathway for delivery to cuproproteins such as PAM. The endosomal
trafficking of both Atp7a and PAM was altered when AP-1 function was diminished, resulting
in increased sensitivity of peptide amidation to copper chelation. Although ATP7A moves
from the Golgi to the cell periphery under high copper conditions in HeLa cells, treatment of
mouse neuroendocrine cells with high copper levels increased Atp7a protein level.
PAM expression profile in the developing cortex and hippocampus indicated that PAM-1,
the major isoform, was distributed in perikaryon, dendrites and axons in cultured hippocampal
neurons. Future directions to investigate AP-1 and PAM-1 trafficking in hippocampal neurons
and neuroendocrine cells are discussed last.
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That is why scientists persist in their investigations, why we struggle so desperately for every
bit of knowledge, stay up nights seeking the answer to a problem, climb steepest obstacles to
the next fragment of understanding, to finally reach that joyous moment of the kick in the
discovery, which is part of the pleasure of finding things out.
- Richard Feynman
Go to school and learn as much as you can because what you’ve learned is the last thing
people can take from you.
- My grandmother, Marie Marcelle Bonnemaison
It all started in 1976
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Sara Frey, an American citizen from West Harftord, Connecticut. Sara went to France to learn
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Sara’s sister, Amy Frey, to help me find an internship or job in the US. Thanks to her, I was
able to spend a summer under the supervision of Dr. George Kuchel, Dr. Carol Pilbeam, Dr.
Lawrence G. Raisz, Olga Voznesensky and Dr. John Taylor at the University of Connecticut
Health Center. These people formed a fantastic scientific group and made me fall in love with
research. I applied for the PhD program thanks to them.
The door
My mentor, Dr. Betty A. Eipper and my co-mentor, Dr. Richard E. Mains put education
as one of their priorities. I have grown and learned so much in their presence and I hope
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this thesis reflects well the knowledge and methodology I have acquired in their laboratory.
Most of what I know today has a lot to do with their office door. Their door was kept open
which meant that they were available to answer questions, to teach new aspects of science, to
help in preparing and designing experiments, to help in writing papers and preparing for oral
presentations. I would like to thank Dr. Eipper and Dr. Mains for leaving their door open and
giving me the tools for a successful career.
I would like to thank the other members of my thesis committee, Dr. Ann Cowan and Dr.
Stephen King. These Professors never lost an opportunity to make me think and look at my
work differently, to help me improve my oral skills and grow as a scientist.
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The work presented in this thesis would not have been possible without the constant support
and constructive criticism of the rest of the laboratory. Most of it happened during our weekly
lab meeting during which Dr. Eipper and Dr. Mains kindly provided bagels for all the
members of the laboratory. After intensive calculations, I had about 145 delicious bagels +/-
3 bagels over the past five years. I again would like to thank Dr. Eipper and Dr. Mains, not
only for the bagels, but for making those meetings in a way that helped everyone in the room
become a better scientist and a better person.
Every lab has a Mother who makes sure everything runs properly. Ours is Darlene
D’Amato. Observing how she works and behaves in a lab was an excellent example of
professionalism and common sense. The meticulousness of Yanping Wang was also a good
source of learning. Molecular biology has no secret to Yanping Wang and working with her
was always a success. Thanks to Darlene and Ping for showing and teaching me your work.
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I would like to thank my colleague and friend, Dr. Vishwanatha Kurutihalli who was
always open to scientific discussions or family stories. I was lucky to have Vishwa as an
office neighbor. His presence made my passage here, at the University of Connecticut Health
Center, much more enjoyable.
I met Taylor LaRese soon after I joined the lab. I would like to thank her for being a good
friend and an excellent co-worker with great optimism. It was always refreshing to talk to
her and I am really grateful to have met this wonderful woman during my graduate studies. I
wish her good luck in her professional career.
I would like to thank Dr. Yan Yan, Jennifer Kirkland and Kristina Carlson, for the lunches
spent together and our friendship. Our conversations helped me think about the job market,
scientific problems and the world in general.
Megan Miller and Dhivya Kumar, the two current graduate students in the lab, are
dedicated and hard-working women. It was reassuring to have them around because we
understood each other when we had to study for Journal Club, Work In Progress, General
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have to thank Dr. Christopher Heinen and my thesis committee for providing feedback after
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1.1 Abstract
In the regulated secretory pathway, secretory granules (SGs) store peptide hormones that are
released on demand. SGs are formed at the trans-Golgi network (TGN) and must undergo
a maturation process to become responsive to secretagogues. The production of mature
SGs requires concentrating newly synthesized soluble content proteins in granules whose
membranes contain the appropriate integral membrane proteins. The mechanisms underlying
the sorting of soluble and integral membrane proteins destined for SGs from other proteins
are not yet well understood. For soluble proteins, luminal pH and divalent metals can
affect aggregation and interaction with surrounding membranes. The trafficking of granule
membrane proteins can be controlled by both luminal and cytosolic factors. Cytosolic adaptor
proteins, which recognize the cytosolic domains of proteins that span the SG membrane,
have been shown to play essential roles in the assembly of functional SGs. Adaptor protein
1A (AP-1A) is known to interact with specific motifs in its cargo proteins and with the
clathrin heavy chain, contributing to the formation of a clathrin coat. AP-1A is present in
patches on immature SG membranes, where it removes cargo and facilitates SG maturation.
AP-1A recruitment to membranes can be modulated by PACS-1 (Phosphofurin Acidic Cluster
Sorting protein 1), a cytosolic protein which interacts with both AP-1A and cargo that has
been phosphorylated by casein kinase II. A cargo/PACS-1/AP-1A complex is necessary
to drive the appropriate transport of several cargo proteins within the regulated secretory
pathway. The GGA (Golgi-localized, γ-ear containing, ADP-ribosylation factor binding)
family of adaptor proteins serve a similar role. We review the functions of AP-1A, PACS-1
and GGAs in facilitating the retrieval of proteins from immature SGs and review examples
of cargo proteins whose trafficking within the regulated secretory pathway is governed by
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adaptor proteins.
1.2 The regulated secretory pathway
Neuroendocrine cells synthesize, process and store peptide hormones so that they are available
for secretion upon demand [1]. These professional secretory cells devote as much as half
of their total protein synthesis to the production of a single hormone [2]. The regulated
secretory pathway allows intracellular storage of peptide hormones until an external stimulus
triggers exocytosis of the secretory granules that contain the peptides. Neuroendocrine tumors
and metabolic disease are linked to defects in hormone secretion, observed via an increase
in circulating hormone levels due to impaired intracellular storage or cellular response.
The alterations which result in loss of storage and secretagogue responsiveness are poorly
understood.
Peptide hormones are first synthesized as inactive precursors. The signal peptide found at
the N-terminus of the preprohormone is recognized by signal recognition particle, which stops
translation and directs entry of the nascent preprohormone into the lumen of the endoplasmic
reticulum [3]; removal of the signal peptide by signal peptidase yields the prohormone. Most
proteins which are going to be secreted undergo this step. The endoplasmic reticulum is
also the site at which disulfide-bond formation and N-linked glycosylation occur (Figure
1.1) [3, 4, 5]. Professional secretory cells have developed specialized sensing mechanisms
to avoid triggering the endoplasmic reticulum stress pathway, which can lead to cell death;
for example, increased expression of SERP1 (Stress-associated Endoplasmic Reticulum
Protein 1) prevents endoplasmic reticulum stress in the anterior pituitary and pancreas [6].
After exiting the endoplasmic reticulum, prohormones are transported to the Golgi apparatus,
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where additional post-translational modifications such as oligosaccharide maturation and
phosphorylation can occur (Figure 1.1) [7, 5]. When they reach the trans-Golgi network
(TGN), prohormones and their processing enzymes are concentrated into granules budding
from the TGN; these structures presumably represent newly forming secretory granules (SGs)
[1]. These new SGs are immature and must undergo a maturation process before they are
capable of secreting peptide hormone in response to secretagogue. Maturation involves
remodeling of the immature SG membrane by removal of non-regulated secretory proteins
and excess membrane; this process involves clathrin-coated vesicles mediated by adaptor
proteins (Figure 1.1) [8, 9], acidification of the lumen, aggregation of content proteins and,
at least in some cell systems, fusion of immature SGs [10, 11]. The final post-translational
modifications needed to generate bioactive peptide hormones occur in immature and mature
SGs [12, 13]. Mature SGs, which appear dense in the electron microscope and during
sucrose density gradient centrifugation, can contain more than 300 mg/ml protein, largely
peptide hormones [14]. Unlike constitutively secreted proteins, which are found in the
extracellular compartment within minutes after exit from the TGN, it takes about 90 minutes
for peptide hormones to go from the TGN to mature SGs (Figure 1.1) [15, 16]. In addition,
mature SG content can be stored for many days before being secreted into the extracellular
compartment in response to a stimulus (Figure 1.1) [17, 18]; proteins and peptides stored
in the regulated secretory pathway are released at a low rate (basal secretion) even in the
absence of secretagogue [19, 20]. The study of immature SGs remains a challenge due
to their transient role as intermediates between the TGN and mature SGs. Morphologists
describe immature SGs as vacuoles found in close proximity to the TGN which contain dense
material surrounded by a loose membrane with a partial clathrin coat, while biochemists
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distinguish immature SGs from mature SGs by their inability to respond to secretagogue or
by their release of incompletely processed newly synthesized products [14, 1]. Early studies
using 35SO4 to label sugars and Tyr residues demonstrated high K+/Ca2+-stimulated release
of 35SO4-labeled SG components as soon as 15 min after synthesis [16]; it is not clear how
to relate 35SO4 labeling to biosynthetic or endocytic trafficking . In the end, what controls
and triggers the formation and maturation of immature SGs remains unclear. Both soluble
and membrane proteins destined for the regulated secretory pathway must enter immature
SGs when they exit the TGN, but how the trafficking of soluble and membrane proteins is
coordinated is still under debate.
1.3 Formation of immature SGs
Proteins destined for the regulated secretory pathway are sorted in the TGN and in imma-
ture SGs. Although the sorting mechanisms are not completely understood, the diverse
biophysical and biochemical properties of soluble and membrane proteins suggest that they
are targeted to the regulated secretory pathway through different mechanisms. The TGN is a
cellular crossroad; departing proteins can enter vesicles targeted to endosomes, lysosomes,
endoplasmic reticulum or the plasma membrane [21, 1]. One of the first studies demonstrating
sorting of regulated secretory proteins at the TGN was performed using a cell free system
from PC12 cells, a neuroendocrine tumor cell line: vesicles budding from the TGN contained
either heparin sulfate proteoglycan, a soluble protein of the constitutive secretory pathway, or
secretogranin II, a soluble protein of the regulated secretory pathway [22].
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1.3.1 View from the luminal side
The mildly acidic pH (pH 6.4) and high calcium (1-10 mM) environment of the TGN
can induce aggregation of selected proteins (e.g., secretogranin II, chromogranin B and
prolactin) destined for the regulated secretory pathway, resulting in their segregation from the
constitutive secretory pathway (Figure 1.2A) [23, 24, 25]. Other regulated secretory granule
proteins bind specific lipids in the TGN, resulting in their sorting and entry into immature
SGs; prohormone convertase 1/3 and prohormone convertase 2 interact with lipid rafts and
secretogranin III binds to cholesterol (Figure 1.2A) [26, 27, 28]. Indeed, chromogranin A,
which enhances prohormone aggregation, interacts at the TGN with secretogranin III and thus
with cholesterol-rich membranes (Figure 1.2A) [28, 29]. If the interaction of chromogranin
A with secretogranin III is blocked, chromogranin A is not sorted correctly [30]. Finally, a
role for receptor-mediated sorting of regulated secretory proteins exiting the TGN has been
considered. Carboxypeptidase E was proposed as a prohormone sorting receptor because it
interacts with the N-terminal region of proopiomelanocortin (POMC), which was previously
reported to serve as a sorting domain [15, 31]. This conclusion is controversial because
the sorting of proinsulin, luteinizing hormone and follicle stimulating hormone does not
depend on carboxypeptidase E [32, 33]. Although the sorting of cargo upon binding to a
receptor is an attractive concept, SG protein sorting appears to involve multiple processes.
Carboxypeptidase E was recently shown to interact with phogrin, a SG membrane protein of
the IA-2 (Insulinoma Associated protein 2) family; this interaction involves the pro-region
of the luminal domain of phogrin and mature carboxypeptidase E (Figure 1.2B). When
one binding partner is missing, the other does not accumulate in SGs, instead localizes
to the perinuclear region; the sorting of carboxypeptidase E and phogrin at the TGN is
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inter-dependent [34].
1.3.2 View from the cytosolic side
Sorting signals contributed by SG membrane protein trafficking.
Membrane proteins cannot aggregate as extensively as soluble proteins. The identification
of trafficking signals in the cytosolic domains of endocytic cargo led to the postulate that
the cytosolic domains of SG membrane proteins would carry signals to ensure their entry
into immature SGs (Figure 1.2B). Indeed, deletion or mutation of the cytosolic domain
of phogrin results in a decrease in its entry into SGs [35, 36]. Similar observations were
made for peptidylglycine α-amidating monooxygenase 1 (PAM-1) (Figure 1.2B). PAM-1
is a bifunctional enzyme catalyzing the amidation of glycine-extended peptides, rendering
them bioactive. Exogenous expression of a truncated PAM-1 protein lacking its cytosolic
domain resulted in its inefficient storage in SGs. Metabolic labeling revealed that 20 to 40%
of the newly synthesized truncated PAM protein entered the regulated secretory pathway,
but endocytic trafficking and SG re-entry of the truncated PAM-1 protein were eliminated
[37]. The cytosolic domain of PAM-1, which is highly phosphorylated, interacts with several
cytosolic proteins [38]. Two sites in the cytosolic domain of PAM-1 are phosphorylated
by casein kinase II (CKII) (Table 1.1); both sites were mutated to Asp (PAM-1/TS/DD) to
try to mimic phosphorylation or to Ala (PAM-1/TS/AA) to prevent phosphorylation. When
expressed in AtT-20 corticotrope tumor cells, exogenous PAM-1/TS/DD entered immature
SGs more efficiently than PAM-1, while PAM-1/TS/AA did not enter immature SGs efficiently
and was degraded [39]. This study suggests that phosphorylation of the cytosolic tail of
PAM-1 enhances its entry into immature SGs.
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Similar conclusions were reached in studies of two different neurotransmitter transporters,
VMAT2 (Vesicular Monoamine Transporter 2) and VAChT (Vesicular Acetylcholine Trans-
porter). Using the pH gradient established by the vacuolar proton pump, VMAT2 and VAChT
translocate monoamines and acetylcholine, respectively, from the cytosol into the lumen.
VMAT2 and VAChT enter two different types of vesicles in PC12 cells: VMAT2 is preferen-
tially targeted to SGs while VAChT is found in synaptic-like microvesicles (Figure 1.2B) [40].
The cytoplasmic domain of the VAChT contains a dileucine motif with adjacent conserved
Glu and Ser residues. Phosphorylation of this Ser by protein kinase C or mutation to a
phosphomimetic residue results in a preference for VAChT entry into SGs, rather than into
synaptic-like microvesicles [40]. Additionally, VMAT2 contains two conserved Glu residues
upstream of its dileucine-like motif (Table 1.1, in blue); mutation of these Glu residues into
Ala results in accumulation of VMAT2 in synaptic-like microvesicles [40].
These studies suggest that the sorting of membrane proteins into the regulated secretory
pathway requires cytosolic signals and/or luminal/transmembrane signals. The negatively
charged region within the cytosolic domain of membrane proteins is probably required for
efficient sorting and entry into SGs. Since the cytosolic domain is involved in their sorting,
cytosolic proteins must come into play in the formation of immature SGs and protein sorting
in the regulated secretory pathway.
ADP ribosylation factor 1 (Arf1) is required for SG biogenesis.
In the 1990’s, the cytosolic protein Arf1, a member of the ADP ribosylation family (Arf),
was shown to promote the formation of immature SGs using cell-free systems from PC12
and GH3 cells, two neuroendocrine cell lines [41, 42]. Arf proteins, which belong to the
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Ras superfamily of small GTPases, were originally identified as necessary for the ADP
ribosylation reaction catalyzed by cholera toxin [43]. Despite their names, the cellular
function of Arfs does not involve ADP ribosylation, but rather membrane trafficking [44].
Arf proteins are divided into three classes: class I (Arf1, Arf2 and Arf3), class II (Arf4 and
Arf5) and class III (Arf6). Class I and class II Arfs are present at the Golgi and their main
function is to regulate Golgi trafficking, while Arf6 functions at the plasma membrane and
in the endocytic pathway. Arfs exist in two states: GDP-bound Arf is cytosolic and inactive
while GTP-bound Arf is membrane-associated and active (Figure 1.3) [44, 45]. All Arfs
contain an N-terminal myristoylated amphipathic helix, which allows their association with
membranes. This region is buried in a hydrophobic pocket when GDP is bound, but becomes
accessible to membranes when GTP replaces GDP, triggering conformational changes in the
switch 1 and switch 2 regions which surround the nucleotide binding site [44, 46, 45]. A
resident TGN protein, cargo or lipid may interact with GDP-bound Arf1, bringing it near the
TGN (Figure 1.3). In the context of COPI vesicles, which are involved in retrograde transport
from the Golgi to the endoplasmic reticulum, p23, a transmembrane resident Golgi protein, is
thought to recruit GDP-bound Arf [47].
The removal of GDP and binding of GTP is catalyzed by a guanine nucleotide exchange
factor (GEF) (Figure 1.3) [44, 45]. The two Arf GEFs identified at the TGN are BIG1 and
BIG2 (brefeldin A inhibited GEFs). Interestingly, GBF1, a GEF known to be involved in
the GDP/GTP exchange of Arf4 and Arf5 in the cis-Golgi compartment, has recently been
identified on the TGN membrane [48]. BIG1 and BIG2 are recruited to the TGN membrane
upon binding to GTP-bound Arf4 and Arf5, whose nucleotide exchange was mediated by
GBF1 [48]. Both BIGs contain a Sec7 domain, which is the active site for the nucleotide
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switch and the target of brefeldin A, a fungal product. Treatment of neuroendocrine and
exocrine cells with brefeldin A blocks the formation and maturation of immature SGs but
does not alter mature SG exocytosis [49, 50].
Once nucleotide exchange has occurred, GTP-bound Arf recruits adaptor proteins, enzyme
modifying lipids and effectors to the membrane before reacting with a GTPase activating
protein (GAP) that promotes hydrolysis of GTP to GDP and release of Arf from the membrane
(Figure 1.3). The Arf-GAP family is composed of 24 members, each with a GAP domain
essential for its activity on Arf [44]. GAP activity is modulated by the presence of coat
proteins previously recruited by the GTP-bound Arf. When COPI is bound to Arf1, GAP
activity is increased [46]. GGA3 (Golgi-localized, γ-adaptin ear-containing, Arf-binding 3)
is a coat protein involved in TGN-to-endosome transport. In contrast, when Arf1 recruits
GGA3, it blocks the hydrolysis of GTP-bound to Arf1 [51].
Using the cell free PC12 system, Arf1 was shown to enhance the formation of SGs
and constitutive vesicles [41]. Moreover, when Arf1 is bound to membranes isolated from
PC12 cells, it recruits a set of different proteins, including the adaptor protein 1A (AP-1A)
[52, 53, 54]. In non-endocrine secretory systems, such as rhoptries in Toxoplasma gondii
[55], glue granules in Drosophila [56] and Weibel-Palade bodies in endothelial cells [57],
AP-1A is required for the formation of SGs. Although it is not clear if AP-1A is required
for SG formation in neuroendocrine cells, there is evidence that AP-1A is required for SG
maturation (Figure 1.4A).
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Membranes and SG formation: phosphatidylinositol-4-phosphate (PI4P) and choles-
terol.
The appropriate lipid composition is essential for normal TGN function and SG biogenesis.
The TGN membrane is enriched in PI4P. In mammalian cells, three enzymes that synthesize
PI4P from phosphatidylinositol (PI) have been found at the Golgi, PI4KIIα, PI4KIIIα and
PI4KIIIβ; PI4KIIα [58] and PI4KIIIβ [59] have been implicated in export of material from
the Golgi to the plasma membrane. PI4KIIα resides primarily in the TGN, endosomes and
SGs [60, 61, 62, 63]. Indeed, PI4KIIα was found on adrenal chromaffin granule membranes
[64, 65, 66], cellugyrin-positive Glucose Transporter 4 vesicles [67], Drosophila salivary
gland glue granules [68], synaptic vesicles [69] and immature SG membranes from PC12
cells [70]. PI4KIIα is recruited to membranes upon palmitoylation of a central CCPCC motif
[61]. Deletion of the CCPCC motif or prevention of its palmitoylation resulted in loss of
PI4KIIα perinuclear localization and loss of PI4KIIα activity [61]. PI4KIIα palmitoylation
is required for kinase activity and for localization to lipid rafts at the TGN but its targeting
motif to Golgi membranes remains to be determined [71, 62]. Lipid rafts are enriched in
cholesterol and reduction of endogenous cholesterol levels resulted in loss of PI4P synthesis by
PI4KIIα [62, 72]. The membranes of neuroendocrine SGs contain high levels of cholesterol
[73, 74]. A decrease in the cholesterol level in AtT-20 cells inhibited the formation of
constitutive secretory vesicles and SGs [75]. Since PI4KIIα requires cholesterol for activity
and membrane localization [62] and cholesterol is required for SG formation, this suggests
that PI4KIIα is required for SG biogenesis.
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1.3.3 Maturation of SGs
Once immature SGs are formed, they are not responsive to secretagogues and must undergo a
maturation process to gain this ability. SG maturation involves a decrease in lumenal pH, SG
fusion and membrane remodeling.
pH decrease
The lumen of the TGN and the lumen of immature SGs are comparable in pH (pH 6.3), while
mature SGs are more acidic (luminal pH 5.5). Secretogranin II processing in PC12 cells
exogenously expressing prohormone convertase 2 occurs in immature SGs but not in the
TGN [76]. Although similar in lumenal pH, the TGN and immature SGs are two distinctly
different compartments; the proteolytic processing of some prohormones and granins starts
in immature SGs, not in the TGN. The decrease in pH during SG maturation is necessary
for full processing of prohormones and granins because some hormone processing enzymes,
such as PAM-1, exhibit maximal catalytic activity at pH 4.5-5 [77].
SG fusions
Maturation of SGs can be characterized by a decrease or an increase in size. Analysis of
immature and mature SGs in PC12 cells and mammotrophs revealed an increase in SG
size during maturation [78, 16]. An elegant biochemical assay revealed that the increase
of SG size in PC12 cells was due to homotypic fusion of immature SGs [11]. SG fusion
involves syntaxin 6, a target (t)-SNARE (SNAP [Soluble NSF (N-ethylmaleimide-Sensitive
Factor) Associated Protein] Receptor) protein and synaptotagmin IV [79, 80]. The SNARE
complex is involved in membrane fusion and is composed of two t-SNAREs, located on the
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target membrane, and one vesicle (v)-SNARE on the vesicle membrane. Members of the
synaptotagmin family are associated with the vesicular membrane and regulate membrane
fusion with the SNARE complex. Syntaxin 6 localizes to the TGN, endosomes and immature
SGs [81, 82], while synaptotagmin IV is largely present at the Golgi and in immature SGs
[83, 84]. Blocking the fusion event decreases prohormone convertase 2 processing and
activity, resulting in impaired SG maturation [79]. Although this concept is attractive, there
is no evidence of SG fusion in other types of neuroendocrine cells. SG fusion of a different
type is clearly observed during compound exocytosis; mature SGs fuse together to promote
rapid release of SG content [85].
Membrane remodeling
The reduction of SG size during maturation may be explained by membrane remodeling.
The presence of a clathrin coat on patches of immature SG membrane revealed egress of
material in clathrin-coated vesicles, mediated by the adaptor protein, AP-1A [53, 8, 9]. As
a result, proteins like VAMP4 [86, 87], furin [88] and both mannose 6-phosphate receptors
[89, 82, 90, 91], each of which is known to have a canonical AP-1A binding site in its
cytosolic domain, are found in immature SGs but not in mature SGs. Although the fate of
the material retrieved from immature SGs is not entirely clear, there are lines of evidence
suggesting that it can be recycled to the TGN or secreted in a process called constitutive-like
secretion (Figure 1.1). The study of constitutive-like secretion is difficult to monitor since it
refers only to the non-stimulated secretion of regulated SG proteins as they traverse immature
SGs; without a means of assessing the time since synthesis, it is impossible to distinguish
basal from constitutive-like secretion. Nevertheless, constitutive-like secretion has held
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many scientists’ attention due to its potential link to cancer and metabolic disease. Much
of our knowledge of constitutive-like secretion comes from studying retrieval of material
from immature SGs. The cytosolic machinery involved in this process contains the adaptor
proteins, AP-1A and GGAs, and their partner PACS-1. The discovery of an interaction
between the cytosolic tail of membrane SG proteins retrieved during SG maturation with
these cytosolic proteins has expanded our understanding of membrane remodeling during SG
maturation. Each cytosolic component essential for maturation is presented below, followed
by the description of SG membrane proteins trafficking involving AP-1A, GGAs or PACS-1.
1.4 Cytosolic Machinery
1.4.1 Adaptor protein 1A (AP-1A)
The adaptor protein (AP) family.
The AP family includes five cytosolic heterotetrameric complexes: AP-1 (γ/β1/µ1/σ1), AP-2
(α/β2/µ2/σ2), AP-3 (δ/β3/µ3/σ3), AP-4 (/β4/µ4/σ4) and AP-5 (ζ/β5/µ5/σ5) [92, 93, 94,
95]. In mammals, several isoforms have been reported for subunits of AP-1, AP-2 and
AP-3: AP-1 has two γ subunits (γ1 and γ2), two µ subunits (µ1A and µ1B) and three σ
subunits (σ1A, σ1B and σ1C); AP-2 has two α subunits (α1 and α2); AP-3 has two β
subunits (β3A and β3B), two µ subunits (µ3A and µ3B) and two σ subunits (σ3A and σ3B)
[92, 96, 97, 98, 99, 100]. Every subunit is ubiquitously expressed except for µ1B, which is
found exclusively in polarized epithelial cells, and β3B and µ3B, which are only found in
neurons and neuroendocrine cells [97, 101, 99]. Each AP carries transmembrane proteins on a
defined intracellular route: AP-1 brings cargo between the TGN and endosomes and removes
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material from immature SGs; AP-2 is an important player in clathrin-mediated endocytosis;
AP-3 carries cargo to lysosomes and lysosome-related organelles; AP-4 transports cargo
from the TGN to the plasma membrane or endosomes; AP-5 is found on late endosomal
membranes.
The cytosolic domains of cargo proteins present motifs which are recognized by AP
complexes. For example, the Tyr sorting motif (YXXφ, where X is any residue and φ is a
hydrophobic residue) is recognized by the µ subunit of all AP complexes, with the possible
exception of AP-5, which has not yet been studied (Figure 1.4A) [102, 103, 104, 98]. The
dileucine sorting motif [(D/E)XXXL(L/I)] interacts at the interface of two subunits: γ/σ1 in
AP-1, α/σ2 in AP-2 and /σ3 in AP-3 (Figure 1.4A) [105, 106]; AP-4 and AP-5 have not
been shown to interact with the dileucine motif. The γ/α/δ//ζ and β1-5 subunits contain a
large N-terminal trunk domain that associates with the other three subunits of the complex,
followed by a hinge region and a C-terminal ear domain, which can interact with cytosolic
proteins (Figure 1.4A) [107, 108, 109, 110]. The hinge region of the β subunits of AP-1,
AP-2 and AP-3 is capable of binding the terminal domain of the clathrin heavy chain in
vitro, while the β subunits of AP-4 and AP-5 lack such a motif (Figure 1.4A) [111, 112, 113].
Although the β3 subunit of AP-3 can bind clathrin, purified clathrin-coated vesicles lack
AP-3, suggesting that AP-3 works independently of clathrin [114]. In addition, there is also
evidence that the γ and α hinge domains of AP-1 and AP-2 interact with clathrin (Figure
1.4A) [115, 116].
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AP-1A recruitment to membranes depends on Arf1 and PI4P.
AP-1A (γ/β1/µ1A/σ1) accumulates at the TGN, which is enriched in PI4P. In vitro binding
assays revealed that purified AP-1A interacts preferentially with PI4P (Figure 1.4A) [58].
Indeed, structural studies on the AP-1A core confirmed the presence of a PI4P binding
site within the γ subunit [117]. Reduction of PI4KIIα levels in a monkey kidney cell line
decreased the TGN content of PI4P and disrupted the TGN localization of AP-1A [58].
However, a recent study on development of the Drosophila salivary gland revealed no change
in the localization of AP-1 in PI4KIIα null flies, suggesting that PI4P synthesis in flies can
be carried out by another PI4K [68]. Although the presence of PI4KIIα on the membranes
of immature SGs suggests that PI4P can be formed there, there is no evidence that AP-1A
recruitment to immature SGs requires PI4P in neuroendocrine cells.
Brefeldin A treatment of intact cells produces a diffuse cytoplasmic localization of AP-1A
instead of the normal perinuclear, membrane-associated localization. However, pretreatment
with GTPγS, a non-hydrolyzable analog of GTP, prevented the membrane dissociation of
AP-1A upon addition of brefeldin A in permeabilized normal rat kidney cells [118]. Indeed,
AP-1A is recruited to membranes upon the binding of GTP-bound Arf1 to the trunk region of
its β1 and γ subunits (Figure 1.4A) [52, 119, 120, 121]. Studies on PC12 cells also show that
AP-1A recruitment to immature SG membranes requires Arf1 [52, 53]. Interestingly, AP-1A
cannot be recruited to mature SG membranes in PC12 cells, in agreement with morphological
studies indicating that AP-1A/clathrin coats are not found on mature SGs [52]. A recent
structural study of AP-1A in complex with GTP-bound Arf1 revealed that Arf1 can change the
conformation of µ1A without the presence of PI4P or cargo; the addition of cargo promotes
this conformational change [119]. This shift in µ1A conformation is thought to promote the
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association of µ1A with cargo.
In addition to Arf1 and PI4P, AP-1A phosphorylation affects its localization; cytosolic AP-
1A is phosphorylated on its β1 subunit, while membrane associated AP-1A is phosphorylated
on its µ1A subunit [122]. Phosphorylation of the β1 subunit prevents clathrin binding, while
phosphorylation of µ1A may promote conformational changes in the subunit that enable it
to interact with cargo [123, 117]. The phosphorylation status of AP-1A is thus essential for
protein trafficking.
1.4.2 Phosphofurin Acidic Cluster Sorting Protein 1 (PACS-1) – an enhancer
of AP-1A function.
AP-1A is not the only adaptor protein involved in the retrieval of material from immature
SGs. Furin, a type I transmembrane endoprotease, cleaves peptides after the last Arg of an
R-X-[K/R]-R motif; its discovery was a key advance contributing to the identification of the
prohormone convertases that are essential to SG function. Furin is concentrated in the TGN
and travels between the TGN, endosomes and plasma membrane [124]. In cells containing
a regulated secretory pathway, furin was identified in immature SGs but not in mature SGs
[88]. The removal of furin from immature SGs involves AP-1A and clathrin-coated vesicles
[88]. Its cytoplasmic domain contains a Tyr-based sorting motif and an acidic cluster, which
includes two Ser residues, both of which are substrates for CKII (Table 1.1) [125, 126]. The
Tyr motif found in the cytosolic domain of furin mediates TGN exit and plasma membrane
internalization; the acidic cluster is important for retrieval of furin from endosomes and
immature SGs [88, 127, 126]. Mutation of the two CKII phosphorylation sites in furin to Ala
(to prevent phosphorylation) resulted in the accumulation in mature SGs in a corticotrope
17
tumor cell line [128, 88]. Since AP-1A does not bind to acidic clusters, another interactor
was sought. A search for proteins with high affinity for the phosphorylated acidic cluster
through yeast two-hybrid screens led to the discovery of Phosphofurin Acidic Cluster Sorting
protein 1 (PACS-1) [126].
PACS-1 is a ubiquitously expressed cytosolic protein comprised of four domains: at its
N-terminus is an ARR (atrophin-1-related region), with limited homology to atrophin-1;
this region is followed by a furin binding region (FBR), the middle region (MR) and the
C-terminal region (CTR) (Figure 1.4B) [126]. The functions of the ARR and the CTR are
unknown. The FBR of PACS-1 interacts with acidic clusters in cargo proteins, with adaptor
proteins (AP-1A, AP-3 and GGA) and with CKII (Figure 1.4B) [128, 129, 126]. The MR
contains an autoinhibition domain, which is composed of an acidic cluster with a CKII
phosphorylation site (Figure 1.4C); when this region is not phosphorylated, the MR binds
the FBR, resulting in inhibition of PACS-1 binding to its cargo [130]. When the MR is
phosphorylated by CKII, it reduces MR affinity for FBR, allowing the FBR to bind to acidic
clusters in cargo proteins [129, 130]. Furin has been identified in a heterotrimeric complex
with AP-1A and PACS-1 [128]. Expression of a PACS-1 mutant capable of binding the furin
acidic cluster, but not AP-1A, does not alter the distribution of AP-1A, instead resulting in
the accumulation of furin in mature SGs [128]. This demonstrates that removal of furin from
immature SGs is a cooperative process involving both AP-1A and PACS-1 (Figure 1.5).
1.4.3 GGAs – another family of adaptor proteins essential for SG maturation.
Golgi-localizing, γ-adaptin ear homology domain, ARF-binding proteins (GGAs) were
discovered by several groups interested in different aspects of the proteins. Boman et al.
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screened for Arf3 binding partners using a yeast two-hybrid system, while Hirst et al. used a
bioinformatic approach to look for proteins with homology to the ear region of the γ subunit
of AP-1 [131, 108]. These studies, combined with the fact that the proteins discovered
concentrated in the TGN area, explain the origin of the name GGA [132, 108]. The GGA
family contains three members in humans (GGA1, GGA2 and GGA3), two in Saccharomyces
cerevisiae (Gga1p and Gga2p), and one in Drosophila melanogaster and Caenorhabditis
elegans [131, 133, 108]. Each member is ubiquitously expressed and acts as a monomeric
clathrin adaptor [131, 134]. From their N-terminus to their C-terminus, they are composed of
a VHS (Vps27, Hrs, Stam) domain, a GAT (GGA and TOM) domain, a hinge and a GAE
(γ-adaptin ear) domain (Figure 1.4D) [133].
The VHS domain was identified based on its role in the trafficking of yeast Vps27p
(Vacuolar Protein Sorting 27) and for its homology to two other monomeric endosome-
localized clathrin adaptor proteins, Hrs (Hepatocyte-growth factor-receptor substrate) and
Stam (Signal-Transducing Adaptor Molecule) [131, 108, 135]. A yeast two-hybrid screen
revealed that the cytosolic domains of proteins containing either a tyrosine sorting motif
(YXXφ) or a dileucine sorting motif [(D/E)XXXL(L/I)] were not recognized by any GGA
proteins, but were specific to AP complexes [125, 136]. The VHS domain of GGAs recognize
a motif called acidic cluster-dileucine motif (DXXLL), which is different from the AP
dileucine sorting motif [(D/E]XXXL(L/I)] (Figure 1.4D) [133, 136].
TOM1 (Target of Myb1), a protein involved in the trafficking of ubiquitinated proteins,
contains a GAT domain similar to the GAT domain in GGAs. Indeed, both yeast Gga1p and
mammalian GGAs bind monoubiquitin via their GAT domain [137, 133, 138, 139, 140]. This
interaction is required for the sorting of some ubiquitinated cargo proteins in S. cerevisiae,
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such as Gap1 and Arn1 [137, 133, 141, 142]. The GAT domain interacts with GTP-bound
Arf1 and Arf3 and the C-terminus of GAT binds PI4P; as for AP-1A, both binding sites are
required for proper membrane localization of GGA in cells (Figure 1.4D) [131, 132, 140].
Indeed, brefeldin A treatment results in the dissociation of GGAs from TGN membranes and
in their accumulation in the cytosol, as seen for AP-1A [131, 132, 108, 134]. Interestingly,
association of the GAT domain of GGA3 to Arf1 blocks GAP proteins from acting on
GTP-bound Arf1, thus stabilizing it on TGN membranes [51].
The hinge region between the GAT and the GAE domains is predicted to lack secondary
structure [133] and contains a clathrin binding motif which is necessary for the recruitment
of clathrin in vitro and in cells (Figure 1.4D) [108, 51]). While the GAE domain of GGA1
also interacts with clathrin heavy chain in vitro, the GAE domains of GGA2 and GGA3 are
unable to do so [51]. GGAs are important for the recruitment of clathrin to membranes;
overexpression of GGAs increases the TGN localization of clathrin while overexpression
of truncated GGA1 lacking the hinge and GAE domains reduces the TGN level of clathrin
[51]. Moreover, in vitro studies revealed that the GGA1-hinge region and the γ subunit
of AP-1 interact (Figures 1.4, A and D) [143, 107]. In addition, the hinge region of both
GGA1 and GGA3 contains a DXXL[L/M] motif, which can bind the VHS domain when the
surrounding Ser residue has been phosphorylated by CKII (Figures 1.4, D and E) [144, 107];
this internal binding results in autoinhibition of the adaptor protein by loss of cargo binding
[144, 107, 122]. The autoinhibition is removed when the Ser residue is dephosphorylated
by a protein phosphatase 2A-like enzyme [145]. In vitro phosphorylation by CKII was not
observed for GGA2, suggesting that GGA2 is controlled differently [125, 144]. Although the
autoinhibition concept is attractive, a recent structural report refutes the existence of such a
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motif within GGA1 and possibly within GGA3 as well [146]. These conflicting results are
currently unclear, but emphasize the fact that our knowledge of GGAs is incomplete.
The GAE domain has homology to the ear domain of γ-adaptin of AP-1 [131, 132, 108,
134, 147]. It interacts with several cytosolic proteins including rabaptin-5, a Rab4/Rab5
effector involved in membrane fusion at the endosomes [108, 148, 149] and γ-synergin [147].
In neuroendocrine cells, reducing the levels of GGA3 or overexpressing a dominant
negative form of GGA1 resulted in impaired egress of syntaxin 6, cation-independent mannose
6-phosphate receptor and VAMP4 from immature SGs and in decreased proteolytic processing
of prohormone convertase 2 and secretogranin II [150]. Thus GGAs, AP-1A and PACS-1 are
all key components in the maturation of SGs in neuroendocrine cells.
1.4.4 Do GGAs and AP-1A work together?
Despite differences in their cargo recognition motifs, GGAs and AP-1A are both recruited
to TGN membranes in an Arf1 and PI4P dependent manner, interact with clathrin and share
common cargoes, such as cation independent mannose 6-phosphate receptor (Table 1.1).
Using transmission electron microscopy, vesicles budding from the TGN were seen to contain
one adaptor protein or both GGA2 and AP-1A [144] . A novel technique developed in
mammalian cells to rapidly inactivate AP-1A or GGA2 revealed that AP-1A is the main
adaptor protein required for trafficking between the TGN and endosomes; when AP-1A is
inactivated, GGA2 is no longer present in clathrin-coated vesicles [151]. In addition, GGA2 is
thought to be required for proper localization of rabaptin-5, a group of lysosomal hydrolases,
both types of mannose 6-phosphate receptors and sortilin in clathrin-coated vesicles. Other
substrates, such as Arf1, carboxypeptidase D, furin, the copper transporters (ATP7A and
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ATP7B) or the SNARE proteins require AP-1A for localization in clathrin-coated vesicles
[151]. In agreement with these data, mutation of the GGA binding site in the cytosolic tail
of the cation independent mannose 6-phosphate receptor decreases its amount in clathrin
coats at the TGN, suggesting that GGAs help recruit specific cargo with adaptor proteins
and clathrin [144]. However, a recent study in yeast using fluorescently tagged proteins
suggested that the Gga proteins come into play first, and then recruit other proteins along
with AP-1A after being released from the membrane [152]. The yeast study also suggested
that AP-1 and Gga proteins work mainly in separate vesicles. This divergence between yeast
and mammals is unclear and may be linked to changes during evolution. Nevertheless, these
studies do not provide information on the mechanism which governs the egress of material at
the immature SG. In addition, yeast do not have a regulated secretory pathway, limiting their
use in understanding SG maturation.
1.5 Real life examples
Most of the integral membrane proteins found in post-TGN membranes contain multiple
signaling motifs in their cytosolic tails. The study of protein retrieval from immature SGs was
facilitated by our growing knowledge of adaptor proteins and the motifs they recognize. While
our understanding of the rules governing retention vs. retrieval of membrane proteins from
immature SGs is not yet complete, detailed studies of the interactions of several immature SG
cargo protein cytosolic tails with multiple adaptor proteins reveals many of the key features
(Figure 1.5 and Table 1.1).
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1.5.1 SNARE proteins
Similar observations to furin were made with the v-SNARE component, VAMP4 (Vesicle
Associated Membrane Protein 4), which contains an AP-1A binding motif (di-leucine sorting
motif) and an acidic cluster surrounding a CKII phosphorylation site (Table 1.1) [86]. VAMP4
accumulates at the TGN, on endosomes and on immature SGs of PC12 and AtT-20 cell lines
[86, 153]. As for furin, overexpression of a PACS-1 mutant unable to interact with AP-1A
but capable of interacting with VAMP4 resulted in accumulation of VAMP4 in mature SG
[86]. Interestingly, VAMP4 accumulates in mature SGs only if both the AP-1A and the PACS-
1 binding motifs are mutated; if either binding motif is remaining, VAMP4 is efficiently
removed from immature SGs [86]. This is different from furin which accumulated in mature
SGs when the CKII sites were mutated. The AP-1A/PACS-1/clathrin sorting system seems to
work differently with VAMP4 and furin.
In addition, VAMP4 interacts with syntaxin 6, which binds synaptotagmin IV [79, 153].
All three proteins are retrieved from immature SGs [83, 82, 153]. Although in vitro studies
failed to show binding between syntaxin 6 and AP-1A [86], observation of immature SGs
using electron microscopy showed that syntaxin 6 is retrieved in AP-1A and clathrin contain-
ing vesicles [82]. It remains unclear whether synaptotagmin IV interacts with AP-1A, but
since the removal of VAMP4 and syntaxin 6 has been linked with AP-1A, it seems likely that
synaptotagmin IV removal is also dependent on the AP-1A/PACS-1/clathrin sorting system
due to its indirect binding with VAMP4. Interestingly synaptotagmin IV is known to inhibit
calcium triggered exocytosis [83], suggesting that its removal is necessary to make mature
SG responsive to secretagogues. Since synaptotagmin IV plays a critical role in SG fusion,
which is an essential step in SG maturation, these studies would suggest that SG fusion occurs
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before membrane remodeling.
1.5.2 The mannose 6-phosphate receptors
Mannose 6-phosphate receptors (MPRs) transport soluble lysosomal hydrolases from the
TGN to endosomes [154, 136]. MPRs are found in immature SGs and are removed during
maturation in clathrin-coated vesicles that contain AP-1A [82]. Two MPRs have been de-
scribed: MPR300, the cation-independent MPR (CI-MPR), and MPR46, the cation-dependent
MPR (CD-MPR). Much has been learned by studying the multiple trafficking signals in both
MPRs. Both MPRs contain Tyr sorting motifs (YXXφ) and an acidic cluster-dileucine motif
(DXXLL) next to a CKII phosphorylation site (Table 1.1). Early studies revealed that the
Tyr motif of CI-MPR is recognized by AP-2 but not by AP-1A [155]. CD-MPR contains
two tyrosine motifs: the first tyrosine motif is located next to the transmembrane domain,
and may not be a signaling motif because of the hindrance caused by the membrane (Table
1.1, Y211QRL). The second tyrosine motif is found away from the membrane (Table 1.1,
Y256RGV) and is implicated in the protein internalization [156].
The DXXLL motif is recognized by the VHS domain of GGAs [136, 149]. Interestingly,
the DXXLL motif found on the cytosolic tail of the CI-MPR binds the VHS domain of all
GGAs while the DXXLL motif of the CD-MPR interacts with the VHS domain of GGA1,
interacts weakly with GGA3 and does not interact with GGA2 [136, 149]. Mutational
analyses revealed that the residues surrounding the motif are important for establishing
GGA specificity [136]. Down-regulation of GGA3 or inhibition of GGA1 results in the
accumulation of CI-MPR in mature SGs, suggesting that retrieval of CI-MPR from immature
SGs requires GGAs [150].
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Independent in vitro studies focusing on either CD-MPR or CI-MPR showed that removal
of the dileucine motif from either receptor had little effect on its ability to recruit AP-1A.
In CI-MPR, elimination of the CKII phosphorylation site abolished recruitment of AP-1A
[89, 126]. Indeed, binding of AP-1A to CI-MPR requires prior phosphorylation of its
cytosolic domain by CKII [90, 157]. These features suggested that PACS-1 might be involved
in the trafficking of CI-MPR. In non-neuroendocrine cells, reducing the cellular level of
PACS-1 or overexpressing a PACS-1 mutant unable to interact with acidic clusters resulted in
accumulation of CI-MPR in endocytic compartments, suggesting that PACS-1 recruitment
is necessary for MPR retrieval from the endosomes to the TGN [128, 126]. AP-1A binding
to CD-MPR requires the acidic cluster; experiments aimed at understanding the role of
phosphorylation at the Ser CKII site in CD-MPR in its binding of AP-1A have yielded
conflicting results (Table 1.1, Ser268) [90, 158]. It is not yet known whether MPRs are
retrieved from immature SGs in a PACS-1 dependent manner.
GGA and PACS-1 interact with the CI-MPR at sites that are overlapping, but not identical
(Table 1.1) [129]. The FBR region of PACS-1 binds CKII, enhancing its kinase activity [129].
This results in phosphorylation of the MR of PACS-1, releasing the FBR for cargo interaction
(Figure 1.4C). In addition, CKII phosphorylates GGA3, decreasing its affinity for cargo and
thus making space for PACS-1 to bind (Figures 1.4E and 1.5B) [129]. Although this study
did not focus on immature SGs, it provides a mechanism of how GGA and AP-1A/PACS-1
are necessary for SG maturation.
25
1.5.3 Carboxypeptidase D (CPD) binds AP-1A
The exopeptidase CPD, a type I transmembrane protein, accumulates in the TGN and cycles
between the TGN and plasma membrane via endosomes [159]. In AtT-20 cells, CPD is found
in immature, but not in mature SGs suggesting that it is removed during SG maturation [160].
The isolated luminal domain of CPD primarily enters the constitutive secretory pathway,
suggesting that signals in its cytosolic tail play an essential role in CPD entry into immature
SGs and in the TGN retention of CPD [160]. The CPD cytosolic tail contains an acidic
cluster with two CKII phosphorylation sites (TDT), but lacks classical AP and GGA binding
motifs (Table 1.1). In vitro binding assays revealed that the CPD cytosolic tail binds to AP-1A
and AP-2 only when its two CKII phosphorylation sites are phosphorylated or have been
mutated to phosphomimetic residues (EDE) (Table 1.2) [161]. Deletion of the C-terminus
of the CPD tail, which contains the CKII phosphorylation sites does not abolish AP-1A or
AP-2 binding (Table 1.2) [161], suggesting a role for additional CPD/AP-1A/2 interaction
motifs. A tyrosine-like motif (Table 1.2, F1332HRL) located upstream of the acidic cluster
is thought to be important for TGN export and endocytosis and is necessary for AP-1A and
AP-2 binding [161]. In addition, the C-terminus of CPD may bind another cytosolic protein
which would prevent adaptor proteins interactions. This unidentified protein probably loses
its affinity for the C-terminus of CPD when the CKII sites are phosphorylated or removed,
allowing adaptor proteins to interact. Phosphorylation of CPD by CKII promotes AP-1A
binding, suggesting that PACS-1 plays a role in its trafficking. The trafficking of CPD at
immature SGs probably results from the coordinated work of multiple cytosolic proteins
including AP-1A and PACS-1.
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1.5.4 VMAT2 suggests the existence of additional adaptor proteins
The monoamine transporter, VMAT2, accumulates in mature SGs in neuroendocrine cells. Its
cytosolic domain contains an acidic cluster with two CKII sites at the C-terminus; upon CKII
phosphorylation, this site interacts with PACS-1 [162]. As for furin, expression of VMAT2 in
which the CKII sites have been replaced with phosphomimetic mutations promotes its retrieval
from immature SGs. Mutation of these same two residues into Ala to prevent phosphorylation
promotes VMAT2 accumulation in mature SGs [162]; interestingly, expression of VMAT2
lacking the acidic cluster/CKII domain resulted in its egress from immature SGs [162]. Unlike
furin, which accumulates in the TGN at steady state, VMAT2 concentrates in mature SG
raising the question of VMAT2 retention mechanism. These findings suggest that additional
cytosolic proteins are involved in the sorting of SG proteins at the immature SG and may
explain the retention of other membrane proteins in SGs during maturation. Indeed the
amidating enzyme, PAM, remains in SGs during maturation and presents an acidic cluster
with two CKII phosphorylation sites [38]. Although direct binding between PAM cytosolic
domain and PACS-1 has not been shown, it is possible that PAM interacts with the same
cytosolic proteins which bind VMAT2 for its retention in SG.
1.5.5 Phogrin
Phogrin is a transmembrane protein that spans the membrane of immature and mature SGs.
The cytosolic domain of phogrin contains a protein-tyrosine phosphatase-like (PTP) domain
preceded by a 105 residue-long domain and followed by 10 residues at its C-terminus (Figure
1.2B and Table 1.1). The PTP domain of phogrin is an active phosphatidylinositol (PI)
phosphatase; its enzymatic activity is thought to play an essential role in its ability to regulate
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peptide hormone secretion [163]. Both domains surrounding the PTP domain are involved in
the correct sorting of phogrin in the regulated secretory pathway [35, 36]. The 105 residue
stretch close to the transmembrane domain contains a tyrosine-extended motif (Table 1.1,
Y655QEL) and the 10 residues at the C-terminus present a dileucine-like motif (Table 1.1,
E993EVNAIL). Both motifs are required for entry of phogrin into SGs and internalization
at the plasma membrane [35, 36]. Interestingly, both motifs are involved in the binding of
phogrin to AP-1A and AP-2. Mutation of one of these motifs decreases the binding strength
of adaptor proteins for phogrin but does not abolish the interaction [35, 36]. Although phogrin
binds AP-1A via unconventional motifs, it still remains to be determined what prevents this
transmembrane protein from being removed during SG maturation.
1.5.6 Sortilin and pro-BDNF
Sortilin, a type I transmembrane protein, binds the pro-region of brain-derived neurotrophic
factor (pro-BDNF) and transports it to SGs for processing [164]. As for CPD, expression
of the luminal domain of sortilin results in its entry into the constitutive secretory pathway,
suggesting that entry into SGs is mediated by the cytosolic tail [165]. A recent study revealed
that interaction of sortilin with Huntingtin associated protein 1 (HAP-1) and pro-BDNF
must occur for pro-BDNF entry into SGs and subsequent proteolytic processing [166]. In
the absence of HAP-1, sortilin and pro-BDNF are targeted to lysosomes. Interestingly, the
cytosolic tail of sortilin contains both a tyrosine motif and an acidic cluster-dileucine motif,
classical AP and GGA binding sites, respectively (Table 1.1). Both motifs are implicated
in sortilin internalization [167]. As expected, the VHS domain of GGA2 interacts with the
acidic cluster-dileucine motif of sortilin [167]. However, the tyrosine motif is recognized by
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the retromer complex, not by AP-1A [168]. The AP-1A binding motif on sortilin remains to
be elucidated. Both GGA2 and AP-1A were shown to be important for the TGN-to-endosome
transport of sortilin. It is possible that HAP-1 interacts with sortilin to prevent GGA and
AP-1A binding and mediates the entry of sortilin and pro-BDNF into SGs. Although sortilin
contains adaptor protein binding motifs, it is not clear if sortilin is retrieved from immature
SGs. One could assume that once in immature SGs, sortilin can release pro-BDNF and be
retrieved during SG maturation.
1.6 Conclusions and future directions
Little is known about the cytosolic machinery involved in sorting membrane proteins at
the TGN for their entry into immature SGs. A recent study in Drosophila suggested that
AP-3, the adaptor protein transporting proteins to lysosomes, was involved in sorting proteins
into the regulated secretory pathway at the TGN level [169]. Unfortunately, it is not known
whether this is also true in the mammalian neuroendocrine system. In addition, studies on the
trafficking of individual proteins raises many questions regarding the cytosolic machinery
necessary for their retrieval or retention during SG maturation. It remains to be explained how
a membrane protein which contains an adaptor protein (AP-1A, PACS-1 or GGAs) binding
motif can remain in SGs during maturation. One possibility is that other cytosolic proteins
bind the tails of membrane proteins, preventing their interaction with adaptor proteins. Recent
proteomic studies on purified SGs are an excellent source of information and may help
identify additional proteins involved in the egress of membrane proteins [170, 171]. Another
possibility is a binding site within the cytosolic tail of membrane proteins which could prevent
adaptor protein interaction; a post-translational modification, such as phosphorylation, can
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abolish this internal interaction while promoting the interaction with adaptor proteins. Lastly,
the membrane of the immature SG may play an important role in concentrating membrane
proteins to be removed during maturation. Katsumata et al. addressed this question using the
rat parotid gland as a source of SGs. The immature SG membrane revealed spatial segregation
of membrane proteins: VAMP2 and Rab3D were in GM1a rich microdomains, while syntaxin
6 and VAMP4 were not. Since VAMP2 and Rab3D remain in mature SGs while syntaxin 6
and VAMP4 are removed from immature SGs, membrane rearrangement could explain how
the right proteins are sorted for retrieval of material at the immature SG [172]. The trafficking
of individual proteins found in immature SGs can differ based on the cell type or animal
model. It is evident that professional secretory cells share a common mechanism, and that the
differences they present are probably required for their physiological function.
1.7 Acknowledgements
This work was supported by National Institutes of Health Grants DK32948 and DK32949.




Table 1.1: Summary of known motifs for membrane proteins in SGs. Protein, host
and ID are shown. Acidic clusters are in red. CKII sites are in bold. AP-1 and AP-1-
like sites are in blue and GGA sites are underlined in green. TMD, transmembrane
domain; COOH, C-terminus of the protein; NH2, N-terminus of the protein.
Table 1.2: Summary of mutational analysis of CPD-tail. Results adapted from [161].
TMD, transmembrane domain; COOH, C-terminus of the protein.
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1.9 Figures
Figure 1.1: Constitutive and regulated secretory pathways. Soluble and membrane
proteins are represented with circles and triangles, respectively. Constitutive secretory
pathway proteins are green; regulated secretory pathway proteins are red. Exam-
ples of post-translational modifications that occur in each organelle are shown. The
time-scale is representative of the time spent by hormones and hormone processing
enzymes in each organelle of the regulated secretory pathway. Until newly synthe-
sized proteins reach the trans-Golgi network (TGN), proteins from both secretory
pathways share the same compartments. Secretory proteins are sorted into constitu-
tive secretory vesicles or immature secretory granule (SGs) in the TGN. Immature
SGs undergo a maturation process to become mature SGs. The yellow lightning
bolt represents the external stimulus triggering secretion of mature SG content. The
maturation process involves remodeling of immature SG membranes, generating
the constitutive-like secretory pathway (blue); the fate of the vesicles leaving im-
mature SGs is not clear; return to an endosomal compartment from which proteins
can be secreted in a constitutive-like fashion or recycled to the TGN is shown. ER,
Endoplasmic Reticulum.
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Figure 1.2: Immature SG formation at the TGN. (A) Granins and prohormones ag-
gregate in response to the high calcium, mildly acidic conditions in the TGN. Several
soluble proteins interact with cholesterol or cholesterol-rich membranes; their sorting
into immature SGs depends on this interaction. (B) Membrane proteins identified
in immature SGs and discussed in the main text are shown; their cytosolic tails can
interact with adaptor proteins. The SNARE and synaptotagmin proteins that enter
immature SGs (synaptotagmin IV, VAMP4, syntaxin 6) are replaced during the matu-
ration process. Proteins known to enter immature SGs are drawn approximately to
scale (except for the vacuolar proton pump, V-ATPase and VMATs). PC, prohormone
convertase; C, catalytic domain; P, P domain; PTP, protein tyrosine-like phosphatase;
PHM, peptidylglycine α-hydroxylating monooxygenase; PAL, peptidylglycine α-
amidating lyase; CI-MPR contains 15 domains; CPD contains 3 similar domains;
Cys, Cysteine-rich domain.
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Figure 1.3: The Arf/GEF/GAP cycle. (A) GDP-Arf is cytosolic and is thought to
be recruited to its target membrane by interaction with a receptor. The exchange of
Arf-bound GDP for GTP is catalyzed by an Arf-GEF, which induces a conformational
change in Arf and release of GDP. GTP-bound Arf binds to the membrane through
its N-terminal myristoylated amphipathic helix and recruits cytosolic proteins which
function in membrane trafficking (effectors). One of these effectors is an Arf-GAP,
which promotes the GTPase activity of Arf, resulting in its detachment from the
membrane. (B) Table identifying type of effectors.
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Figure 1.4: Schematic of the AP-1 complex, PACS-1 and mammalian GGAs.
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Figure 1.4: (A) AP-1 is made of four different subunits: γ (blue), β1 (pink), µ1
(green) and σ1 (yellow). For each subunit, binding partners or binding motifs that are
recognized are indicated; φ indicates a hydrophobic residue; X can be any amino acid.
The overall organization of the complex is shown at the bottom right. (B) PACS-1 is
composed of four domains: ARR (black), FBR (grey), MR (tan) and CTR (white).
The autoinhibition sequence in the MR is shown (CKII phosphorylation site is in bold
and the acidic cluster in red), along with the CKII binding site in the FBR. AP-1 and
AP-3 interact with the same site in the FBR while GGA3 interacts with a different
site. The FBR is also responsible for interactions with cargo. (C) Autoinhibition
mechanism: the autoinhibition domain binds FBR, preventing PACS-1 interaction
with cargo. When CKII phosphorylates Ser276 of the autoinhibition domain, it inhibits
the internal binding and promotes cargo interaction with PACS-1. ARR, atrophin-
1-related region; FBR, furin binding region; MR, middle region; CTR, C-terminus
region; PP2A, protein phosphatase 2A. (D) Each GGA is composed of four domains:
VHS (pink), GAT (green), hinge (bar) and GAE (purple). Regulatory domain and site
of proteins-protein interaction are shown. Autoinhibition sequence is shown (CKII
phosphorylation site is in bold and the DXXLL motif in green). VHS, Vps27p, Hrs,
Stam; GAT, GGA and TOM; GAE, γ-adaptin ear. (E) Autoinhibition mechanism:
when phosphorylated by CKII, the autoinhibition domain binds VHS preventing
cargo interaction. When the autoinihibition is dephosphorylated, no internal binding
occurs allowing cargo interaction with GGA. The single letter code for amino acids
was used; CHC, clathrin heavy chain; CKII, casein kinase II.
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Figure 1.5: Segregation of proteins at the immature SG during membrane remodeling.
Schematic of proteins introduced in Figure 2 are reused. (A) Proteins removed during
SG maturation involving the recruitment of clathrin and clathrin adaptor protein.
Proteins shown to interact with AP-1 and/or PACS-1 or GGAs are shown. In the case
of CI-MPR, it is not clear whether GGAs help the recruitment of PACS-1 and AP-1
thus promoting its retrieval. (B) Model of adaptor protein recruitment for CI-MPR
transport: GGA3 binds CI-MPR cytosolic tail (step 1). Then, PACS-1, presumably
already interacting with CKII, is recruited to the GGA3/cargo complex (step 2). CKII
phosphorylates the GGA3 hinge autoinhibitory region (step 3) resulting in GGA3
dissociation from membranes (step 4). PACS-1 then recruits AP-1 for the CI-MPR
transport (step 5). Model adapted from [173].
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Summary of the thesis
The Golgi complex is a sorting organelle which receives newly synthesized proteins along
with proteins from the endocytic pathway and release cargo to go to the plasma membrane or
the endocytic pathway. In professional secretory cells, peptides and their processing enzymes
leave the Golgi complex in secretory granules, which is a storage organelle for bioactive
peptides until a stimulus triggers their exocytosis. The adaptor protein 1 complex (AP-1) is
a cytosolic complex involved in the trafficking of cargo between the Golgi apparatus and
endosomes and mediates the biogenesis and maturation of secretory granules in professional
secretory cells. This thesis explores the function of the adaptor protein 1 complex (AP-1) in
post-Golgi trafficking into the following six chapters:
• The second chapter provides evidence about the necessity of AP-1 in generating
secretagogue responsive secretory granules in a classical neuroendocrine cell line.
• Since AP-1 was reported to traffic cargo between the Golgi apparatus and endosomes,
AP-1 function in the endocytic pathway of the same cell line was explored in the third
chapter.
• MEDNIK, a rare disorder caused by lack of a subunit of AP-1, is characterized by
altered copper homeostasis. The consequences of reducing AP-1 function on the
trafficking of Atp7a, a copper pump bring copper from the cytosol to the lumen of the
secretory pathway, and the function of PAM, a peptide processing enzyme requiring
copper for activity, were investigated in chapter 4.
• Many studies have focused on copper in the liver and the brain; chapter 5 introduces
what the copper concentration and distribution is in the pituitary gland.
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• PAM is an essential enzyme for development in mice and flies and is highly expressed in
the brain. PAM expression profile during the development of cortex and hippocampus
and the distribution of PAM in hippocampal neurons were studied in chapter 6.
• Unravelling the dynamics of PAM trafficking in neuroendocrine cells and neurons and
the information this can provide to the scientific community are discussed last.
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2.1 Abstract
The adaptor protein 1A complex (AP-1A) transports cargo between the trans-Golgi network
(TGN) and endosomes. In professional secretory cells, AP-1A also retrieves material from
immature secretory granules (SGs). The role of AP-1A in SG biogenesis was explored
using AtT-20 corticotrope tumor cells expressing reduced levels of the AP-1A µ1A sub-
unit. A two-fold reduction in µ1A resulted in a decrease in TGN cisternae and immature
SGs and the appearance of regulated secretory pathway components in non-condensing
SGs. Although basal secretion of endogenous SG proteins was unaffected, secretagogue-
stimulated release was halved. The reduced µ1A levels interfered with the normal trafficking
of carboxypeptidase D (CPD) and peptidylglycine α-amidating monooxygenase-1 (PAM-1),
integral membrane enzymes that enter immature SGs. The non-condensing SGs contained
POMC products and PAM-1, but not CPD. Based on metabolic labeling and secretion experi-
ments, the cleavage of newly synthesized PAM-1 into PHM was unaltered, but PHM basal
secretion was increased in sh-µ1A PAM-1 cells. Despite lacking a canonical AP-1A binding
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motif, yeast two-hybrid studies demonstrated an interaction between the PAM-1 cytosolic
domain and AP-1A. Co-immunoprecipitation experiments with PAM-1 mutants revealed an
influence of the luminal domains of PAM-1 on this interaction. Thus, AP-1A is crucial for
normal SG biogenesis, function and composition.
2.2 Introduction
Pituitary endocrine cells, islet β-cells and peptidergic neurons store bioactive peptides in
mature secretory granules (SGs) and release them upon stimulation. SG biogenesis starts
in the trans-most cisterna of the Golgi and requires acquisition of the appropriate peptide
precursors, processing enzymes, granule membrane proteins and cytosolic machinery for
trafficking to the plasma membrane and regulated exocytosis. The mildly acidic pH and
high calcium concentration in the lumen of the trans-Golgi network (TGN), along with the
properties of the soluble content proteins, contribute to their aggregation and association with
lipid rafts and cholesterol-rich membranes [26, 24, 25, 174]. Integral membrane proteins
cannot aggregate as extensively and SG entry by the vesicular monoamine transporter, phogrin,
carboxypeptidase D (CPD) and peptidylglycine α-amidating monooxygenase (PAM) involves
both luminal and cytosolic domain signals [175, 161, 40, 176, 35].
The process of SG formation is poorly understood, but early observations in pituitary
lactotropes, pancreatic β-cells and AtT-20 corticotrope tumor cells revealed clathrin coats
on the trans-most cisterna of the Golgi and on immature SGs, the vesicular compartments
formed from these cisternae [177]. Members of the adaptor protein (AP) complex family
interact with the heavy chain of clathrin and membrane proteins to form clathrin coats. These
complexes bind specific membrane cargo proteins and localize to different regions of the cell
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[92, 93, 94, 95]. Each member of the AP family (AP-1 through AP-5) is composed of two
large subunits (γ/α/δ//ζ, and β1-5), a medium subunit (µ1-5) and a small subunit (σ1-5).
AP-1A (γ/β1/µ1A/σ1) is concentrated in the TGN area and on endosomes, where it binds the
cytosolic tails of transmembrane protein cargo, facilitating their entry into budding vesicles
[115, 178, 179]. AP-1 interacts directly with clathrin [115, 179], and mediates the transport
of cargo between the TGN and endosomes [178]. Cargo recognition by AP-1A is mediated
by the µ1A subunit, which binds a tyrosine-based sorting signal (YXXφ, where X is any
residue and φ is a hydrophobic residue), and by the γ/σ1 interface, which interacts with a
dileucine-based sorting signal ([D/E]XXXL[L/I]) [105, 106, 98]. The interaction of cargo
proteins with AP-1 affects its oligomerization and coordination of the sorting process [178].
Immature SGs are not responsive to secretagogues [180]. It is clear that AP-1A plays an
essential role in the maturation process that leads to secretagogue responsiveness. The removal
of VAMP4, furin and mannose-6-phosphate receptors from immature SGs involves AP-1A
binding motifs in their cytosolic domains [125]. During the maturation process, soluble
content proteins are also removed from immature SGs; these soluble proteins undergo basal
or constitutive-like secretion [14, 181, 174]. For prohormones like pro-opiomelanocortin
(POMC) and pro-brain derived neurotrophic factor, the more highly processed products re-
leased from mature SGs have biological effects distinct from their basally secreted precursors
[164, 182], making the balance between basal and stimulated secretion an important variable.
Although SGs play an essential role in many endocrine systems, the endocrine conse-
quences of limited AP-1A function have not been explored. Yeast lacking AP-1 and AP-2
are viable [92], but mice lacking γ-adaptin die before implantation and mice lacking µ1A
develop only until E13.5 [178, 183]. Growth is stunted in mice heterozygous for γ-adaptin
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[183] and patients with mutations in PREPL, which binds to µ1A and regulates AP-1A
recycling, exhibit growth retardation and anorexia [184]. In hippocampal neurons, AP-1A
plays a key role in excluding somatodendritic proteins from the SGs that enter axons [185].
Genetic studies demonstrate a role for AP-1A in the biogenesis of glue granules in the larval
salivary gland of Drosophila [56], secretory lysosomal granules (rhoptries) in Toxoplasma
gondii [55] and Weibel-Palade bodies in endothelial cells [57]. AP-1 plays an essential role in
melanosome biogenesis and in delivering cargo from endosomes to maturing melanosomes, a
lysosome-related organelle that stores pigment in melanocytes [186].
AtT-20 corticotrope tumor cells have served as a model system in which to explore SG
biogenesis and maturation [83, 187, 9, 75]. The behavior of soluble granule content proteins
can be assessed by monitoring POMC and prohormone convertase 1 (PC1) processing and
secretion. The behavior of SG membrane proteins can be assessed by monitoring CPD,
which enters immature SGs but is removed during SG maturation [161]. AtT-20 lines stably
expressing PAM-1 provide another means of monitoring the behavior of a SG membrane
protein that catalyzes one of the final modifications in peptide processing. A SG-specific
cleavage in its luminal domain makes it possible to monitor PAM-1 entry into immature
SGs [188]. Although the cytosolic domain of PAM (PAM-CD) affects its trafficking, it is
important to note that its two luminal domains each enter immature SGs efficiently on their
own [188, 189].
To investigate the role of AP-1A in SG biogenesis, expression of its medium subunit, µ1A,
was reduced in AtT-20 corticotrope tumor cells and in AtT-20 cells expressing exogenous
PAM-1 (PAM-1 cells). PAM-CD lacks a consensus site for interacting with AP-1A, but
metabolic labeling studies suggest that PAM-1 is retrieved from immature SGs [190], a
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process that generally involves AP-1A.
2.3 Results
Down-regulation of the medium subunit of AP-1A in PAM-1 cells alters TGN morphol-
ogy
We first compared the localization of AP-1A and adrenocorticotropic hormone (ACTH), an
accepted marker for the regulated secretory pathway, in PAM-1 cells (Figure 2.1A) [191, 189,
192]. AP-1A was visualized using an antibody for γ-adaptin. Use of an ACTH antibody
that recognizes its precursors (referred to as POMC/ACTH staining) allowed visualization
of the entire regulated secretory pathway. In PAM-1 cells, POMC products accumulate in
the perinuclear TGN area, while tip staining corresponds to mature SGs (open arrowhead
in Figure 2.1A) [193, 194, 189]. As expected, γ-adaptin staining was concentrated in the
same perinuclear region, with little γ-adaptin staining at the tips of processes (Figure 2.1A).
For our immunofluorescence studies, we distinguished three regions: the perinuclear region
containing the Golgi (which can be demarcated using antisera to TGN38, PAM or GM130)
(Figures 2.11A and B), the tips of processes and the intervening region (referred to as
intermediate). Signal intensity in each region was quantified (see Materials and Methods),
confirming the enrichment of POMC/ACTH, but not of γ-adaptin, at the tips of processes
(Figures 2.11A and C). Vesicular staining for POMC/ACTH and γ-adaptin was observed
throughout the region between the Golgi and the tips; although the POMC/ACTH and γ-
adaptin staining patterns in this intermediate region clearly differed, the intensity ratios for
POMC/ACTH and γ-adaptin staining in the intermediate region vs. the Golgi region were
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similar (Figure 2.11C).
SG biogenesis begins at the TGN, where both γ-adaptin and POMC/ACTH are located.
To test the hypothesis that AP-1A is necessary for SG formation and maturation, we generated
PAM-1 cells with reduced levels of µ1A; µ1A was selected as our target because its cargo
recognition motifs are known [105, 106, 98]. Lentiviruses encoding shRNAs targeted to
five regions of µ1A mRNA were used to generate multiple stable cell lines (see Materials
and Methods). Infected PAM-1 cells were selected using puromycin and µ1A levels were
determined by Western blot analysis. In PAM-1 cells infected with lentivirus #549 (sh-µ1A
PAM-1 cells), µ1A levels were reduced to 50% of their normal value, the greatest effect
observed. Removal of one subunit of the AP-1A core complex alters the stability of the
remaining complex [117]; consistent with this, levels of other AP-1A subunits are reduced in
fibroblasts lacking µ1A [178, 183]. To see whether a similar effect was observed in PAM-1
cells, γ-adaptin levels were quantified; levels of γ-adaptin in sh-µ1A PAM-1 cells were
80% +/- 4% of control values (data not shown). Cells infected with a lentivirus encoding
a non-target shRNA were used as a control (scramble PAM-1 cells) (Figure 2.1B). The
morphology of sh-µ1A and scramble PAM-1 cells was not consistently different.
To resolve the complex cisternal and vacuolar structures in the TGN region and the small,
punctate structures observed with AP-1A and POMC/ACTH immunofluorescent staining, we
turned to transmission electron microscopy and compared the morphology of the TGN in
scramble and sh-µ1A PAM-1 cells (Figure 2.1C). The TGN was defined as the tubulovesicular
cellular domain at the trans-side of the Golgi stack, bordered by endoplasmic reticulum and
mitochondria. This domain corresponds to the distribution of the TGN marker syntaxin 6
and the steady state distribution of PAM in these cells; the distribution of the TGN marker
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TGN38 is more restricted within this domain [195, 189]. Stereological analyses of the Golgi
stacks revealed no difference in stack membrane area (Figure 2.1Ca) and the percentage of
the whole Golgi volume fraction attributed to the TGN was not different in the two cell lines
(Figure 2.1Cb). However, the surface area of TGN cisternal membranes decreased in sh-µ1A
PAM-1 cells compared to scramble PAM-1 cells; pronounced vacuolization of the TGN was
observed in sh-µ1A PAM-1 cells (Figure 2.1Cc).
When newly synthesized SG content proteins reach the TGN, the decreased luminal
pH and increased calcium concentration facilitate the formation of aggregates, which must
acquire membrane of the appropriate composition before budding from the TGN to form
immature SGs [1, 174]. To investigate this process, immature and mature SGs were examined
in scramble and sh-µ1A PAM-1 cells.
2.3.1 The formation of immature SGs is impaired in sh-µ1A PAM-1 cells
SGs in scramble and sh-µ1A PAM-1 cells were first analyzed using the POMC/ACTH
antibody; the Golgi region was visualized using antibody to GM130, a cis-Golgi marker,
(Figure 2.2A); as expected from the TGN and endosomal localization and function of AP-1A,
the steady state distribution of GM130 was unaltered in scramble and sh-µ1A PAM-1 cells.
POMC/ACTH positive puncta accumulated at the tips of processes in both cell types; the
ratio of tip to Golgi area POMC/ACTH signal intensities did not differ between scramble
and sh-µ1A PAM-1 cells (Figure 2.2A and Figure 2.12A). However, the POMC/ACTH-
positive puncta located between the Golgi/TGN region and the tips differed in sh-µ1A PAM-1
cells. Instead of the evenly distributed, small POMC/ACTH-positive puncta observed in
scramble PAM-1 cells, a smaller number of what appeared to be larger and more scattered
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POMC/ACTH positive puncta were observed in sh-µ1A PAM-1 cells (red arrows in Figure
2.2A). The ratio of intermediate to Golgi POMC/ACTH signal intensities decreased by 40%
in sh-µ1A PAM-1 cells compared to scramble PAM-1 cells (Figure 2.12A).
To understand why POMC/ACTH staining differed in scramble vs sh-µ1A PAM-1 cells,
we turned to transmission electron microscopy. Mature SGs of similar appearance were
observed at the tips of cellular processes in both cell lines (Figure 2.2B, left). Immature SGs
can be distinguished from mature SGs in these cells by their localization in the TGN area and
their electron dense core surrounded by an electron lucent halo. The number of immature
SGs in the TGN area decreased by 50% in sh-µ1A PAM-1 cells (Figure 2.2B).
In sh-µ1A PAM-1 cells, vacuolar structures were common in the region between the
Golgi complex and the surrounding plasma membrane (Figures 2.1C and 2.2C). In contrast to
the high density consistently observed in mature SGs, the electron density of these vacuolar
structures varied from lucent to moderately dense. Vacuoles located in a 500 nm peripheral
zone of cytoplasm overlying the Golgi complex were counted in scramble and sh-µ1A PAM-1
cells; their number increased almost three-fold in sh-µ1A PAM-1 cells (Figure 2.2C).
Since a decrease in the number of immature SGs and the appearance of these vacuolar
structures were the most dramatic morphological changes observed in response to reducing
levels of µ1A, we hypothesized that these vacuolar structures derived from the regulated
secretory pathway. We thus searched for additional markers that could be used to characterize
them.
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2.3.2 Diminished levels of µ1A result in altered localization of PAM and CPD
Immature SGs contain proteins targeted to mature SGs along with proteins that function in the
regulated secretory pathway but are removed during the maturation process. Since PAM-1 and
CPD fall into this category [190, 160], we used immunofluorescence to determine whether
reducing µ1A expression altered their localization. We visualized PAM-1 and GM130 in
scramble and sh-µ1A PAM-1 cells (Figure 2.3A). As expected, using an antiserum to its
C-terminus, PAM-1 was found in the perinuclear Golgi region identified by GM130 and in
vesicular structures distributed throughout the cell [189]. Quantification of PAM-staining
intensities in the tips vs. the Golgi region did not differ (Figure 2.12B). As observed for
POMC/ACTH staining (Figure 2.2A and Figure 2.12A), bright PAM-positive puncta located
between the Golgi/TGN region and the tips of processes were prevalent in sh-µ1A cells (red
arrows in Figure 2.3A). The ratio of intermediate to Golgi PAM signal intensities decreased
by 30% in sh-µ1A PAM-1 cells compared to scramble PAM-1 cells (Figure 2.12B).
CPD, which removes Arg or Lys residues from the C-terminus of proteins and peptides,
enters immature SGs but is absent from mature SGs [160]. Despite lacking an AP binding
motif, in vitro studies demonstrated that its cytosolic domain (CPD-CD) interacts with AP-1A
and AP-2 [161]. In scramble PAM-1 cells, endogenous CPD localized to the Golgi (GM130)
area, with some staining of nearby vesicles (Figure 2.3B). A clear change in CPD localization
occurred in sh-µ1A PAM-1 cells; CPD was more prevalent in vesicles distributed throughout
the cytoplasm. The ratio of intermediate to Golgi CPD signal intensities increased almost
3-fold in sh-µ1A PAM-1 cells (Figure 2.12C). Decreasing the levels of µ1A in HeLa cells
resulted in a similar shift in the localization of a CD8/CPD chimera [196].
We took advantage of the dramatic difference in CPD localization observed in sh-µ1A
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cells to verify that the phenotype could be reversed by expressing mCherry-µ1A*, in which the
coding sequence was mutated to make the fluorescently-tagged protein resistant to the shRNA
#549. CPD was visualized in sh-µ1A PAM-1 cells transiently expressing mCherry-µ1A*
(Figure 2.3C). Transfected sh-µ1A PAM-1 cells expressed varying levels of mCherry-µ1A*.
Only sh-µ1A PAM-1 cells expressing mCherry-µ1A* whose distribution resembled that of
γ-adaptin (Figure 2.1A) were used for the analysis; in these cells, the endogenous CPD was
concentrated in the perinuclear region, as seen in scramble PAM-1 cells. Average intensity of
intermediate over Golgi ratios from transfected and non-transfected cells showed an almost
50% decrease in cells transfected with the rescue plasmid. sh-µ1A PAM-1 cells expressing
high levels of the construct showed a diffuse mCherry-µ1A* distribution and were excluded
from the analysis (not shown). These data confirmed that the phenotype observed in sh-µ1A
PAM-1 cells was due to the diminished levels of µ1A.
Reducing the levels of µ1A in PAM-1 cells altered the localization of three regulated
secretory pathway markers, POMC/ACTH, PAM and CPD. To find out whether the vacuolar
structures that appeared in the sh-µ1A PAM-1 cells derived from the regulated secretory
pathway, we turned to immunoelectron microscopy using these three marker proteins.
2.3.3 ACTH and PAM accumulate in the vacuolar structures that appear in
sh-µ1A PAM-1 cells
POMC endoproteolytic cleavage generates multiple products (Figure 2.4A). The initial
cleavage occurs at the C-terminus of ACTH; although detectable in the TGN, this cleavage
occurs primarily in immature SGs. An antiserum specific for the C-terminus of ACTH and
unable to cross-react with POMC allowed identification of cleaved product [192]. Using
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immunoelectron microscopy, we previously identified PAM-1 in the TGN cisternae, mature
SGs and multivesicular bodies of PAM-1 cells [195]. Cisternal structures in the TGN area of
scramble and sh-µ1A PAM-1 cells did not differ from the same structures in PAM-1 cells;
an accumulation of PAM protein was apparent (Figure 2.4B, left). The morphology of the
PAM-1 positive SGs at the tips of scramble and sh-µ1A PAM-1 cells did not differ; in both
cell lines, staining for ACTH was concentrated in these structures (Figure 2.4B, right).
To determine whether the vacuoles observed in sh-µ1A PAM-1 cells (Figure 2.2C) derived
from the regulated secretory pathway, ACTH and PAM-1 were visualized simultaneously
(Figure 2.4C). The vacuolar structures were enriched in both ACTH and PAM; as expected, the
multivesicular bodies (MVBs) in the sh-µ1A cells contained PAM, but did not contain ACTH.
The vacuoles did not accumulate at the tips of processes, where mature SGs accumulated
(Figure 2.4C, left). The presence of ACTH in these vacuolar structures identified them as a
derivative of the regulated pathway. The vacuoles lack the high electron density consistently
observed in immature and mature SGs, suggesting a lack of content condensation and are
tentatively referred to as non-condensing SGs.
To determine whether these vacuolar structures were part of the endosomal system, we
assessed the ability of wheat germ agglutinin (WGA) tagged with horseradish peroxidase
(HRP) to enter them. The sh-µ1A PAM-1 cells were incubated with tagged WGA for 10
minutes at 37◦C; cells were then fixed and stained for HRP (Figure 2.4D). WGA-HRP was
readily detected on the plasma membrane and in early endosomes; it was not, however,
apparent in the vacuolar structures. The vacuolar structures that appear near the plasma
membrane in the region of the cell that contains the Golgi complex in cells with reduced µ1A
levels are therefore referred to as non-condensing SGs.
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Like PAM-1, CPD was located in cisternal and vacuolar structures in the TGN area of
scramble PAM-1 cells (Figure 2.4Ea). Double staining for CPD and ACTH confirmed their
co-localization in immature SGs in the TGN area of scramble PAM-1 cells (Figure 2.4Eb).
Very few mature SGs in scramble or sh-µ1A PAM-1 cells contained CPD (Figures 2.4Ec
and Ef). In the TGN area of sh-µ1A PAM-1 cells, CPD was identified in cisternal structures
rather than vacuolar structures (Figure 2.4Ed) and was absent from immature SGs containing
PAM (Figure 2.4Ee). Very few of the PAM containing non-condensing SGs found in sh-µ1A
PAM-1 cells contained CPD (Figure 2.4Eg); instead, CPD was localized in small vesicular or
tubular structures generally devoid of PAM (Figure 2.4Eh). Immunofluorescent and immuno-
EM staining indicated that the trafficking of PAM-1 and CPD responded very differently to
reduced µ1A levels. To evaluate the functional consequences of these morphological changes,
the cleavage of SG proteins and their basal and stimulated secretion were assessed.
2.3.4 Regulated secretion of soluble SG proteins is impaired in sh-µ1A cells
The non-condensing SGs that appeared in sh-µ1A PAM-1 cells contain ACTH and PAM
and would be expected to contain prohormone convertase 1 (PC1), a soluble SG component
[197, 198, 199]. Based on previous studies, analysis of PC1 and POMC products provides a
means of distinguishing secretion from immature vs. mature SGs [12]. PC1 is synthesized
as an 87 kDa precursor (proPC1); autoproteolytic cleavage in the endoplasmic reticulum
generates an 81 kDa intermediate (Figure 2.5A). When exiting the TGN, 81 kDa PC1 is
cleaved to generate a more active 63 kDa form. While 81 kDa PC1 is secreted basally,
secretion of 63 kDa PC1 is secretagogue responsive. Using an antibody which recognizes
all three forms of PC1, no significant differences were observed in the steady state levels of
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these PC1 cleavage products in the three cell lines (Figure 2.5B).
In order to determine whether the content of these non-condensing SGs was stored or
released rapidly into the medium, we assessed secretion using a simple stimulation paradigm.
Duplicate wells of cells were exposed to control medium or to medium containing 2 mM
BaCl2, a mimic of calcium that causes sustained secretion of mature SGs [20]. As expected,
proPC1 (87 kDa) was not detected in the medium. The 81 kDa form of PC1, which is not
stored in mature SGs, was secreted at a similar rate by all three cell lines. The 63 kDa form
of PC1 is stored in mature SGs; stimulation with BaCl2 produced a significant increase in
its secretion in all three cell lines. Basal secretion of 63 kDa PC1 was not altered in sh-µ1A
PAM-1 cells but BaCl2 stimulated secretion of 63 kDa PC1 was significantly diminished
(Figure 2.5C). These data indicate that the decrease in µ1A levels observed in sh-µ1A PAM-1
cells was sufficient to impair SG maturation.
Since AtT-20 cells are specialized in producing and storing ACTH, we next asked whether
POMC processing and secretion was altered when µ1A levels were reduced. In order to
generalize our observations beyond the PAM-1 cell line and since exogenous expression of
PAM-1 alters cytoskeletal organization and limits POMC processing and secretion [193], we
addressed this question using wild-type (wt) AtT-20 cells; wt AtT-20 cells were infected with
the non-target virus (scramble wt) or the #549 virus (sh-µ1A wt) and multiple stable cell lines
were selected. Levels of µ1A were reduced by about 40% in the sh-µ1A wt lines (Figure
2.6A).
In addition to ACTH, POMC cleavage generates 16 kDa fragment (Figure 2.4A). An-
tibodies to 16 kDa fragment also recognize intact POMC and its cleavage product, ACTH
biosynthetic intermediate (ABI). The amount of 16 kDa fragment stored in the three cell lines
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at steady state was indistinguishable (Figure 2.6B). Basal secretion of 16 kDa fragment was
unaltered in sh-µ1A wt AtT-20 cells, but BaCl2 stimulated secretion of 16 kDa fragment was
reduced by almost a factor of two (Figure 2.6C).
Analysis of two soluble SG content proteins (POMC and proPC1) supports the conclusion
that µ1A plays an essential role in SG maturation in both wt and PAM-1 AtT-20 cells. The
fact that basal secretion of processed products of POMC and PC1 was not increased in
sh-µ1A cells supports the hypothesis that the vacuolar structures characteristic of sh-µ1A
cells are non-condensing SGs. We next turned to PAM-1, a SG membrane protein whose
localization is altered when expression of µ1A is reduced, to examine the role of µ1A in
granule membrane protein processing.
2.3.5 PAM processing is altered in sh-µ1A PAM-1 cells
When PAM-1 enters immature SGs, it can be cleaved by prohormone convertases; the major
cleavage takes place between the two catalytic core domains, forming soluble PHM and
PAL membrane (PALm). Cleavage between PAL and the transmembrane domain occurs less
frequently, generating soluble PAL (Figure 2.7A). Unlike soluble SG proteins, PAM-1 and
PALm can be retrieved from the regulated secretory pathway; in addition, PAM-1 and PALm
that reach the plasma membrane undergo endocytosis and can be returned to the regulated
pathway or degraded [190, 176]. PAM-1 cleavage in non-infected, scramble and sh-µ1A cells
was assessed using Western blots and antisera specific for PHM or PAL (Figures 2.7B and C).
The percentage of the total PHM or PAL signal represented by cleaved product (soluble PHM
or PALm) was significantly lower in sh-µ1A PAM-1 cells than in non-infected or scramble
PAM-1 cells (Figures 2.7B and C). Although metabolic labeling studies indicated that PAM-1
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was synthesized at similar rates in sh-µ1A and scramble PAM-1 cells, total levels of PAM
protein were consistently lower in sh-µ1A PAM-1 cells; increased secretion and increased
degradation could each contribute to this difference.
The steady state level of PAM protein reflects newly synthesized PAM-1 trafficking
through the biosynthetic pathway along with a substantial amount of PAM that has traversed
the endocytic pathway [195]. Metabolic labeling was used to assess the trafficking of newly
synthesized PAM-1, which must enter the regulated secretory pathway before it can be
cleaved to form soluble PHM. Cells incubated in medium containing [35S]Met/Cys for
20 minutes were either collected after 10 min (pulse) or incubated in medium containing
unlabeled Met/Cys for 0.5, 1 or 2 hours (chase). PHM-containing proteins were isolated
from cell extracts and spent media by immunoprecipitation; following SDS-PAGE, newly
synthesized PAM proteins were visualized by fluorography (Figure 2.7D). The time course
over which newly synthesized 120 kDa PAM-1 was converted into PHM was indistinguishable
in scramble and sh-µ1A PAM-1 cells (Figure 2.7E). Data from several metabolic labeling
experiments were quantified, supporting the conclusion that access of PAM-1 to the protease
that produces PHM was unaltered in sh-µ1A PAM-1 cells (Figure 2.7F). AP-1A was shown
to play a role in the regulated, but not in the basal, release of 63 kDa PC1 and the 16 kDa
fragment of POMC. We next evaluated the role of AP-1A in the basal and stimulated secretion
of PHM.
2.3.6 Regulated secretion of PHM is impaired in sh-µ1A PAM-1 cells
We used non-infected, scramble and sh-µ1A PAM-1 cells for these studies. As above, we
used 2 mM BaCl2 [20] to stimulate secretion from mature SGs (Figure 2.8A). The sh-µ1A
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PAM-1 cells secreted about twice as much PHM under basal conditions as non-infected or
scramble PAM-1 cells (Figure 2.8A, boxed graph). Metabolic labeling experiments also
indicated that more of the newly synthesized PHM appeared in the medium during the 0-1 h
and 0-2 h chase periods in sh-µ1A PAM-1 cells than in scramble PAM-1 cells (Figure 2.7D).
Contributions from newly synthesized PAM-1 in the biosynthetic pathway and from recycled
PAM-1 in the endocytic pathway could explain the increase in PHM basal secretion. This
result is consistent with the decreased steady state content of PHM observed by Western blot
(Figure 2.7B). The ability of BaCl2 to stimulate the secretion of PHM from mature SGs was
reduced by 40% in sh-µ1A PAM-1 cells (Figure 2.8A).
To determine whether the reduced regulated secretion seen in sh-µ1A PAM-1 cells was
due to an impairment in SG maturation, we again turned to metabolic labeling. Based
on studies of rat intermediate pituitary and parotid cells, it takes about 2 hours for newly
synthesized POMC products and amylase to get to mature SGs [17, 200]. A metabolic labeling
experiment was designed to compare the time at which secretion of newly synthesized PHM
produced in scramble vs. sh-µ1A PAM-1 cells became responsive to secretagogue. After
the pulse, media were collected every hour for the next 4 hours of chase. After 2 hours
of chase, one well received medium containing 2 mM BaCl2 (stim.) while the other well
received control medium (basal). After 3 hours of chase, both wells were incubated in basal
medium for 1 hour (Figure 2.8B). PAM proteins were isolated from cells and spent media by
immunoprecipitation and newly synthesized PAM proteins were visualized by fluorography.
Secretion of newly synthesized PHM was barely detected during the first collection period.
Addition of 2 mM BaCl2 to the 2-3 h chase medium increased PHM secretion by 50% in
scramble PAM-1 cells but failed to stimulate secretion of newly synthesized PHM from
56
sh-µ1A PAM-1 cells (Figures 2.8C and D). Taken together, our data suggest that the entry
of newly synthesized PHM into secretagogue-responsive granules requires a longer time in
sh-µ1A PAM-1 cells than in scramble PAM-1 cells.
2.3.7 The cytosolic domain of PAM interacts with the µ subunit of AP-1A
Since our analysis revealed a role for AP-1A in PAM trafficking, we hypothesized that the
cytosolic domain of PAM-1 interacts with AP-1A; the trafficking determinants in this 86
amino acid unstructured region of PAM-1 have been localized to residues 933-950 (Figure
2.9A) [176]. We turned to the yeast two-hybrid system to screen for an interaction between
the cytosolic domain of PAM (PAM-CD) and µ1A, µ2, µ3A, µ3B and µ4 (Figure 2.9B):
in this system, PAM-CD interacted only with µ1A. We used several PAM-CD mutants to
identify the region responsible for this interaction and to assess its biological relevance
(Figure 2.9C). PAM-1 truncated at residue 961 is trafficked normally and PAM-CD 961s
interacted with µ1A. PAM-1 in which the only Tyr residue in the cytosolic domain had been
mutated to Ala (Y936A) is endocytosed less rapidly, a process expected to be dependent
of AP2 [176]; PAM-CD bearing this mutation continued to interact with µ1A. The major
trafficking determinants in the cytosolic domain of PAM are located between residues 933
and 950; PAM-CD lacking these residues (∆933-950) did not interact with µ1A in the yeast
two-hybrid screen.
In order to determine whether PAM and AP-1A interact in vivo, we turned to pituitary, a
tissue in which PAM-1 is highly expressed [201]. A solubilized particulate fraction prepared
from adult mouse pituitary was immunoprecipitated using antibodies to γ-adaptin (Figure
2.9D) or to the linker region between PHM and PAL (Figure 2.9E). The availability of an
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excellent antibody to γ-adaptin and the fact that γ-adaptin (100 kDa), but not µ1A (50
kDa), could be readily resolved from the IgG heavy chain governed the choice of antibody.
In both cases, co-immunoprecipitation of PAM-1 and the AP-1A complex was observed.
Based on quantification of multiple experiments, 3% of the PAM-1 in pituitary lysates co-
immunoprecipitated with γ-adaptin while only 0.6% of the AP-1A co-immunoprecipitated
with PAM-1 (graphs in Figures 2.9D and E).
To allow manipulation of the interaction, similar co-immunoprecipitation experiments
were conducted using lysates prepared from PAM-1 cells (Figures 2.9F and G). When the
γ-adaptin antibody was used to capture the endogenous AP-1A complex, PAM-1 was again
co-immunoprecipitated. Although the cytosolic domain of PALm has the same amino acid
sequence as the cytosolic domain of PAM-1, PALm was not co-immunoprecipitated by the
γ-adaptin antibody. Quantification revealed a significant interaction (graph in Figure 2.9F).
The different behavior of PALm and PAM-1 could reflect their phosphorylation state [38] or a
contribution from their luminal domains. Using affinity-purified PAM-1 antibody, γ-adaptin
was again co-immunoprecipitated (Figure 9G; quantification shown in graph in Figure 2.9G).
As for the pituitary, about 2% of the total PAM-1 co-immunoprecipitated with γ-adaptin
(Figure 2.9E). Almost 2% of the γ-adaptin co-immunoprecipitated with PAM-1, a higher
percentage than observed in pituitary tissue (Figure 2.9G).
When expressed independently as soluble secretory pathway proteins, both catalytic
domains of PAM are efficiently stored in regulated secretory granules [190, 188]. To de-
termine whether luminal interactions contributed to the co-immunoprecipitation of PAM-1
and AP-1A, we prepared lysates from AtT-20 cells stably expressing PAM-1 899s, which
includes the transmembrane domain but only nine of the 86 residues in PAM-CD (Figure
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2.9A, blue arrow). Co-immunoprecipitation of PAM-1 899s with γ-adaptin was observed
using antibodies to PAM-1 or γ-adaptin (Figures 2.10A and B). While the PAM-CD/µ1A in-
teraction revealed using the yeast two-hybrid assay presumably contributes to the interactions
that occur in cells, it is clear that mutations that eliminate the ability of PAM-CD to interact
with µ1A in the yeast two-hybrid screen are not readily detected by co-immunoprecipitation
from cells with a regulated secretory pathway.
We turned to transient transfection of pEAK Rapid cells, a cell line that lacks a regulated
secretory pathway, to see if these cells could be used to explore the interactions of µ1A
with the cytosolic domain of PAM. Co-immunoprecipitation of endogenous AP-1A with
transiently expressed PAM-1 or PAM-1 899s was detected using antibody to PAM (Figure
2.10C); an exploration of the interaction between the cytosolic domain of PAM and AP-1
will require the use of PAM proteins that lack their luminal domains.
2.4 Discussion
2.4.1 The role of AP-1A in SG formation and function
It is striking that a 50% reduction in µ1A levels had such a profound effect on the architecture
of the TGN and on SG maturation in AtT-20 corticotrope tumor cells. This could reflect both
the role of AP-1A in the trafficking of newly synthesized proteins as they exit the TGN and
the role of AP-1A in endocytic trafficking. Formation of clathrin coats on TGN membranes is
dependent on close cooperation between AP-1A and GGA proteins [152, 151]. Lack of this
membrane sorting mechanism and membrane proteins normally retrieved after endocytosis
may contribute to the breakup of cisternal elements seen in the TGN of sh-µ1A PAM-1 cells.
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The structure of the Golgi stacks was unperturbed when µ1A levels were reduced.
Ultrastructural analysis indicated that sh-µ1A PAM-1 cells had fewer immature SGs and
more vacuolar structures than scramble cells. The fact that cleavage of proPC1, POMC and
PAM-1 proceeded normally in sh-µ1A PAM-1 and sh-µ1A wt AtT-20 cells supports the
conclusion that these vacuoles are cleavage competent. Based on their appearance, staining
for PAM-1 and ACTH and lack of accessibility to an endocytic marker, these vacuolar
structures were referred to as non-condensing SGs. They cluster in the mid-region of the
cell instead of accumulating at the tips of processes, where mature SGs accumulate [194].
In AtT-20 cells, as in pancreatic β-cells and exocrine pancreatic cells, immature SGs have
a clathrin-coat which is lost during maturation [177, 202, 9] and the simplest hypothesis is
that non-condensing SGs accumulate when the formation and maturation of SGs is inhibited.
The molecular mechanisms involved in condensation are not yet clear, but isolation and
examination of these non-condensing SGs may provide insight into the process.
Efficient sorting and packaging of proteins in SGs involves the pH and calcium dependent
formation of aggregates and their interaction with TGN membranes of the appropriate
composition. With its ability to interact with transmembrane cargo proteins, AP-1A is
thought to assist in the sorting of granule membrane proteins into forming vesicles. The
accumulation of non-condensing SGs in sh-µ1A PAM-1 cells may be a consequence of the
absence of multiple AP-1A cargo proteins. A failure to acidify the lumen or an inability
to accumulate calcium could also contribute. Early work on mammotrophs demonstrated
interactions between the regulated secretory pathway and the degradative pathway [203].
Steady state levels of the products of proPC1 and POMC processing were unaltered in sh-
µ1A cells, suggesting that the degradative pathway is not altering the state of the regulated
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secretory pathway.
Basal secretion of proPC1 and POMC cleavage products was unaltered in sh-µ1A PAM-1
and sh-µ1A wt AtT-20 cells, suggesting that non-condensing SGs are not rapidly released.
As SGs mature, their ability to respond to secretagogues increases [83]. Our metabolic
labeling experiments indicated that it takes longer for the SGs in sh-µ1A PAM-1 cells to
become secretagogue responsive than it does for immature SGs in scramble PAM-1 cells. The
formation of secretagogue-responsive SGs is known to require the AP-1 mediated removal
of VAMP4 and synaptotagmin IV, leaving VAMP2 and synaptotagmin I in mature SGs
[83]. Consistent with this, BaCl2-stimulated secretion of PHM, ACTH and 63 kDa PC1 was
reduced to half in sh-µ1A cells. Mature SGs of normal appearance were located at the tips of
cellular processes in sh-µ1A PAM-1 cells. Non-condensing SGs may contain proteins that
block their maturation and transport to the tips or processes. Decreased responsiveness to
secretagogue, as observed in sh-µ1A PAM-1 cells, is a hallmark of metabolic diseases like
diabetes [204, 205] and of peptide secreting neuroendocrine tumors [206, 207].
2.4.2 The role of AP-1A in PAM-1 and CPD trafficking
Reducing µ1A levels had vastly different effects on PAM-1 and CPD, proteins selected
for study because both were known to enter into and be retrieved from immature SGs
[175, 161, 12]. PAM accumulated in non-condensing SGs and in mature SGs in sh-µ1A
PAM-1 cells. Cleavage of newly synthesized PAM-1 by PC1, which produces PHM and
PALm, does not start until PAM-1 enters immature SGs [12]; the timing of this event was
unaltered in sh-µ1A PAM-1 cells. The ability of its PHM and PAL domains to enter SGs [188]
may minimize the need for signal-mediated entry of PAM into immature and non-condensing
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SGs.
Reducing µ1A levels had a very different effect on endogenous CPD trafficking; instead
of its normal localization in TGN cisternae and immature SGs, CPD appeared in small
vesicles dispersed throughout sh-µ1A PAM-1 cells. Most notably, CPD and PAM rarely
co-localized in sh-µ1A PAM-1 cells. CPD is a major transmembrane glycoprotein in clathrin-
coated vesicles in human placenta and rat liver [196]. Its cytosolic domain is well conserved
and essential for its trafficking [175, 161]. The cytosolic domain of CPD lacks a canonical
AP binding motif, but in vitro binding assays revealed that it interacts with AP-1A when
phosphorylated by CKII [161].
The different effects of µ1A knockdown on PAM-1 and CPD trafficking may in part
reflect the properties of their luminal domains. Membrane and soluble forms of duck CPD
have been expressed in AtT-20 cells [160]. About 80% of the membrane form was located at
the TGN, with 14% in immature SGs; the soluble form was found in small vesicles (45%)
and immature SGs (40%). Metabolic labeling studies indicated that soluble duck CPD was
primarily targeted to the constitutive secretory pathway. The entry of membrane CPD into
immature SGs seems to require AP-1A. Consistent with our data, down-regulation of µ1A in
HeLa cells expressing a CD8/CPD chimera (luminal and transmembrane domains of CD8
linked to the cytosolic domain of CPD) caused its redistribution from the TGN to small
vesicles throughout the cell [196].
Although PAM-1 was synthesized at the same rate in sh-µ1A and scramble PAM-1 cells,
steady state levels of PAM were reduced in sh-µ1A PAM-1 cells; a detailed evaluation of the
endocytic trafficking of PAM-1 in sh-µ1A cells will be required to interpret these observations.
The secretion of cleavage products unique to the regulated secretory pathway in the absence
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of secretagogue, often referred to as constitutive-like secretion [14, 208], is a major pathway
in AtT-20 cells [49, 12]. The increased constitutive-like secretion of PHM observed in
sh-µ1A PAM-1 cells could be due to a change in PAM trafficking in both the regulated
secretory and endocytic pathway. AP-1A/clathrin coated vesicle budding from immature
SGs has a well-established role in the retrieval of lysosomal and constitutive membrane
proteins from the regulated secretory pathway [82, 208]. Increased aggregation of POMC
and PC1 products would be expected to decrease their entry into budding vesicles [187],
accounting for the unaltered constitutive-like secretion of 16K fragment and 63 kDa PC1.
The kinetics of constitutive-like secretion suggest the occurrence of an additional sorting step
in an endosomal intermediate [209, 210, 211], presumably allowing additional sorting for
secretion or recycling toward the TGN.
2.4.3 PAM-1 and AP-1A: a novel interaction
The PAM-1/AP-1A interaction described here is not driven by a canonical AP interaction
motif. Non-canonical interactions of cargo with AP-2 and AP-4 have been described. The
Kir2.3 potassium channel is internalized in clathrin-coated vesicles containing AP-2; muta-
tional analysis revealed a tandem di-hydrophobic motif at its C-terminus that recognizes an
α/σ2 interface in AP-2 [212]. The cytosolic domain of amyloid precursor protein contains a
tyrosine-based signal (YKFFE) that binds to µ4 at a site that is different from that of canonical
YXXφ signals [213]. Our findings suggest that AP-1A can also bind non-canonical signals.
Immunoprecipitation of the AP-1A complex pulled down PAM-1 but not PALm. The
cytosolic domains of PAM-1 and PALm are identical in amino acid sequence, but differ in
phosphorylation status [38, 214]. While our yeast two-hybrid screen pointed to a role for PAM
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(933-950), co-immunoprecipitation of the AP-1A complex and a truncated PAM-1 protein
lacking its cytosolic domain (PAM-1 899s) revealed an important role for the luminal domains.
The proteins that contribute to this interaction have not been identified, but studies using
luminal fragments of ATP7A, the P-type ATPase responsible for transporting copper into
the lumen of the secretory pathway, demonstrated an interaction with PAM-1 [215]. ATP7A
localizes to the TGN when copper levels are low, receiving copper from a cytosolic chaperone
and delivering it to luminal cuproenzymes like PHM [216]. Mutations in the genes encoding
the σ1A [217] or σ1B [218] subunits of human AP-1 result in two developmental disorders,
MEDNIK (mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis and
keratodermia) and Fried syndrome, respectively. Deficiency in σ1A correlates with a defect
in copper metabolism recently characterized by abnormal localization of ATP7A [219]. The
C-terminus of ATP7A contains a di-leucine motif that could be recognized by AP-1A and
ATP7A recycling from the plasma membrane to the TGN in HeLa cells is AP-1A dependent
[220].
Our studies suggest that diminished responsiveness of peptide secreting neurons and
endocrine cells may occur in response to minor alterations in AP-1A function. Lack of
AP-1A recycling due to reduced levels of PREPL alters growth hormone secretion [184].
Furthermore, γ-adaptin+/- mice are smaller than wild-type, which could also reflect impaired
endocrine function [183]. In our study, a modest reduction in µ1A levels in corticotrope
tumor cells resulted in vacuolization of the TGN and accumulation of cleavage competent,
non-condensing SGs. Although processing of POMC and proPC1 in the regulated secretory
pathway proceeded normally, the ability of the cells to secrete stored product in response
to secretagogue was substantially diminished. The interaction of AP-1A complexes with
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membrane proteins known to enter and exit immature SGs is affected by their luminal domains
and may not rely only on canonical interaction sites.
2.5 Materials and Methods
2.5.1 Antibodies
The antibodies used in this study are summarized in Table 2.1.
2.5.2 Cell Culture
A mouse corticotrope tumor cell line, AtT-20, was grown at 37◦C with 5% CO2 in Dulbecco’s
modified Eagle’s medium/F-12 (DMEM/F-12) containing 25 mM HEPES, 10% NuSerum,
10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and passaged
weekly using trypsin. Stably transfected AtT-20 cells expressing wild-type PAM-1 or PAM-1
899s were grown in the same medium and selected using 0.5 mg/ml G418 [176].
2.5.3 Lentiviruses
Wild type AtT-20 cells and stably transfected AtT-20 cells expressing PAM-1 were grown
until about 80% confluency and then infected with a lentivirus expressing an shRNA directed
against µ1A (Sigma) (Table 2.2). In parallel, cells were infected with a lentivirus expressing a
non-target shRNA (Sigma # SHC002V). At 24 hours post-infection, the medium was removed
and cells were selected using growth medium containing 0.4 µg/ml puromycin. In order to
obtain lines expressing a constant level of µ1A, cells were subcloned; for each type of cell
line, nine to ten clones were used to measure the level of µ1A (Figures 2.1B and 2.6A). Three
sh-µ1A clones were selected based on their low level of µ1A and three scramble clones were
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selected based on their unaltered µ1A levels.
2.5.4 Immunofluorescent staining, confocal imaging and image quantification
Cells were plated onto 0.16 to 0.19 mm thick, 12-mm round coverslips (Fisher Scientific)
which were coated with 0.1 mg/ml poly-L-lysine for 5 minutes followed by a rinse in
NuSerum and two rinses in growth medium. Cells were fixed in 4% formaldehyde in PBS
(50 mM NaH2PO4, 150 mM NaCl, pH 7.4) for 20 minutes at room temperature. After rinsing
in PBS, cells were permeabilized in 0.075% Triton X-100, 2 mg/ml BSA in PBS for 20
minutes at room temperature and then incubated in block buffer (2 mg/ml BSA in PBS) for
20 minutes at room temperature. Primary antibodies diluted in block buffer were incubated
with the cells overnight at 4◦C. After three rinses in PBS, cells were incubated for one hour
in block buffer containing either fluorescein isothiocyanate (FITC, 1:500 dilution) or Cy3
(1:2000 dilution) conjugated donkey antibody to mouse or rabbit immunoglobulin (Jackson
ImmunoResearch). After three rinses, coverslips were mounted on slides using ProLong R©
Gold (Invitrogen). Cells were visualized on a Zeiss LSM 510-Meta using an oil immersion
63X Plan Apochromat objective (NA 1.4). Linescans were done using Metamorph; for both
markers, the value with the highest fluorescence intensity value was set to 1. Quantification of
fluorescence images was done using Metamorph. Three regions were identified in each cell
analyzed: Golgi (based on staining for GM130, TGN38 or PAM), Tip (based on morphology)
and Intermediate (non-nuclear, located between the Golgi and a tip, but clearly distinct from
each). Figure 2.11 identifies the three regions in line scans. For each picture, red and green
colors were first separated. Background values were determined by measuring the average
intensity in parts of the picture without cells for both green and red images. Background
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was then subtracted for both green and red images using the average intensity measured as
a constant value for the entire image. One to nine 2.5 x 2.5 µm boxes were systematically
placed over each region and the average fluorescence signal intensity in each region was
measured for 10 to 37 cells. Tip/Golgi and Intermediate/Golgi ratios are shown. Statistical
analyses were made using paired t-tests on the ratios calculated.
2.5.5 Electron microscopy
For electron microscopy, cells were fixed with 2.5% glutaraladehyde in 0.1 M cacodylate
buffer, scraped and pelleted in gelatin, postfixed with 1% osmium tetroxide and 1.5% potas-
sium ferrocyanide, dehydrated and embedded in an Epon resin. Ultrathin sections were
post-stained with uranyl acetate and lead citrate and 30 Golgi complexes in each specimen
were systematically sampled and photographed at 6000X with a Jeol JEM-1400 electron
microscope equipped with a Gatan Orius SC 1000B bottom mounted CCD-camera. The
pictures were viewed at a final magnification of 160,000X. A point grid [221] was overlaid
and the volume fractions of the Golgi stack and the TGN were determined by point counting.
A line grid was used for measuring the surface to volume ratios of Golgi stack membrane and
cisternal membrane in the TGN according to the formula S/V = 4c/lh, where c is the number
of times the lines intersected the surface of interest, h is the number of times the end points of
the lines fell on the structure and l is the length of a test line. Immature granules in the TGN
were identified on the basis of their electron dense interior surrounded by an electron lucent
halo. Vacuoles/granules in the middle of the cells were counted in the 500 nm peripheral
zone of the cytoplasm surrounding the Golgi complex (extending 2.5 µm in both directions
from the point overlying the center of the Golgi complex). All graphs represent the results
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from 3 experiments. Statistical analyses were made with Student’s t-test for the mean values
of each experiment (n = 3).
For immunoelectron microcopy, cells were fixed with 4% paraformaldehyde (for PAM
staining) or 4% paraformaldehyde + 0.5 % glutaraldehyde (for CPD staining) in 0.1 M phos-
phate buffer for 2 h, scraped, pelleted and embedded in gelatin. Polyvinylpyrrolidone/sucrose
infiltrated specimens were sectioned at -120oC; sections were collected with methyl cellu-
lose/sucrose, blocked with 1% fish skin gelatin (Sigma) and 1% BSA (Sigma) and incubated
with antibody (JH629 diluted 1:200 for PAM; AE142, diluted 1:50 for CPD) for 1 h followed
by Protein A conjugated to 10 nm gold particles (University of Utrecht, Utrecht, Nether-
lands) for 1 h and embedded in uranyl acetate-methyl cellulose. For double staining with
ACTH or CPD antibody, PAM was first detected with Protein A/10 nm gold conjugate; the
sections were then fixed for 5 min with 1% (for ACTH) or 0.5% (for CPD) glutaraldehyde to
block interfering binding, then incubated with antibody to ACTH (antiserum Kathy diluted
1:1000) (Schnabel et al., 1989) or CPD (antiserum AE142 diluted 1:50) followed by protein
A conjugated to 15 nm gold particles.
For the detection of endosomal uptake cells were incubated with 30 µg/ml peroxidase
conjugated wheat germ agglutinin (Sigma) on ice for 30 min, rinsed, chased for 10 min at
37◦C and fixed with 1.5% glutaraldehyde in 0.1M phosphate buffer, then incubated with 0.25




Briefly, sh-µ1A PAM-1 cells were transfected with a plasmid encoding µ1A mRNA resistant
to shRNA provided by virus #549. The rescue was tested by immunofluorescent staining
looking at the distribution of carboxypeptidase D. pReceiver-M55-mCherry-Ap1m1A was
purchased from GeneCopoeia (catalog number: EX-Mm01216-M55; Rockville, MD). In
order to create shRNA-resistant mCherry-µ1A (µ1A*), mutations that did not alter the amino
acid sequence were introduced using site-directed mutagenesis with the following primer:
5’ CTGTCACCTATCTTGGCCCATGGTGGGGTGAGATTCATGTGGATTAAGCACAA-
CAACCTGTAC 3’ (Tm = 70.2◦C). Scramble and sh-µ1A PAM-1 cells were plated onto
12-mm diameter coverslips (0.16 to 0.19 mm thick, Fisher Scientific) in 24-well dishes; the
coverslips were coated with 0.1 mg/ml poly-L-lysine for 5 minutes followed by a rinse in
NuSerum and two rinses in growth medium. Two days later, cells were incubated in serum
free medium for 30 minutes before being transfected (0.125 µg DNA/well); the Lipofectamine
2000 R© and DNA were mixed in Optimem (Optimem:DNA:Lipofectamine 2000 R© = 200
µl:1 µg: 2.5 µl) and allowed to sit for 25 minutes. After application of the mixture, cells
were incubated at 37◦C for 6 hours. Transfection medium was then replaced with growth
medium and the cells were allowed to recover overnight. Cells were fixed the following day
in 4% formaldehyde in PBS and immunostained as described above.
2.5.7 Stimulation of secretion
Cells were plated into 12-well dishes. Secretion experiments were carried out in DMEM/F-12
air medium containing ITS, 25 mM HEPES, pH 7.4, 50 µg/ml bovine serum albumin (BSA).
Cells were equilibrated in air medium during two consecutive 30 minute incubations at 37◦C.
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Each experiment consisted of a 30 minute incubation in air medium (basal secretion) followed
by a 30 minute incubation in either air medium (basal secretion) or in air medium containing
2 mM BaCl2 (stimulated secretion). After each incubation, the medium was centrifuged to
remove any non-adherent cells and protease inhibitors were added to the supernatant. After
the final incubation, cells were extracted into SDS lysis buffer [0.5% (w/v) SDS, 50 mM Tris,
pH 8.0, 1 mM DTT, 2 mM EDTA, 50 mM NaF] containing protease inhibitors.
2.5.8 Biosynthetic labeling
Cells plated into a 4-well dish were equilibrated in DMEM/F-12 air medium as described
above for secretion experiments. Cells were incubated in DMEM/F-12 air medium lacking
methionine (Met- medium) for 10 minutes at 37◦C before incubation in Met- medium contain-
ing [35S]Methionine/Cysteine protein labeling mix (final activity 1 mCi/ml; PerkinElmer) for
20 minutes. Radioactive medium was removed and replaced with DMEM/F-12 air medium.
Cells were either harvested 10 minutes after removal of the radioactive medium (Pulse) or
after a 30-240 min incubation in non-radioactive medium (Chase). Cells were lysed in 200
µl of TMT, pH 7.4 containing protease inhibitors. After centrifugation at 8,000 x g for 15
minutes, supernatants were used for immunoprecipitation. Medium samples were centrifuged
at 2,000 x g for 5 minutes and protease inhibitors were added before analysis. To assess
labeling efficiency, incorporation of [35S]Methionine/Cysteine into protein was assessed
using aliquots (2 µl) of cell extracts and media. Proteins were precipitated by adding 25%
tricholoracetic acid (TCA) to 1% of the total cell extract, resuspended in 2% SDS, 0.2M
NaHCO3 and added to liquid scintillation fluid for measurement in a scintillation counter.
Typically, 1-2 % of the label was incorporated into protein during the 20 min labeling/10
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minute pulse.
For immunoprecipitation, affinity-purified PHM antibody (0.8-1 µg) was added to cell
extracts, which were incubated at 4◦C overnight; after centrifugation for 15 minutes, super-
natants were incubated with protein A agarose beads (10 µl packed beads) for 30 minutes at
room temperature. Beads were pelleted and washed twice in TMT, pH 7.4 containing protease
inhibitors, and once in TM, pH 7.4 containing protease inhibitors. Bound proteins were eluted
by incubation for 5 minutes at 95◦C in Laemmli sample buffer. Immunoprecipitates were
fractionated by SDS-PAGE on 4-15% gradient gels (Bio-Rad). After electrophoresis, gels
were incubated in 10% acetic acid, 30% isopropanol for 20 minutes at room temperature,
followed by 20 minutes in Enhance (Perkin Elmer) at room temperature. After two rinses in
water, the gel was dried and analyzed by fluorography.
2.5.9 Yeast two-hybrid screen
A cDNA fragment encoding the cytosolic domain of rat PAM (PAM-CD; R891WK to
PSS976) was inserted into pGBKT7 (Gal4 DNA-binding domain, TRP1). A cDNA encoding
medium subunit µ1A, 2, 3A, 3B or 4 was inserted into pACTII (Gal4 Activation Domain,
LEU2) as described [102, 222]. The AH109 yeast reporter strain was grown on Yeast Peptone
Dextrose agar plates. Yeast were co-transfected with a PAM-CD plasmid and a medium
subunit plasmid; to test the PAM-CD/µ interaction, yeast were grown for 5 days at 30◦C on
medium lacking leucine, tryptophan and histidine. The growth medium contained 3-amino-
1,2,4-triazole (3-AT), a competitive inhibitor of HIS3, where indicated. Construction of the
following mutants was previously described: PAM-CD truncated at residue 961 (961s), PAM-




A confluent well of a 6-well dish of AtT-20 cells expressing PAM-1 or a PAM-1 mutant
were lysed in 500 µl of 20 mM Na-N-Tris[hydroxymethyl]methyl-2-aminoethanesulfonic
acid (TES), 10 mM mannitol (TM), 1% Triton X-100 (TMT), pH 6.4, 1 mM EDTA and
a cocktail of protease inhibitors (final concentrations 0.34 mg/ml phenylmethylsulfonyl
fluoride, 50 µg/ml lima bean trypsin inhibitor, 2 µg/ml leupeptin, 16 µg/ml benzamidine, and
2 µg/ml pepstatin) were added. Cell extracts were centrifuged at 22,000 x g for 15 minutes at
4◦C. Anterior pituitaries were collected from adult mice and homogenized in TM, pH 6.4
containing 1 mM EDTA and protease inhibitors. Homogenates were centrifuged at 1,000 x g
for 5 minutes at 4◦C to remove cell debris. Particulate material was collected by centrifugation
at 435,000 x g for 15 minutes at 4◦C. Membrane associated proteins were solubilized by
suspending this pellet in 250 µl TMT, pH 6.4 containing 1 mM EDTA and protease inhibitors.
After incubation at 4◦C for 30 min, pituitary lysates were clarified by centrifugation at 22,000
x g for 15 minutes at 4◦C. Supernatants (250 µl - PAM-1 cells and pituitary cells) were
pre-cleared by incubation with 10 µl packed protein A (Repligen BioProcessing) or protein
A/G (Thermo Scientific) beads for 30 minutes at 4◦C. After centrifugation at 1,000 x g
for 5 minutes, 10 µl of supernatant was collected as the input for the Western blot and the
rest of supernatant was transferred into a new tube containing 1 µg of antibody (affinity-
purified rabbit antibody to PAM exon 16 or mouse monoclonal antibody to γ-adaptin); as a
control, lysates were incubated with mouse or rabbit immunoglobulin. Samples were tumbled
overnight at 4◦C and then centrifuged at 22,000 x g for 15 minutes at 4◦C to remove insoluble
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material. The supernatants were added to protein A (rabbit antibodies) or protein A/G (mouse
antibodies) beads (10 µl packed resin) and tumbled for 1 hour at 4◦C. Beads were washed
twice in pH 6.4 TMT containing 1 mM EDTA and protease inhibitors, and once in pH 6.4
TM containing 1 mM EDTA and protease inhibitors. The bound fraction was eluted by
incubation for 5 minutes at 95◦C in Laemmli sample buffer, fractionated by SDS-PAGE on
4-15% gradient gels (Bio-Rad) and subjected to Western blot analysis.
2.5.11 Transfection of pEAK Rapid cells
pEAK Rapid cells (Edge Biosystems, Gaithersburg, MD) a derivative of HEK293 cells,
were plated on a 6-well dish which had been coated with 0.1 mg/ml poly-L-lysine for 5
minutes followed by a rinse in NuSerum and two rinses in growth medium. When about
70% confluent, cells were transfected with 1 µg DNA/well using Lipofectamine 2000 R© as
described above. After 6 hours, transfection medium was replaced with growth medium; cell
extracts were collected the following day for co-immunoprecipitation experiments.
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2.7 Tables
Antigen Working dilution Identity, source
rat PAM-1:
C-STOP, PAM-1(965-976) 1:1000 C-stop [223]
Exon 16, PAM-1(409-497) 1:1000 JH629 [224]
PHM, PAL-1(37-382) 1:1000 JH1761 [225]
PAL, PAM-1(498-604) 1:1000 JH877 [77]
SG proteins:
PC1(359-373) 1:1000 JH888 [199]
POMC(γ3MSH) 1:1000 JH189 [226]
Carboxypeptidase D 1:1000 and CPD AE 142, gift
see EM from Dr. Lloyd Fricker [227]
ACTH (Rabbit) See EM C-terminus of ACTH [192]
POMC/ACTH (Rabbit) 1:1000 JH93 (N-terminus of ACTH) [228]
AP-1 components:
µ1A 1:500 ProteinTech Group
γ-adaptin 1:1000 BD Biosciences
Golgi:
GM130 1:1000 BD Biosciences
TGN38 (155-249) 1:1000 [189]
Table 2.1: List of antibodies with working dilutions for Western Blot and fluorescent
immunostaining along with the source used in this study.










Figure 2.1: PAM-1 cells expressing reduced levels of µ1A have a more vacuolated
TGN structure. (A) Indirect immunofluorescent staining of γ-adaptin (FITC anti-
mouse) and POMC/ACTH (Cy3 anti-rabbit) in AtT-20 cells stably expressing PAM-
1 (PAM-1 cells); #, nucleus; filled arrowhead, vesicle positive for γ-adaptin and
POMC/ACTH; red arrow, vesicle positive for POMC/ACTH but negative for γ-
adaptin; open arrowhead, tip of the cell where SGs accumulate; scale bar, 10 µm.
Quantification is shown in Figure 2.11C. (B) Left, Western blot comparing µ1A
expression in non-infected (N.I.) PAM-1 cells, PAM-1 cells infected with a non-target
shRNA expressing lentivirus (scramble, scr.) or PAM-1 cells infected with the #549
lentivirus (sh-µ1A); Coomassie staining showed similar amounts of protein in the
three cell lines. Right, quantification of µ1A level in nine clones for the scramble
PAM-1 cells and ten clones for the sh-µ1A PAM-1 cells. (C) Left, Architecture
of the Golgi stack and TGN in scramble and sh-µ1A PAM-1 cells. Vacuoles of
varying electron density were more frequent in the TGN of sh-µ1A PAM-1 cells
(black arrowheads): G, Golgi stack; IMG, immature SG; scale bar, 200 nm. Right,
graphs show the surface to volume ratio of Golgi stack membrane (a), the volume
fraction of the TGN in relation to the total volume of the Golgi complex (b) and the
surface to volume ratio of cisternal elements in the TGN (c) (* p<0.05).
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Figure 2.2: The formation of immature SGs is impaired in sh-µ1A PAM-1 cells.
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Figure 2.2: (A) Indirect immunofluorescent staining of GM130 (FITC anti-mouse), a
cis-Golgi marker, and POMC/ACTH (Cy3 anti-rabbit) in scramble and sh-µ1A PAM-
1 cell lines; #, nucleus; red arrows, bright puncta positive for POMC/ACTH seen
only in sh-µ1A PAM-1 cells; open arrowhead, tip of the cell, where SGs accumulate;
scale bar, 10 µm. Quantification of Golgi, intermediate and tip staining is shown
in Figures 2.12A (PAM) and 2.12B (CPD). (B) Transmission electron micrographs
showing mature SGs at the tips of cell processes (left) and immature SGs in the TGN
area (black arrowheads, right) in scramble (scr.) and sh-µ1A PAM-1 cells. The graph
shows the number of immature SGs in the TGN area (* p<0.01). (C) Transmission
electron micrographs of sh-µ1A PAM-1 cells; black stars mark vacuolar structures
located between the Golgi complex and the plasma membrane. Inset: graph shows
the number of vacuoles in the 500 nm peripheral zone (between the dashed line and
the cell membrane, * p<0.05).
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Figure 2.3: CPD and PAM-1 localization are sensitive to µ1A knockdown.
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Figure 2.3: (A) Indirect immunofluorescent staining of PAM-1 (C-terminus, Cy3-anti-
rabbit) and GM130 (FITC-anti-mouse), a cis-Golgi marker, in scramble (scr.) and
sh-µ1A PAM-1 cell lines. Red arrows point to bright PAM-1 puncta seen only in sh-
µ1A PAM-1 cells. (B) Immunofluorescent staining of endogenous CPD and GM130
in scramble and sh-µ1A PAM-1 cells; CPD was visualized using an antibody to its
luminal domain (Cy3-anti-rabbit). #, nucleus; open arrowhead, tip of the cell; scale
bar, 10 µm. Quantification of Golgi, intermediate and tip staining is shown in Figures
2.12B (PAM) and C (CPD). (C) sh-µ1A PAM-1 cells were transiently transfected with
plasmid encoding mCherry-µ1A*. Cells were fixed the day following transfection
and stained for CPD (FITC-anti-rabbit). Blue arrows point to non-transfected cells
where CPD distribution was diffuse throughout the cell. Open arrowheads point to
the Golgi apparatus of transfected cells; CPD was concentrated in the Golgi region,
as in scramble PAM-1 cells. Quantification is shown in Figure 2.12D.
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Figure 2.4: Formation of PAM and ACTH containing vacuoles in sh-µ1A PAM-1
cells.
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Figure 2.4: (A) Diagram of POMC processing: the cleavage generating ACTH
biosynthetic intermediate (ABI) and β-lipotropin (βLPH) starts in the TGN [indicated
as (1)] while cleavages producing 16 kDa fragment, joining peptide (JP), ACTH,
γ-lipotropin (γLPH) and β-endorphin (βE) occur in SGs [(indicated as (2)] [12]. (B)
ACTH (15 nm gold) and PAM (10 nm gold) co-localized in the TGN and in mature
SGs at the tips of scramble and sh-µ1A PAM-1 cells. G, Golgi. (C) Cryosections
(two panels) of sh-µ1A PAM-1 cells show immunoreactivity for ACTH and PAM
in vacuolar/non-condensing SG structures; the PAM-positive multivesicular body
(MVB) defines the middle of the cell. Black arrowheads indicate the cell membrane.
(D) HRP was detected at the plasma membrane (black arrowheads) and in early
endosomes (EE) after sh-µ1A PAM-1 cells were incubated in HRP-WGA for 10
min. Black arrows point to non-condensing SGs which lack HRP staining. Scale
bar, 500 nm. (E) CPD, ACTH and PAM were localized using 15 nm and 10 nm
gold as indicated. CPD was present in cisternal and vacuolar elements of the TGN
in scramble and sh-µ1A PAM-1 cells (a, d). Although CPD was found in immature
SGs in scramble PAM-1 cells (immature SGs, IMG, identified by ACTH; black
arrowhead) (b), CPD was largely absent from PAM positive immature SGs or non-
condensing SGs in sh-µ1A PAM-1 cells (e, open arrowheads); only one of these
structures contained CPD (e, upper black arrowhead). CPD was readily identified
in TGN membranes (e, lower black arrowhead). Very few mature SGs contained
CPD (c,f, black arrowhead). The non-condensing SGs found in sh-µ1A PAM-1 cells
contained PAM, but rarely contained CPD (g, black arrowhead). Peripheral vesicular
or tubular structures usually stained distinctly for CPD or PAM (h, black arrowhead).
Except for panel D, scale bar, 200 nm.
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Figure 2.5: Regulated secretion of soluble content proteins is impaired in sh-µ1A
PAM-1 cells. (A) Diagram showing the processing of PC1: arrow (1) indicates a
cleavage occurring in the endoplasmic reticulum; arrow (2) points to a cleavage
happening in mature SGs. (B) Left, Western blot of non-infected (N.I.), scramble
(scr.) and sh-µ1A PAM-1 cell extracts using a PC1 antibody showed no change in
the amounts of PC1 processed products. Coomassie staining showed similar amounts
of protein among the three cell lines. Right, quantification of the 63 kDa form of PC1
(63 kDa/(63 kDa + 81 kDa + 87 kDa)) using densitometry (n = 3-8; no statistical
differences were seen using a t-test). (C) Left, Western blot showing the level of the
different forms of PC1 secreted under basal and stimulated conditions in N.I., scr.
and sh-µ1A PAM-1 cells. Right, graph showing the secretion rate of the 63 kDa form
of PC1 (63 kDamdm/(63 kDamdm + 63 kDacell)) after densitometry. Four sets of data
from two independent experiments are represented in the graphs. (* p<0.05)
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Figure 2.6: Regulated secretion of soluble content proteins is impaired in wt cells.
(A) Left, Western blot showing the level of µ1A after infection of wild type (wt)
AtT-20 cells with the non-target virus (scr. wt) or with the #549 virus (sh-µ1A wt).
Right, quantification of µ1A level of nine sh-µ1A wt clones and ten scramble wt
clones relative to µ1A level in non-infected cells (N.I. wt). (B) Graph representing
the percentage of 16 kDa fragment in all three cell lines (16 kDa/(16 kDa + POMC)).
These data were collected by densitometry (n = 5-7; no statistical differences were
seen using a t-test). (C) Left, Western blot after stimulation of secretion experiment
looking at 16 kDa fragment secretion. Right, graph showing 16 kDa fragment
secretion rate (16 kDamdm/(16 kDamdm + 16 kDacell)) after densitometry. Four sets
of data from two independent experiments are represented on the graphs (* p<0.05
when comparing secretion rate in sh-µ1A wt with N.I.wt and scr. wt cells using a
t-test; mdm, medium; B, basal; S, stimulated).
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Figure 2.7: PAM-1 trafficking is altered in sh-µ1A PAM-1 cells. (A) Diagram
showing the sites at which PAM-1 is cleaved in SGs (green arrow) and the cleavage
products created; endoproteolytic cleavage between PHM and PAL occurs more
frequently than cleavage between PAL and the transmembrane domain. (B, C) Left,
Western blots of non-infected (N.I.), scramble (scr.) and sh-µ1A PAM-1 cell extracts
using a PHM antibody (B) or a PAL antibody (C). Coomassie staining showed similar
amounts of protein among the three cell lines for each blot. Right, quantification of
the level of PHM (PHM/(PHM + PAM-1)) (B) and PAL (PALm/(PALm + PAM-1))
(C) using densitometry (n = 3 for the data shown; * p<0.05 from a t-test comparing
sh-µ1A values with N.I. and Scr.; no statistical difference was observed between N.I.
and scr.). (D - F) PAM-1 cells (scramble and sh-µ1A) were incubated in medium
containing [35S]Met/Cys for 20 min. PAM-1 cells were either collected 10 minutes
later (P) or chased for 0.5, 1 or 2 hours; medium was collected for each chase
time. Samples were immunoprecipitated with a PHM antibody and analyzed after
fractionation by SDS-PAGE and fluorography. (D) Films from two independent
experiments were densitized. (E) The stability of the newly synthesized PAM-1
was quantified with reference to the amount present after the pulse ([35S]PAM-
1chase/[35S]PAM-1pulse). (F) Total PHM synthesis (cells plus medium) from newly
synthesized PAM-1 was similar in scramble and sh-µ1A PAM-1 cells (([35S]PHMcell
+ [35S]PHMmdm)/[35S]PAM-1pulse).
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Figure 2.8: Regulated secretion of PHM is impaired in sh-µ1A PAM-1 cells. (A)
Left, Western blot showing the level of PHM secreted under basal and stimulated
conditions in non-infected (N.I.), scramble (scr.) and sh-µ1A PAM-1 cells. Right,
graph showing the secretion rate of PHM (PHMmdm/(PHMmdm + PHMcell)) after
densitometry. Four sets of data from two independent experiments are represented
on the graph. Boxed graph shows PHM secretion rate under basal conditions. (B)
Experimental paradigm for both scramble and sh-µ1A PAM-1 cells: identical wells
of cells were rinsed (R) and incubated with [35S]Met/Cys medium for 20 min (P).
Spent medium was collected and replaced by basal medium every hour for 4 hours,
except during the 2-3 h chase period, when well A received basal medium and well
B received secretagogue (stim., basal medium with 2 mM BaCl2). (C) Fluorograms
showing secretion of newly synthesized PHM purified by immunoprecipitation. (D)
Graph showing the ratio of newly synthesized PHM secreted under stimulated vs.
basal conditions during the 2-3h chase period (mdm, medium; B, basal; S, stimulated;
* p<0.05).
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Figure 2.9: The cytosolic domain of PAM (PAM-CD) interacts with the µ1A subunit
of AP-1A.
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Figure 2.9: (A) Amino acid sequence of the cytosolic domain of PAM. Phosphoryla-
tion sites are shown with asterisks. Gray rectangles show regions of PAM-CD which
do not alter PAM-1 trafficking upon deletion; striped rectangle shows region involved
in trafficking. The blue and black arrows mark residues 899 and 961, respectively. (B)
Yeast two-hybrid screen for interaction between PAM-CD and the medium subunits
of the AP family. Left set, yeast grown in absence of tryptophan and leucine. Right
set, yeast grown in absence of tryptophan, leucine and histidine. 3AT, 3-amino-1,2,4-
triazole, an inhibitor of histidine synthesis, was used to prevent false positive results.
The p53 and SV40 T Ag interaction served as a positive control. (C) Yeast two-hybrid
screen for interaction of wild-type and mutant PAM-CD with µ1A. Top set, growth
of yeast in absence of tryptophan and leucine. Middle and bottom sets, yeast grown
in absence of leucine, tryptophan and histidine in presence of increasing amounts
of 3AT (+: 0.25 mM 3AT; +++: 1 mM 3AT). Co-immunoprecipitation was used to
demonstrate an interaction of PAM-1 and the AP-1A complex in mouse pituitary
(D, E) and in PAM-1 AtT-20 cells (F, G). Tissue and cell lysates were prepared in
TMT, pH 6.4 to preserve the clathrin coat [229]. Mouse γ-adaptin antibody was used
to capture the AP-1A complex (D, F) and affinity-purified rabbit antibody directed
against the linker region between the PHM and PAL domains of PAM-1 was used
to immunoprecipitate PAM-1 (E, G); mouse and rabbit IgG were used as controls
for background. The amount of input analyzed represents 1/20th of the amount
of immunoprecipitate analyzed. Quantification of each blot revealed a significant
interaction between PAM-1 and AP-1A. I, input; B, bound; n = 4-6; *P<0.05.
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Figure 2.10: PAM luminal domain contribution to the PAM/AP-1 interaction. (A,
B) Co-immunoprecipitation of PAM and AP-1A was examined in AtT-20 cells
expressing PAM-1 or PAM-1 899s (PAM-1 lacking its cytosolic domain) as described
in Figure 2.9. Although it includes only 9 amino acids of the cytosolic domain,
PAM-1 899s co-immunoprecipitated with the γ-adaptin antibody (n=4) and γ-adaptin
co-immunoprecipitated with the PAM antibody. (C) pEAK Rapid cells transiently
expressing PAM-1 or PAM-1 899s were analyzed as described for AtT-20 cells.
Co-immunoprecipitation was observed using antibody to PAM (n=4).
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Figure 2.11: γ-adaptin and PAM-1 both concentrate in the TGN area in AtT-20 cells.
(A) Single color and merged images for γ-adaptin (FITC-anti-mouse) and TGN38
(Cy3-anti-rabbit) in PAM-1 AtT-20 cells. Scale bar, 10 µm. Linescan (white arrow
on merged image) showing relative fluorescence intensity; γ-adaptin and TGN38
strongly colocalized. Regions identified as Golgi, Intermediate, nucleus and tips
are shown. (B) Single color and merged images for γ-adaptin (FITC-anti-mouse)
and PAM-1 (C-terminus of PAM; Cy3-anti-rabbit) in PAM-1 AtT-20 cells. Scale
bar, 10 µm. Linescan (white arrow on merged image) showing relative fluorescence
intensity. Both γ-adaptin and PAM-1 concentrated at the Golgi region; PAM-1 was
also seen at the tips of the cells. Regions identified as Golgi, Intermediate and Tips
are shown. (C) Quantification of images stained for γ-adaptin (FITC-anti-mouse) and
POMC/ACTH (Cy3-anti-rabbit) in PAM-1 AtT-20 cells (Figure 2.1A). Ratio of Tip to
Golgi signals and Intermediate to Golgi signals are shown; when compared to Golgi
staining, γ-adaptin staining was not as concentrated at the tips as POMC/ACTH
staining. (n =10 cells; p < 0.0001).
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Figure 2.12: Steady state localization of POMC/ACTH, CPD and PAM-1 is altered
in sh-µ1A PAM-1 cells. Images from scramble and sh-µ1A PAM-1 cells were
quantified as described in Materials and Methods. (A) Images from cells stained
for GM130 (FITC-anti-mouse) and POMC/ACTH (Cy3-anti-rabbit) (Figure 2.2A).
The Tip/Golgi ratios did not differ (NS) but the Intermediate/Golgi ratio was lower
in sh-µ1A PAM-1 cells (n = 14-15 cells; p <0.001). (B) Images from cells stained
for GM130 (FITC-anti-mouse) and PAM (Cy3-anti-rabbit) (Figure 2.3A). As for
POMC/ACTH, the Tip/Golgi ratios did not differ, but the Intermediate/Golgi ratio
was lower in sh-µ1A PAM-1 cells (n = 19-37 cells; p < 0.005) (C) Images from cells
stained for GM130 (FITC-anti-mouse) and CPD (Cy3-anti-rabbit) (Figure 2.3B).
The Intermediate/ Golgi ratio was significantly increased in sh-µ1A PAM-1 cells
(n = 12-18 cells; p <0.0001). (D) Images from sh-µ1A PAM-1 cells transiently
transfected with a plasmid encoding mCherry-µ1A* were stained for CPD (FITC-
anti-mouse). The Intermediate/Golgi ratio was significantly decreased in transfected
sh-µ1A PAM-1 cells (n = 24-28 cells; p <0.0001).
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3.1 Abstract
The endocytic pathway is essential for the uptake of nutrients into cells. Endocytosed material
first enters early endosomes, where it can be routed to the plasma membrane, trans-Golgi
network (TGN) or lysosomes. Material to be recycled to the plasma membrane can travel
directly or indirectly, via recycling endosomes. The bulk of early endosomes then undergoes
a maturation process to become late endosomes and their cargo can either be recycled to the
TGN or degraded in lysosomes. Professional secretory cells produce peptides, which serve
as messengers to communicate between cells. Synthesized as inactive precursors, peptides
must undergo post-translational modifications in order to gain bioactivity. One of the peptide
modifications is catalyzed by peptidylglycine α-amidating monooxygenase 1 (PAM-1), a
membrane protein which generates an α-amide moiety at the C-terminus of peptides. Once
at the plasma membrane after exocytosis of peptides, PAM-1 is internalized in endosomes
from which it can be recycled to the TGN or degraded in lysosomes. The adaptor protein
1 complex (AP-1) is a cytosolic complex involved in the transport of cargo between the
TGN and endosomes and, in professional secretory cells, AP-1 mediates secretory granule
biogenesis and maturation. Because exocytosis is balanced with endocytosis, we explored
the function of AP-1 in the endocytic pathway of AtT-20 cells, a corticotrope tumor cell
line. AtT-20 cells stably expressing PAM-1 were infected with a lentivirus expressing a non-
target shRNA (scramble) or an shRNA against the medium subunit of AP-1A, µ1A (sh-µ1A)
to abrogate AP-1 function. Early and recycling endosomes concentrated above the Golgi
apparatus in sh-µ1A PAM-1 cells instead of being more widely distributed. Late endosomes
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were smaller in sh-µ1A PAM-1 cells compared with scramble PAM-1 cells, suggesting that
AP-1 controls endosome maturation. Cholesterol, transferrin and PAM-1 trafficking were
altered in sh-µ1A PAM-1 cells. Overall, AP-1 is not only a key player in the formation of
secretory granules, it plays a critical role in the endocytic pathway as well.
3.2 Introduction
The endocytic pathway performs a vital process in the uptake of nutrients, solute and lipids
and is used by viruses and bacteria to invade cells. Internalized material first enters early
endosomes (also named sorting endosomes), which are evenly distributed throughout the cell
and move toward the perinuclear region during maturation in most cells [230]. The early
endosomes consist of a tubular domain containing material to be recycled and a vacuolar
domain composed of proteins destined for endosomal maturation, recycling to the TGN and
eventually protein degradation in lysosomes. Recycling of cargo to the plasma membrane
can occur directly from early endosomes (regulated by Rab4 and Rab35) or indirectly, via
recycling endosomes (regulated by Rab11) [230]. Early endosomes undergo a maturation
process to become late endosomes, also known as multivesicular bodies, which can either
send material back to the TGN for recycling or fuse with lysosomes, the final step of the
endocytic pathway for digestion of macromolecules. Key maturation steps involve a drop
in pH, from pH 6.4 in early and recycling endosomes to pH 4.9 in lysosomes, along with
a switch in the associated small Rab GTPase (from Rab5 for early endosomes to Rab7 for
late endosomes). Endosomal maturation is a complex process involving the formation of
intraluminal vesicles along with a change in size, morphology, protein content and lipids
(Figure 3.1) [230].
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Endosomes move along microtubules, powered by a dynein or a kinesin motor. Dynein
brings cargo to the minus end of microtubules (from the cell periphery to the cell center)
while most kinesins bring cargo to the plus end of microtubules (from the cell center to the
cell periphery). The kinesin superfamily can be divided into 15 families containing between
one and eight members, referred to as KIFs [231]. Endosomes are connected to microtubules
by multiple cytosolic proteins including adaptor protein 1 (AP-1), which interacts with
microtubule associated protein 1a and KIF13A, a member of the kinesin 3 family [232, 233].
AP-1 belongs to the adaptor protein family, which is composed of five heterotetrameric
complexes, each of which drives a specific cellular transport step. AP-1 carries cargo between
the Golgi and endosomes and in secretory cells, AP-1 mediates secretory granule biogenesis
and maturation [234, 56, 196, 57, 235, 55]. AP-1 is composed of two large subunits (γ and
β1), a medium subunit (µ1) and a small subunit (σ1). Structural and knockout animal models
indicate that lack of any one subunit of the AP-1 complex affects the stability and function of
the remaining complex [117, 178, 183]. Work done on mouse embryonic fibroblasts isolated
from µ1A knockout mice and on HeLa cells transfected with siRNA targeting an AP-1 subunit
revealed that AP-1 plays a central role in protein sorting and early and recycling endosome
dynamics and distribution [178, 236]. In HeLa cells, Rab4b recruits AP-1 to the tubules of
early endosomal membranes [236] and KIF13A, which interacts with Rab11 along with AP-1,
is required to generate and transport tubules from early endosomes to recycling endosomes
[237]. KIF13A colocalizes with several markers identified on recycling endosomes and the
tubular structures of early endosomes, and does not colocalize with EEA1, a Rab5 effector of
the vacuolar domain of early endosomes (Figure 3.1) [237].
Peptides are first synthesized as inactive precursors which undergo a maturation process
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driven by a set of enzymes in order to become bioactive. Neuroendocrine cells store peptides
in secretory granules until a stimulus triggers their secretion. Secretion of the stored peptides
results in the fusion of secretory granule membranes with the plasma membrane; retrieval of
the granule membrane proteins is accomplished through the endocytic pathway. Although
fibroblasts, HeLa cells and neurons have served as a good model to study the function of
AP-1 in the endocytic pathway, our knowledge of AP-1 function in the endocytic pathway
in neuroendocrine cells, which must retrieve granule membrane proteins for re-use in secre-
tory granules, is limited. Neuroendocrine cells produce several essential secretory granule
membrane proteins, one of which is the peptide amidating monooxygenase (PAM). PAM,
which acts late in the peptide biosynthetic pathway, is essential for life [238]. PAM-1, a
major splice variant, spans the membranes of secretory granules and endosomes (Figure 3.2).
When PAM-1 enters secretory granules, prohormone convertase 1/3 can cleave it, producing
soluble PHM (45 kDa) and PAL membrane (70 kDa, PALm) [12]. Although less frequent,
cleavage between PAL and the transmembrane domain produces soluble PAL (48 kDa) and
intermediate 1 (25 kDa), which includes the transmembrane and cytosolic domains of PAM
[214]. PAM-1 retrieved from the cell surface can traverse the endocytic pathway, return
to secretory granules and generate soluble PHM [195]. On the cell surface or within the
endocytic pathway, α-secretase-mediated cleavage closer to the transmembrane domain gen-
erates soluble PAM (PAMs) and intermediate 2 (~20 kDa) [214]. Lastly, γ-secretase cleaves
intermediates 1 and 2 within the transmembrane domain to generate a soluble fragment of
the cytosolic domain (sf-CD) that can enter the nucleus and alter gene expression [223, 214].
To investigate AP-1 function in the endocytic pathway and the trafficking of membrane
secretory granule proteins, the AtT-20 corticotrope tumor cell line stably expressing PAM-1
96
was stably infected, using a lentivirus expressing shRNA against the µ1A subunit of AP-1.
The global effects of reduced AP-1 function on the endocytic pathway were investigated first
and the endocytic trafficking of PAM-1 was evaluated next.
3.3 Results
3.3.1 Down-regulation of the medium subunit of AP-1 alters the localization
of early and recycling endosomes in AtT-20 cells stably expressing PAM-
1
AtT-20 cells stably expressing PAM-1 (PAM-1 cells) and infected with a virus encoding an
shRNA against the medium subunit of AP-1 (µ1A) (sh-µ1A cells) or encoding a non-target
shRNA as a control (scramble cells) were described previously [234]. Since AP-1 plays
key functions in early stages of the endocytic pathway, the location of early and recycling
endosomes was investigated. Members of the Rab family of small GTPases have served as
useful markers to distinguish between early and recycling endosomes. Each Rab exists in a
GDP-bound, cytosolic, inactive form plus a GTP-bound, membrane-associated, active form
[239].
Rab5 is recruited to early endosome membranes upon activation by Rabex-5, its GDP/GTP
exchange factor [240]. In order to visualize early endosomes, sh-µ1A and scramble PAM-1
cells were transiently transfected with a plasmid encoding fluorescently tagged Rab5 (mRFP-
Rab5). In scramble PAM-1 cells, mRFP-Rab5 formed a cluster near the nucleus along
with puncta evenly distributed throughout the cell (Figure 3.3A). In contrast, in sh-µ1A
PAM-1 cells, vesicles formed a cluster near the nucleus with few peripheral puncta. Staining
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for EEA1, another early endosomal marker, in embryonic fibroblasts prepared from µ1A
knockout mice also revealed an accumulation of EEA1 positive puncta near the nucleus
[178]. The formation of a cluster of Rab5 near the nucleus in scramble cells could be due to
the overexpression of this protein because it stimulates the association and motility of early
endosomes to the minus end of microtubules in vitro [241]. Altogether, our data suggest that
early endosome location in AtT-20 cells may be driven by a similar AP-1 dependent process
in AtT-20 cells and mouse embryonic fibroblasts.
Rab11 has been a useful marker for recycling endosomes [242]. Staining of scramble
and sh-µ1A PAM-1 cells with an antibody against endogenous Rab11 revealed puncta and
tubular structures along with diffuse staining (Figure 3.3B). The puncta and tubular structures
correspond to Rab11 bound to membranes whereas the diffuse staining derives from cytosolic
Rab11. While scramble PAM-1 cells contained Rab11-positive structures near the nucleus
along with a significant population of Rab11-positive vesicles distributed throughout the cell,
sh-µ1A PAM-1 cells contained a more pronounced cluster of Rab11-positive vesicles near
the nucleus. A similar phenomenon was also seen in the human melanoma cell line, MNT-1,
after the medium subunit of AP-1 had been knocked-down [186].
3.3.2 Cholesterol distribution is altered in sh-µ1A PAM-1 cells
Lack of µ1A in mouse embryonic fibroblasts alters cholesterol trafficking in the endocytic
pathway [243]. Two proteins involved in cholesterol trafficking in endosomes are Niemann-
Pick type C 1 (NPC1) and NPC2. NPC1, a lysosomal membrane protein, interacts with
AP-1 in order to be trafficked to lysosomes. NPC2, a soluble protein, traffics to lysosomes
via binding to the mannose-6-phosphate receptor, which requires AP-1 for proper transport.
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Cholesterol uptake is first characterized by entry into the endocytic pathway and exit from
lysosomes to go to the endoplasmic reticulum. In neuroendocrine cells, cholesterol is an
important component of secretory granule membranes and is required for their biogenesis
[244, 75]. Use of the dye BODIPY-CHOL allowed the visualization of cholesterol in live
cells in non-infected and sh-µ1A PAM-1 cells (Figure 3.3C). In non-infected PAM-1 cells,
cholesterol accumulated at the Golgi region, in vesicles surrounding the Golgi and at the tips,
where mature secretory granules accumulate. In sh-µ1A PAM-1 cells, cholesterol staining
was only concentrated in the Golgi area, with very few positively stained vesicles around the
Golgi. No cholesterol staining was seen at the tips of processes in sh-µ1A PAM cells. These
data suggested that AP-1 is also required for cholesterol transport in AtT-20 cells.
3.3.3 Trafficking of transferrin is perturbed in sh-µ1A PAM-1 cells
Transferrin, which brings iron into cells, has been widely used to probe endocytic trafficking
[245, 246]. Apo-transferrin binds more weakly to the transferrin receptor than Fe3+-loaded
transferrin. Once the complex is formed, it is rapidly internalized into early endosomes, where
the acidic pH is sufficient to dissociate Fe3+ from transferrin but not transferrin binding to its
receptor. Transferrin and its receptor are either targeted back to the plasma membrane directly
or via recycling endosomes. The neutral pH of the extracellular compartment promotes
apo-transferrin dissociation from its receptor to collect more iron (Figure 3.1). Fluorescently-
tagged transferrin is thus a good marker for both early and recycling endosomes.
Scramble and sh-µ1A PAM-1 cells were incubated with 25 µg/mL Alexa fluor 546
transferrin for 10 minutes before fixation (Figure 3.4). In scramble PAM-1 cells, puncta of
Alexa fluor 546 transferrin were seen distributed throughout the cell, with some accumulation
99
in the perinuclear region, which could correspond to recycling endosomes. On the other hand,
in sh-µ1A PAM-1 cells, puncta of Alexa fluor 546 transferrin were clearly accumulated near
the nucleus. These data, along with the staining of Rab5 and Rab11, suggested that early and
recycling endosomes form clusters near the nucleus and that endocytic protein trafficking is
perturbed in sh-µ1A PAM-1 cells. Knock-down of AP-1 function in HeLa and MNT-1 cells
resulted in a similar accumulation of internalized transferrin near the nucleus [186, 236].
3.3.4 Early endosome transport on microtubules is altered in sh-µ1A PAM-1
cells
During maturation, endosomes are transported along microtubules. Since AP-1 interacts
directly and indirectly with the kinesins involved in early and recycling endosome function,
we hypothesized that the change in early and recycling endosomal location was due to changes
in plus-end directed microtubule transport [232, 247]. In order to test this hypothesis, we
treated scramble and sh-µ1A PAM-1 cells for a short time with a low dose of nocodazole,
a microtubule destabilizing agent; this approach has been shown previously to prevent the
accumulation of early and recycling endosomes near the nucleus [39]. Uptake of Alexa
fluor 546 transferrin was used to monitor the effect of nocodazole (Figure 3.4). As expected,
treatment of scramble PAM-1 cells with nocodazole resulted in the dispersion of Alexa
fluor 546 transferrin puncta. However, the effect of nocodazole on sh-µ1A PAM-1 cells
was much more dramatic. Alexa fluor 546 transferrin puncta no longer accumulated in the
perinuclear region; instead, puncta were broadly distributed throughout the cell. These data
clearly demonstrated that early and recycling endosome location in AtT-20 cells is both
microtubule and AP-1 dependent; our data suggest that sh-µ1A PAM-1 cells exhibit a deficit
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in kinesin-mediated endosomal transport.
3.3.5 The endocytic trafficking of PAM-1 is altered in sh-µ1A PAM-1 cells
Internalized transferrin revealed an AP-1 dependent change in distribution (Figure 3.4),
suggesting that the trafficking of additional proteins might be altered. The key function of
neuroendocrine cells is to provide sufficient amounts of bioactive peptides when needed. After
fusion at the plasma membrane, secretory granule membrane proteins are rapidly internalized
into the endocytic pathway, where they can either be degraded or recycled to the secretory
granules via the TGN. The amidating enzyme, PAM-1, is a type I transmembrane protein
spanning the membranes of secretory granules and endosomes [195]. PAM-1 trafficking
in the regulated secretory pathway requires AP-1, but it remains unknown whether AP-1
also controls PAM-1 routing within the endocytic pathway [234]. To investigate PAM-1
trafficking in the endocytic pathway, PAM-1 antibody and Alexa fluor 546 transferrin were
added to the medium and cells were fixed after a 10 minute pulse. Internalized PAM-1 was
distributed in vesicles throughout the cells and commenced to accumulate in the perinuclear
region in scramble PAM-1 cells (Figure 3.5). According to the Bäck et al. study, PAM-1
starts to accumulate in late endosomes after 10 minutes, suggesting that the perinuclear
concentration of PAM-1 in scramble cells could correspond to late endosomes. In sh-µ1A
PAM-1 cells, PAM-1 accumulated in the perinuclear region (Figure 3.5). Internalized PAM-
1 strongly overlapped with Alexa fluor 546 transferrin in both cell lines, suggesting that
most internalized PAM-1 is in early endosomes and possibly in recycling endosomes too.
These data suggested that changes in PAM-1 and transferrin trafficking were similar. Using
electron microscopy, after a 20 minute incubation of AtT-20/PAM-1 cells in gold-labeled
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PAM antibody, internalized PAM antibody accumulated in late endosomes in both cell lines
(Figure 3.6). However, internalized PAM antibody was also visualized in small vesicles near
the Golgi apparatus in sh-µ1A PAM-1 cells; this was not observed in scramble PAM-1 cells
(Figure 3.6B). The exact nature of these vesicles is unknown, but could correspond to vesicles
targeted toward the TGN for recycling.
3.3.6 Down-regulation of the medium subunit of AP-1A in PAM-1 cells alters
endosome maturation
Because the location of early endosomal compartments and the trafficking of transferrin in
the endocytic pathway were perturbed when AP-1 function was reduced, we hypothesized
that endosome maturation might also be altered. Late endosomes, or multivesicular bodies,
are characterized by intraluminal vesicles contained in spherical organelles with sizes ranging
from 250 to 1000 nm. In previous studies, the endocytic trafficking of PAM-1 in AtT-20 cells
was characterized using transmission electron microscopy to follow the uptake of gold-tagged
PAM-1/antibody complexes [195]. The same approach was used to compare the endocytic
trafficking of PAM-1 in scramble and sh-µ1A PAM-1 cells. Late endosomes appeared small
and irregular in shape in sh-µ1A PAM-1 cells, suggesting that reduced AP-1 function altered
endosome maturation (Figure 3.6, red arrows). Late endosomes fuse with lysosomes to
form endolysosomes and allow protein degradation. Lysosomes are irregular in shape, with
electron dense material on the edges in scramble PAM-1 cells, while they appeared smaller
and more rounded in sh-µ1A PAM-1 (Figure 3.6).
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3.3.7 The cytosolic domain of PAM-1 is no longer phosphorylated at Ser949 in
sh-µ1A PAM-1 cells.
The cytosolic domain of PAM-1 controls its trafficking within the biosynthetic and endocytic
pathways. Casein kinase II and P-CIP2/KIS/Uhmk1 phosphorylate Ser949, generating a
small acidic cluster near the C-terminus of PAM-1 [38, 39]. Phosphorylation at Ser949
promotes entry into secretory granules from the TGN but slows down PAM-1 recycling
from endosomes to TGN [195, 39]. In order to measure the levels and distribution of
PAM-1 phosphorylated at Ser949 in scramble and sh-µ1A PAM-1 cells, an antibody that
specifically recognizes phosphorylated Ser949 was used. As a positive control, we used AtT-20
cells stably expressing PAM-1, where T946S949 have been mutated into D946D949 (PAM-1
TS/DD) to mimic phosphorylation. Previous work established that the PAM-1 TS/DD mutant
protein was seemingly stuck in endosomes and was detected by the phosphospecific antibody;
dephosphorylation of these sites in PAM-1 seemed essential to the completion of endocytic
trafficking [39]. Scramble and sh-µ1A PAM-1 cells were co-stained with the rabbit antibody
that recognizes pSer949 and a mouse monoclonal antibody that targets the C-terminus of PAM-
1 representing total PAM-1 (Figure 3.7A). In scramble PAM-1 cells, the pSer949 distribution
was perinuclear and colocalized with the other PAM-1 antibody. Surprisingly, sh-µ1A PAM-1
cells were devoid of signal when visualized using the pSer949 antibody, suggesting that
phosphorylation of Ser949 was reduced in sh-µ1A PAM-1 cells or that PAM-1 phosphorylated
at Ser949 was more dispersed in the cells. To find out if the reduced PAM-1 pSer949 signal
were due to a reduction in the level of PAM-1 phosphorylated at this site, cell extracts from
AtT-20 cells stably expressing PAM-1 TS/DD, scramble and sh-µ1A PAM-1 cells were
collected and analyzed by Western blot (Figure 3.7B). The signal from the antibody that
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recognizes the C-terminus of PAM-1 independent of PAM-1 phosphorylation status indicated
that scramble and sh-µ1A PAM-1 cells had a similar amount of PAM-1, while the levels of
PAM-1 phosphorylated at Ser949 in sh-µ1A PAM-1 cells were significantly lower than in
scramble PAM-1 cells.
PAM-1 is subject to endoproteolytic cleavage in both secretory granules and in the
endocytic pathway; the cleavage products produced in secretory granules and endosomes
differ. We demonstrated previously that the levels of PAM-1 secretory granule products
(PALm and soluble PHM) were lower in sh-µ1A PAM-1 cells compared with scramble
PAM-1 cells (Figure 3.7B), confirming previous results [234]. Production of sPAM and
Intermediate 2 is largely limited to the endocytic pathway. Levels of intermediate 2, a PAM-1
processed product generated upon cleavage by α-secretase in endosomes, were lower in
sh-µ1A PAM-1 cells than in scramble PAM-1 cells (data not shown). These data along with
the PAM-1 antibody uptake experiment demonstrate that PAM-1 endocytic trafficking has
changed in sh-µ1A PAM-1 cells.
3.3.8 Recycling of PAM-1 from the endocytic pathway to secretory granules
is enhanced in sh-µ1A PAM-1 cells
A study done on AtT-20 cells stably expressing PAM-1 TS/DD showed that PAM-1 recycling
from endosomes to secretory granules was reduced [195]. Because PAM-1 is less phospho-
rylated at Ser949 in sh-µ1A PAM-1 cells than in scramble PAM-1 cells, this suggested that
PAM-1 might be more efficiently recycled to the biosynthetic pathway. Biotinylation, an
irreversible means of tagging proteins on the cell surface, makes it possible to measure the
fate of a given protein that has reached the plasma membrane. Scramble and sh-µ1A PAM-1
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cells were biotinylated for 10 min at 37◦C and chased for 1 hour or for 4 hours. At the end of
each time point, cell extracts and media were collected, and biotinylated PAM-1 protein levels
were evaluated by western blot (Figure 3.8, top graph). In both scramble and sh-µ1A PAM-1
cells, PAM-1 was degraded at a similar rate. Treatment of scramble and sh-µ1A PAM-1 cells
with cycloheximide, which prevents protein synthesis, did not show any difference in the
degradation rate of PAM-1, confirming the conclusions drawn with biotin (data not shown).
PHM is only generated from PAM-1 by endoproteases that are in secretory granules
(Figure 3.2), meaning that biotinylated PAM-1 that is recycled from endosomes to secretory
granules is characterized by the formation of soluble biotinylated PHM. Biotinylated PHM
levels were measured in the cell extracts and the medium after a 1 hour and a 4 hour chase. sh-
µ1A PAM-1 cells generated more biotinylated PHM than scramble PAM-1 cells, suggesting
that, in sh-µ1A PAM-1 cells PAM-1 was more recycled to secretory granules than in scramble
PAM-1 cells (Figure 3.8, middle graph). In addition, soluble PHM was more evident in the
medium of sh-µ1A PAM-1 cells than of scramble PAM-1 cells after 4 hours of chase (Figure
3.8, bottom graph), confirming previous results where PHM basal secretion was increased
[234].
3.4 Discussion
Internalized transferrin trafficking and distribution of early and recycling endosomes is
similarly affected between HeLa, fibroblasts and AtT-20 cells where AP-1 function has been
reduced, suggesting that the endocytic machinery is similar between different cell types.
Surprisingly, the secretory granule membrane protein PAM-1 is recycled to the TGN faster in
sh-µ1A PAM-1 cells. Because neuroendocrine function is to produce, store and then release
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bioactive peptides upon addition of secretagogues, the endocytic trafficking of secretory
granule membrane proteins may be very specialized to prevent trapping of essential secretory
granule membrane proteins in the endocytic pathway.
3.4.1 The cellular location of early endosomes in AtT-20 cells is dependent on
AP-1
Reducing the function of AP-1 in AtT-20 cells resulted in the formation of a cluster of
early endosomes. This is similar to the study in mouse embryonic fibroblasts lacking µ1A
expression and in HeLa cells transfected with an siRNA against γ-adaptin, a subunit of AP-1
[178, 236]. The connection between AP-1 and early endosomes is cell type specific, however,
because MNT-1 cells lack colocalization between AP-1 and EEA1, and reducing AP-1
function in these cells does not perturb the distribution of early endosomes [186]. Treatment
of AtT-20 cells with nocodazole prevented the formation of the perinuclear cluster in sh-µ1A
PAM-1 cells, suggesting that the transport of early endosomes on microtubules is prevented
when µ1A levels are reduced. Although in vitro studies have shown that kinesin 1 (KIF5A,
KIF5B, KIF5C) and kinesin 2 (KIF3A, KIF3B, KIF3C and KIF17) families interact with early
endosomes, studies done in the fungus Ustilago maytis (KIF1A-like), HeLa cells (KIF16B)
and Drosophila S2 cells (KIF1A-like) pointed to a role for the kinesin 3 family (KIF1A,
KIF1B, KIF1C, KIF13A, KIF13B, KIF14, KIF16A and KIF16B) [248, 249, 250, 251].
Endosomes are connected to microtubules by an interaction between AP-1 and the kinesin 3,
KIF13A [237, 232]. Overexpression of KIF13A redistributed mannose-6-phosphate receptor
and AP-1 to the periphery, instead of localizing near the nucleus in MDCK cells [232]. In line
with this observation, reducing KIF13A levels in MNT-1 cells, a human melanoma cell line
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where AP-1 distribution is normally evenly spread in vesicles throughout the cells, resulted
in accumulation of AP-1 near the nucleus [186]. It was recently proposed that KIF13A is
necessary to generate tubular structures from early endosomes which will be targeted to the
recycling endosomes in HeLa cells [237]. It would be interesting to find out whether AP-1
connects early endosomes to KIF13A in AtT-20 cells.
3.4.2 The cellular location of recycling endosomes in AtT-20 cells is dependent
on AP-1
Loss of AP-1 function also resulted in accumulation of recycling endosomes near the nu-
cleus in MNT-1, HeLa and AtT-20 cells [186]. In HeLa cells, AP-1 interacts with the
S-palmitoylated protein, Gadkin (γ-adaptin and kinesin interactor), which then binds the
kinesin 1 KIF5C to transport TGN-derived endosomal recycling vesicles to the cell periphery
[247]. Overexpression of Gadkin in HeLa cells resulted in accumulation of Gadkin, AP-1
and several markers of recycling endosomes (transferrin, transferrin receptor, Rab11 and
mannose-6-phosphate receptor) to the cell periphery, but did not alter the distribution of
EEA1 positive vesicles [247]. Depletion of AP-1 or kinesin 1 prevented endosomal vesicles
containing transferrin from locating to plus-end of microtubule tracks in HeLa cells [247].
This is consistent with our results in AtT-20 cells where reducing AP-1 function resulted in
perinuclear accumulation of Rab11 positive organelles.
3.4.3 Endosome maturation requires AP-1 to sort proteins out
Sh-µ1A PAM-1 cells had smaller and irregularly shaped late endosomes and lysosomes
compared with scramble PAM-1 cells. KIF13A was proposed to form the tubular domains
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of early endosomes to sort out proteins in recycling endosomes. When KIF13A levels are
diminished, transferrin is found in late endosomes of HeLa cells, suggesting a problem in
protein sorting and an alteration of endosome maturation [237]. In addition, Rab4b was shown
to interact with the γ-subunit of AP-1 to promote transferrin sorting from early endosomes
to recycling endosomes [236]. Down-regulation of AP-1 levels inhibited the slow recycling
pathway to the advantage of the fast recycling pathway in HeLa cells [236, 247]. It remains
unknown if transferrin fast recycling is more prominent in sh-µ1A PAM-1 cells than in
scramble PAM-1 cells.
3.4.4 AP-1 is required for protein sorting in the endosomes of AtT-20 cells
One of the first indications that AP-1 was essential for protein sorting in endosomes came from
studies of both types of mannose-6-phosphate receptors, which were trapped together in the
endocytic pathway; these proteins bind mannose-6-phosphate groups that are located on the
surface of lysosomal proteins, allowing receptor mediated sorting and transport to lysosomes
[178]. Cathepsin D, a soluble protease driven to lysosomes by mannose-6-phosphate receptor,
is re-routed to the secretory pathway in the absence of AP-1 [178]. Similarly, cholesterol
transport and the distribution of Niemann Pick type C protein 2, an important protein for
cholesterol transport in lysosomes that interacts with mannose-6-phophate receptor, are
altered in µ1A knockout fibroblasts [243]. The tips of AtT-20 cells accumulate secretory
granules whose membrane is enriched in cholesterol. Live cell imaging of cholesterol
showed accumulation at the tips of non-infected PAM-1 cells but not in sh-µ1A PAM-1
cells, indicating a change in how cholesterol is handled and agreeing with the study on µ1A
knockout fibroblasts.
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Although both PAM-1 and mannose-6-phosphate receptors interact with AP-1 [234,
252, 90], PAM-1 transport from endosomes to the TGN was increased in sh-µ1A PAM-1
cells. PAM-1 trafficking is driven by both its luminal domain and by the phosphorylation
status of its cytosolic tail. Using PAM-1 phosphomimetic mutants, it was observed that
PAM-1 TS/DD (Thr946Ser949 -> Asp946Asp949) does not enter intraluminal vesicles of late
endosomes and is not recycled to the TGN as efficiently as PAM-1 TS/AA (Thr946Ser949 ->
Ala946Ala949), where phosphorylation events are prevented [195]. Using an antibody that
recognizes phosphorylated Ser949, sh-µ1A PAM-1 cells are quite deficient in phosphorylation
at this site compared with scramble PAM-1 cells, agreeing with the increased recycling
event from endosomes to secretory granules seen in sh-µ1A PAM-1 cells. Why Ser949 is
less phosphorylated when µ1A levels are reduced remains to be explored. Ser949 can be
phosphorylated by casein kinase II or Uhmk1. Phosphofurin Acidic Cluster Sorting protein 1
(PACS-1) interacts with casein kinase II, acidic clusters found on the cytosolic domain of
cargo proteins and AP-1. PACS-1 recruitment to membranes is enhanced once the cargo has
been phosphorylated by casein kinase II. PAM-1 contains an acidic cluster at its C-terminus
which could interact with PACS-1, and then recruit casein kinase II. In the case of furin, it
is known that furin, PACS-1 and AP-1 work in concert to drive the trafficking of furin. The
complex of casein kinase II/PACS-1 might be misplaced in sh-µ1A PAM-1 cells, resulting in
a decrease of PAM phosphorylation.
In conclusion, AP-1 is a key cytosolic complex involved in protein sorting, as well as
early and recycling endosomal localization and function. Because exocytosis is coupled
with endocytosis, this study had the goal to investigate the effects of AP-1 on the endocytic
pathway and compare the consequences of reduced AP-1 function with other cell lines.
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Overall, most of AP-1 functions described in the literature comes from studies done with
fibroblasts and other cell types that are not specialized for regulated secretion. AP-1 functions
identified in AtT-20 cells were similar, suggesting a conserved mechanism. It would be
important to find out if the transport of secretory granule membrane proteins is cell-type and
protein specific.
3.5 Materials and methods
3.5.1 Tissue culture and generation of scramble and sh-µ1A PAM-1 cells
AtT-20 cells were grown at 37◦C with 5% CO2 in Dulbecco’s modified Eagle’s medium/F-12
(DMEM/F-12) containing 25 mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin,
10% fetal bovine serum, 10% NuSerum. AtT-20 cells stably expressing PAM-1 were described
previously [188]. Generation of sh-µ1A and scramble PAM-1 AtT-20 cells using lentivirus
targeted to µ1A (Sigma; clone ID TRCN0000111549) and a non-target shRNA (Sigma #
SHC002V), respectively, was described previously [234].
3.5.2 Transfection with mRFP-Rab5
Scramble and sh-µ1A PAM-1 cells were plated in 4-well dishes on 12-mm round coverslip
(0.16 to 0.19 mm thick, Fisher Scientific) coated with 0.1 mg/ml poly-L-lysine for 5 minutes
followed by a rinse in NuSerum and two rinses in AtT-20 growth medium. Two days later,
cells were incubated in serum free medium for 30 minutes before being transfected (0.25
µg DNA/well); the Lipofectamine 2000 R© and pmRFP-Rab5 (Addgene, plasmid 14437)
were mixed in Optimem (Optimem:DNA:Lipofectamine 2000 R© = 200 µl:1 µg: 2.5 µl) and
allowed to sit for 25 minutes. After application of the mixture, cells were incubated at 37◦C
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for 6 hours. Transfection medium was then replaced with growth medium and the cells were
allowed to recover overnight. Cells were fixed the following day in 4% formaldehyde in PBS
and immunostained as described above.
3.5.3 Immunofluorescent staining
Cells were plated on coverslips coated as described above. Cells were fixed in 4% formalde-
hyde in PBS (50 mM NaH2PO4, 150 mM NaCl, pH 7.4) for 20 minutes at room temperature.
After rinsing in PBS, cells were permeabilized in 0.075% Triton X-100, 2 mg/ml BSA in
PBS for 20 minutes at room temperature and then incubated in block (2 mg/ml BSA in PBS)
for 20 minutes at room temperature. Primary antibodies diluted in block were incubated with
the cells overnight at 4◦C. After three rinses in PBS, cells were incubated for one hour at
room temperature in block containing either fluorescein isothiocyanate (FITC, 1:500 dilution)
or Cy3 (1:2000 dilution) conjugated donkey antibody to mouse or rabbit immunoglobulin
(Jackson ImmunoResearch). After three rinses in PBS, cells were incubated with Hoechst
(1:1000 dilution in PBS) for 10 minutes at room temperature. After three rinses in PBS, cells
were mounted using ProLong R© Gold (Invitrogen).
3.5.4 Cell treatment
Cells were incubated in DMEM/F-12 air medium containing 25 mM HEPES, pH 7.4, 1 mg/ml
BSA for 30 minutes at 37◦C without CO2. For transferrin uptake experiments, cells were
then incubated in DMEM/F-12 air medium containing 25 mM HEPES, pH 7.4, 1 mg/ml BSA,
25 µg/mL Alexa fluor 546 transferrin (Life Technologies) for 10 minutes at 37◦C without
CO2. Cells were fixed using 4% formaldehyde in PBS for 20 minutes at room temperature.
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For nocodazole treatment experiments, cells were treated as described above and treated with
DMEM/F-12 air medium containing 10 µM nocodazole (Sigma) or the equivalent volume
of DMSO for 20 minutes at 37◦C without CO2. For the PAM antibody uptake experiment,
PAL antibody was diluted at 1:50 in medium and added onto the cells for 10 minutes at 37◦C
before fixation.
3.5.5 Cholesterol uptake
BODIPY-cholesterol uptake was done as described previously [253]. Briefly, one day after
plating, non-infected and sh-µ1A PAM-1 cells were incubated in lipid depleted medium
containing 1 µM of BODIPY-cholesterol overnight, then live cells were photographed with a
Leica TCS CARS SP8 confocal microscope equipped with a 37◦C chamber.
3.5.6 Electron microscopy
PAM antibody uptake at the electron microscope level was done as described previously [195].
Briefly, for colloidal gold labelling, cells were incubated with exon 16 antibody (JH629,
1:250) in DMEM-Hepes-2 mg/ml BSA for 1 h at 4◦C, rinsed with DMEM-Hepes-BSA at
4◦C, incubated in DMEM-Hepes with protein A-15 nm colloidal gold (University of Utrecht,
Utrecht, Netherlands) at the concentration suggested for immunolabeling by the provider
(1:60-75) for 1 h at 4◦C, rinsed in DMEM-Hepes at 4◦C and then chased in culture medium
at 37◦C for 20 minutes. Control cells were incubated with protein A-colloidal gold only.
After the chase, cells were fixed with 2.5% glutaraldehyde and 2% sucrose in 0.1 M sodium
cacodylate buffer, post-fixed with 1% osmium tetroxide and 1.5% potassium ferrocyanide,
dehydrated and embedded in Epon. Sections were poststained with uranyl acetate and lead
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citrate.
3.5.7 Biotinylation stabilization paradigm
AtT-20 cells plated in a 12-well plate were first incubated for 30 minutes in DMEM/F-12 air
medium containing ITS, 25 mM HEPES, pH 7.4, 100 µg/ml BSA. Cells were equilibrated
in air medium during two consecutive 30 minute incubations at 37◦C without CO2. Cells
were then rinsed with warm HSG buffer (15 mM HEPES, 120 mM NaCl, 2 mM CaCl2, 4
mM KCl, 25 mM glucose, pH 7.4). A solution containing 1.25 mM sulfo-NHS-LC-biotin
(Thermo Scientific) in HSG buffer was made fresh and added to the cells for 10 minutes at
37◦C. After removing the biotin solution, cells were rinsed twice for 5 minutes with CSFM-
air containing 2 mg/ml BSA at 37◦C. Cells were either collected directly using TMT (20
mM Na N-Tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid (TES), 10 mM mannitol,
1% Triton X-100, pH 7.4) containing a cocktail of protease inhibitors (final concentrations
0.34 mg/ml phenylmethylsulfonyl fluoride, 50 µg/ml lima bean trypsin inhibitor, 2 µg/ml
leupeptin, 16 µg/ml benzamidine, and 2 µg/ml pepstatin) or were incubated at 37◦C with
air medium for 1 hour or 4 hours before extraction. Cells were solubilized in TMT for 30
minutes at 4◦C. Cell extracts were collected into microfuge tubes and centrifuged at 22,000 g
for 15 minutes at 4◦C. Solubilized cell extracts were then incubated with Streptavidin-agarose
beads for 1 hour at 4◦C. Beads were rinsed twice with TMT and once with TM (no Triton
X-100). The bound fraction was eluted into Laemmli sample buffer by heating the samples
for 5 minutes at 95◦C.
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3.6 Tables
Antigen Working dilution Identity, source
C-STOP, PAM-1(965-976) 1:1000 C-stop [223]
Exon 16, PAM-1(409-497) 1:1000 JH629 [224]
C-terminus, PAM-1 (898-976) 1:10 6E6 [189]
PAL, PAM-1(498-604) 1:50 (uptake) JH877 [77]
pSer949, PAM-1 (942-953) 1:500 JH2541 [39]
Rab11 1:250 Millipore
Table 3.1: List of antibodies.
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3.7 Figures
Figure 3.1: Diagram of the endocytic pathway. Internalized material first reaches
early endosomes (EE), which sort proteins that can be recycled either directly to the
plasma membrane (mediated by Rab4a) or indirectly via recycling endosomes (RE).
The bulk of early endosomes not recycled undergo a maturation process characterized
by the formation of late endosomes (or multivesicular bodies, MVB). Proteins can
be degraded in lysosomes or recycled back to the Golgi. According to the literature,
AP-1 is present on early and recycling endosomes, where it connects multiple proteins
to microtubules and endosomes.
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Figure 3.2: PAM processing in the regulated secretory pathway vs. the endocytic
pathway. In secretory granules, PAM-1 can be cleaved between the two catalytic
core domains, PHM and PAL by prohormone convertase 1/3 (PC1/3) to produce
soluble PHM and PAL membrane (PALm). Although less frequent, a second cleavage
occurs between PAL and the transmembrane domain generating soluble PAL and
intermediate 1. Soluble PAM-1 formation involves α-secretase mediated cleavage
between PAL and the transmembrane domain; the other product from this cleavage is
intermediate 2. Intermediates 1 and 2 are then cleaved by γ-secretase to generate the
soluble fragment of the cytosolic domain (sf-CD).
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Figure 3.3: The endocytic pathway of sh-µ1A PAM-1 cells is altered. (A) Scramble
and sh-µ1A PAM-1 cells were transiently transfected with mRFP-Rab5 in order to
visualize early endosomes (see Figure 3.1). Scramble PAM-1 cells contained Rab5
positive vesicles distributed throughout the cells along with a concentrated group
near the nucleus while sh-µ1A PAM-1 cells only contained vesicles clustered near
the nucleus. (B) Scramble and sh-µ1A PAM-1 cells were immunostained for Rab11
(Cy3 anti-rabbit), a marker of recycling endosomes (see Figure 3.1). Rab11 was
more concentrated near the nucleus in sh-µ1A PAM-1 cells than in scramble PAM-1
cells. (C) BODIPY-cholesterol, a dye allowing the visualization of cholesterol in live
cells, was applied onto non-infected PAM-1 cells and sh-µ1A PAM-1 cells. BODIPY-
CHOL accumulated in vesicles near the Golgi and at the tips of scramble PAM-1 cells
while sh-µ1A PAM-1 cells were devoid of signal at the tips and BODIPY-cholesterol
formed less dispersed clusters near the nucleus. Scale bar, 10 µm.
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Figure 3.4: Trafficking of internalized transferrin is altered in sh-µ1A PAM-1 cells.
Top, scramble and sh-µ1A PAM-1 cells were incubated with 25 µg/mL Alexa fluor
546 transferrin for 10 minutes at 37◦C before fixation. Internalized transferrin formed
a cluster of vesicles near the nucleus in sh-µ1A PAM-1 cells while transferrin positive
vesicles were evenly distributed throughout scramble PAM-1 cells. Bottom, treatment
with nocodazole prior to transferrin uptake dispersed transferrin positive vesicles in
both cell lines, indicating that transferrin trafficking on microtubules was altered in
sh-µ1A PAM-1 cells. Scale bar, 10 µm.
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Figure 3.5: Internalization of PAM-1 is altered in sh-µ1A PAM-1 cells. Scramble
and sh-µ1A PAM-1 cells were incubated with PAL antibody (1:50 dilution) and 25
µg/mL Alexa fluor transferrin 546 for 10 minutes at 37◦C before fixation. Cells were
permeabilized and secondary antibody (FITC anti-rabbit) was added to examine the
distribution of internalized PAM that was bound to PAL antibody. Strong colocal-
ization between PAM/Antibody complex and transferrin was seen in both cell lines.
PAM distribution resembled that of transferrin in each cell line. Scale bar, 10 µm.
119
Figure 3.6: Internalized PAM is located in multivesicular bodies and in small vesicles
near the Golgi in sh-µ1A PAM-1 cells. Scramble (A) and sh-µ1A (B) PAM-1 cells
were incubated with Exon 16 antibody linked to gold particles for 20 minutes at
37◦C before fixation and visualization under TEM. Gold particles were identified in
multivesicular bodies (red arrows) in both cell lines. Sh-µ1A PAM-1 cells contained
a lot of gold particles in small vesicles near the Golgi complex (yellow arrows).
Gold particles were also seen in lysosomes of sh-µ1A PAM-1 cells (green arrow).
Multivesicular bodies appeared smaller and lysosomes were more rounded in sh-µ1A
PAM-1 cells than in scramble PAM-1 cells.
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Figure 3.7: Ser949 of PAM-1 cytosolic domain is less phosphorylated in sh-µ1A
PAM-1 cells. (A) Indirect immunostaining of AtT-20 cells stably expressing PAM-1
TS/DD (TS/DD), scramble and sh-µ1A PAM-1 cells using a PAM antibody which
targets the cytosolic tail (FITC-anti-mouse) and a PAM antibody which recognizes
PAM cytosolic tail only when Ser949 is phosphorylated (Cy3-anti-rabbit). TS/DD
served as a positive control. PAM-1 phosphorylated at Ser949 concentrated at the
Golgi of scramble PAM-1 cells. Although sh-µ1A PAM-1 cells express PAM-1,
pSer949 antibody failed to reveal a signal at the Golgi; the image shown for sh-µ1A
was exposed for a longer time than the images shown for scramble cells. Scale bar,
10 µm. (B) Western Blot analysis looking at phosphorylated Ser949 levels (left) or
an antibody which targets the C-terminus of PAM-1 independent of phosphorylation
(right) in TS/DD, scramble and sh-µ1A PAM-1 cells. The same volume of cell
homogenates was loaded for both blots. Levels of pSer949 in sh-µ1A PAM-1 cells
were considerably lower than in scramble PAM-1 cells.
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Figure 3.8: Biotinylated PAM-1 is more recycled to secretory granules in sh-µ1A
PAM-1 cells than in scramble PAM-1 cells. (A) Scramble and sh-µ1A PAM-1 cells
were treated with cell-impermeant activated biotin for 10 minutes at 37◦C and then
harvested immediately or chased for 1 or 4 hours. Media were collected after the
1 and 4 hour chase incubations. Biotinylated PAM proteins recovered from cells
and media were analyzed by Western blot. (B) Quantification of PAM-1 levels
over time indicated that the PAM-1 degradation rate was similar between scramble
and sh-µ1A PAM-1 cells. (C) Quantification of biotinylated PHM obtained after
cleavage of biotinylated PAM-1 in secretory granules was quantified. At 4 hour chase,
more biotinylated PHM was generated in sh-µ1A PAM-1 cells than scramble cells.
(D) Bbiotinylated PHM obtained after cleavage of biotinylated PAM-1 in secretory
granules and secreted in the medium was quantified. At 4 hour chase, secreted
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4.1 Abstract
The adaptor protein 1 complex (AP-1), which transports cargo between the trans-Golgi
network and endosomes, is known to play a role in the trafficking of Atp7a, a copper-
transporting P-type ATPase, and peptidylglycine α-amidating monooxygenase (PAM), a
copper-dependent secretory granule membrane enzyme. Lack of any of the four AP-1
subunits is sufficient to impair function and patients with MEDNIK syndrome, a rare genetic
disorder caused by lack of expression of the σ1A subunit, exhibit clinical and biochemical
signs of impaired copper homeostasis. To explore the role of AP-1 in copper homeostasis
in neuroendocrine cells, we used corticotrope tumor cells in which AP-1 function was
diminished by reducing expression of its µ1A subunit. Cellular levels of copper and Atp7a
were unchanged when AP-1 function was impaired. When AP-1 function was reduced, more
internalized transferrin accumulated in the Golgi region, where much of the endogenous
Atp7a localized. Nocodazole treatment dispersed the internalized transferrin, revealing that
reducing AP-1 function increased the amount of endogenous Atp7a that co-localized with the
internalized transferrin. Impaired AP-1 function also led to a significant increase in the ability
of bathocuproine disulfonate, a cell impermeant Cu(I) chelator, to inhibit PAM function.
Atp7a localization continued to respond to increased copper levels when AP-1 function was
impaired; unlike fibroblasts and HeLa cells, little Atp7a appeared on the surface of pituitary
cells, even when copper levels were elevated. Co-immunoprecipitation of PAM with Atp7a
suggested direct transfer of copper from Atp7a to PAM.
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4.2 Introduction
Copper is required in several essential biological processes, including mitochondrial res-
piration, skin pigmentation, iron transport, connective tissue and blood vessel formation,
antioxidant defense, catecholamine synthesis and peptide amidation [254]. It is transported
into cells via copper transporter 1 (CTR1), transferred to a cytosolic chaperone and delivered
to its final destinations. The chaperone ATOX1 transfers copper to ATP7A and ATP7B,
P-type ATPases that transport the metal from the cytosol into the lumen of the secretory
pathway for incorporation into luminal cuproproteins. Luminal copper chaperones have not
been identified [255], and it has been proposed that a His/Met-rich luminal loop in ATP7A
plays an essential role in the delivery process [256, 215].
ATP7A, which is ubiquitously expressed, mediates copper uptake from the gut and
delivery in the brain, while ATP7B is expressed primarily in the liver and exports copper
into bile. Mutations in ATP7A result in Menkes disease, which is characterized by lack
of copper in most tissues, while mutations in ATP7B lead to Wilson disease, which is
associated with copper overload. MEDNIK (Mental retardation, Enteropathy, Deafness,
peripheral Neuropathy, Ichtyosis, Keratodermia) syndrome is a rare autosomal recessive
disorder characterized by symptoms of both Menkes and Wilson disease [254]. MEDNIK
syndrome is caused by mutations in the AP1S1A gene, which encodes σ1A, the small subunit
of the adaptor protein 1 complex (AP-1) [217]. This cytosolic complex is composed of
four subunits: two large subunits (γ and β1), a medium subunit (µ1) and a small subunit
(σ1). AP-1 drives the transport of proteins between the trans-Golgi network (TGN) and
endosomes; in neuroendocrine cells, it mediates secretory granule formation and maturation
[234, 168, 257].
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Ceruloplasmin, a copper-dependent secreted ferroxidase and the major carrier of copper
in serum, incorporates copper during its biosynthesis; lacking copper, apoceruloplasmin is
rapidly degraded in plasma [258]. In sera from MEDNIK patients, ceruloplasmin and total
copper levels are low while free copper levels are elevated, suggesting that copper delivery
to ceruloplasmin is impaired [254, 219]. Consistent with this, in fibroblasts from MEDNIK
patients, ATP7A is localized near the cell periphery instead of the Golgi region [219]. Lack
of any one AP-1 subunit impairs AP-1 function. Indeed, down-regulation of a different AP-1
subunit, µ1A, in HeLa cells also resulted in accumulation of ATP7A at the cell periphery and
the inability of ATP7A to concentrate in the Golgi region when copper levels were diminished
[220].
In neuroendocrine cells, ATP7A provides copper to peptidylgylcine α-amidating monooxy-
genase (PAM), an essential enzyme that requires copper to catalyze peptide amidation, one
of the final steps in the conversion of inactive peptide precursors into their bioactive peptide
products [259]. Although ATP7A trafficking in neuroendocrine cells has not been extensively
explored [260, 261], AP-1 was recently shown to play an essential role in secretory granule
biogenesis and PAM trafficking in AtT-20 mouse corticotrope tumor cells [234, 220, 219].
In this study, AP-1 function was diminished using an shRNA that reduced expression of
the medium subunit of AP-1 (µ1A) to half in AtT-20 cells stably expressing PAM-1. We used
cells sh-µ1A PAM-1 cell and cells expressing a control shRNA (scramble PAM-1 cells) to
determine whether this modest reduction in AP-1 levels altered Atp7a trafficking and copper
delivery to PAM. Impaired production of amidated peptides as a result of diminished delivery




4.3.1 Decreased expression of µ1A does not alter levels of Atp7a or intracellu-
lar copper
AtT-20 cells stably expressing PAM-1 (PAM-1 cells) infected with a lentivirus expressing
shRNA directed against µ1A (sh-µ1A) or a non-target shRNA (scramble) were described
previously [234]. In this study, the trans-Golgi network region of sh-µ1A PAM-1 cells was
vacuolated and non-condensing secretory granules accumulated at the expense of immature
secretory granules [234]. In addition, the ability of sh-µ1A PAM-1 cells to secrete secretory
granule proteins in response to secretagogue was diminished.
Western blot analysis demonstrated the expected 50% reduction in levels of µ1A in
sh-µ1A PAM-1 cells compared to non-infected (N.I.) and scramble PAM-1 cells (Figure
4.1A). As expected, in scramble PAM-1 cells, γ-adaptin, an AP-1 subunit, and TGN38 were
largely co-localized in the perinuclear region (Figure 4.1B). In HeLa cells and µ1A-/- mouse
embryonic fibroblasts, lack of the µ1A subunit resulted in a more diffuse distribution of the
remaining complex [220, 178]. Consistent with these observations, µ1A was more diffusely
distributed in sh-µ1A PAM-1 cells, than in scramble PAM-1 cells (Figure 4.1B).
Since copper homeostasis was altered in MEDNIK patients, intracellular copper levels in
scramble and sh-µ1A PAM-1 cells were compared. In order to determine whether copper
levels differed in scramble and sh-µ1A PAM-1 cells, trypsinized cells were suspended
in isotonic buffer lacking copper and used for cell counting, protein determination and
measurement of copper levels by atomic absorption (see Materials and Methods). No
difference in intracellular copper levels, whether normalized to cell number or to cell protein,
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was seen between scramble and sh-µ1A PAM-1 cells (Figure 4.1C).
We turned to Western blot analysis to compare steady state levels of Atp7a in non-infected,
scramble and sh-µ1A PAM-1 cells (Figure 4.1E); no changes in the steady state levels of this
pump were observed. Atp7a delivers copper to the lumen of the secretory pathway, where
cuproenzymes like PAM must bind it in order to function. When PAM-1 enters secretory
granules, it can be cleaved between its two catalytic core domains, PHM (peptidylglycine
α-hydroxylating monooxygenase) and PAL (peptidyl-α-hydroxyglycine α-amidating lyase),
generating a soluble protein (PHM, ~45 kDa) and a membrane fragment (PALm, ~70 kDa).
Using an antibody that recognizes PHM, we observed intact PAM-1 (~120 kDa) and soluble
PHM (Figure 4.1D). As seen previously, the diminished steady state levels of PHM in sh-µ1A
PAM-1 cells compared with non-infected and scramble PAM-1 cells reflect an increase in
basal secretion of PHM when AP-1 function is diminished (Figure 4.1E) [234].
Since AtT-20 cells express amyloid precursor protein (APP), which is known to bind
copper with very high affinity [216], we assessed levels of APP in non-infected, scramble and
sh-µ1A PAM-1 cells (Figure 4.1E). The levels of APP did not differ in the three cell lines.
4.3.2 Atp7a concentrates at the Golgi region of AtT-20 cells and primary pitu-
itary cells
Because the localization of ATP7A in fibroblasts from MEDNIK patients lacking σ1A and
HeLa cells expressing reduced levels of µ1A was altered, we assessed the localization of
endogenous Atp7a in AtT-20 cells. Unlike fibroblasts and HeLa cells, AtT-20 cells are profes-
sional secretory cells and store the products of prohormone processing in secretory granules
for release in response to secretagogue. AtT-20 cells must deliver copper to the secretory
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pathway to support the synthesis of amidated peptides. Atp7a concentrates in the perinuclear
region, where its distribution overlaps that of the cis-Golgi marker, GM130 and γ-adaptin
(Figure 4.2A). Co-staining for Atp7a and PAM revealed a strong colocalization in the Golgi
region and partial colocalization in vesicles. The tips of AtT-20 cells, where mature secretory
granules containing ACTH and the other final products of proopiomelanocortin (POMC)
processing accumulate, lack Atp7a (Figure 4.2A, arrows). Internalization of fluorescently
tagged transferrin has served as a good marker for early and recycling endosomes [262].
Cells were incubated with Alexa fluor 546 transferrin for 10 minutes at 37◦C before fixation;
very little overlap between the internalized transferrin and Atp7a was observed.
In order to determine whether the Atp7a distribution in AtT-20 cells was representative
of anterior pituitary endocrine cells in vivo, dissociated rat primary pituitary cells were
maintained in culture for several days and then stained for Atp7a along with several organelle
markers (Figure 4.2B). As in AtT-20 cells, Atp7a localized to the Golgi region, where its
distribution overlapped that of GM130 and γ-adaptin. PAM expression varies in the different
cell types found in the anterior pituitary [263]. In cells expressing high levels of PAM, it either
colocalized with secretory granules or was found in secretory granule and in the Golgi region,
where it colocalized with Atp7a (Figure 4.2B). In corticotropes, ACTH positive secretory
granules were evenly distributed throughout the cell; although ACTH positive secretory
granules occupied most of the cellular space, Atp7a staining rarely overlapped staining for
ACTH (Figure 4.2B).
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4.3.3 Atp7a distribution is altered in sh-µ1A PAM-1 cells
In HeLa cells, reducing levels of µ1A, impaired Atp7a retrograde trafficking from endosomes
to the Golgi [220]. In order to find out whether Atp7a localization depended on AP-1 function
in AtT-20 cells, scramble and sh-µ1A PAM-1 cells were stained for Atp7a and the cis-Golgi
marker, GM130. In both neuroendocrine cell lines, Atp7a was concentrated in the Golgi area,
largely overlapping with GM130 (Figure 4.3A). Outside of the Golgi area and nucleus, Atp7a
appeared evenly dispersed in both cell lines. No difference in the steady state localization of
Atp7a was apparent in scramble and sh-µ1A PAM-1.
The Golgi region of AtT-20 cells contains immature secretory granules as well as a
complex mixture of endocytic compartments containing secretory granule membrane pro-
teins targeted to the secretory pathway [195, 9]. Early and recycling endosomes are more
concentrated toward the cell center when AP-1 function is reduced in HeLa cells or mouse
embryonic fibroblasts [178, 236]. In order to disperse early and recycling endosomes to the
cell periphery and try to reveal a difference between scramble and sh-µ1A PAM-1 cells, cells
were treated with 10 µM nocodazole for 20 minutes [39]. Early and recycling endosome
distribution was monitored by internalization of Alexa fluor 546 transferrin for 10 minutes
(with or without nocodazole, Figure 4.3B). In scramble PAM-1 cells treated with DMSO as a
control, internalized transferrin was found in puncta evenly spread out in the cells, with an ac-
cumulation near the nucleus, where recycling endosomes concentrate. In contrast, in sh-µ1A
PAM-1 cells, more of the internalized transferrin was concentrated near the nucleus, with less
found in peripheral vesicles. After treatment with nocodazole, internalized transferrin was
diffusely distributed in both cell lines (Figure 4.3B).
We next examined the localization of Atp7a in scramble and sh-µ1A PAM-1 cells after
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treatment with DMSO or nocodazole. Atp7a seemed to colocalize more with internalized
transferrin in sh-µ1A PAM-1 cells than in scramble PAM-1 cells. In order to measure the
degree of colocalization between the Atp7a and internalized transferrin, scramble and sh-µ1A
PAM-1 cells treated with nocodazole were imaged using confocal microscopy (Figure 4.3C).
Quantification of images revealed that Atp7a colocalized 1.6 times more with internalized
transferrin in sh-µ1A PAM-1 cells than in scramble PAM-1 cells. In AtT-20 cells, as reported
in HeLa cells, a decrease in AP-1 function resulted in the accumulation of Atp7a in an
endosomal compartment [220].
4.3.4 Establishing an assay for PAM function in intact cells
The decreased ceruloplasmin and increased free copper levels observed in MEDNIK pa-
tients suggested a deficit in copper delivery to ceruloplasmin and perhaps to other luminal
cuproenzymes [219]. Failure to load copper into ceruloplasmin and its integral membrane
homolog, hephaestin, as they are synthesized leads to their degradation [264, 265]. We
carried out Western blot analysis to see whether copper chelation affected steady state levels
of PAM-1 in scramble or sh-µ1A PAM-1 cells (Figure 4.4A). Overnight incubation with
bathocuproine disulfonate (BCS), a membrane impermeant Cu(I) chelator, was used to reduce
intracellular copper levels [266, 267]. Unlike ceruloplasmin and hephaestin, which must
acquire copper as they are synthesized, the two copper atoms bound to PHM are readily
exchangeable. Both newly synthesized PAM-1 and PAM-1 retrieved from the endocytic
pathway participate in secretory granule function. Entry of PAM-1 into secretory granules
allows its prohormone convertase 1/3 mediated cleavage, producing soluble PHM (45 kDa)
and PAL membrane (70 kDa) (Figure 4.1D). Although less frequent, cleavage between PAL
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and the transmembrane/cytosolic domain can occur, producing soluble PAL (50 kDa) and a
25 kDa transmembrane/cytosolic domain fragment. In the endocytic pathway, PAM-1 can be
cleaved at a site closer to the transmembrane domain, generating soluble PAM-1 (100 kDa)
and a 20 kDa transmembrane/cytosolic domain fragment. Using an antibody that recognizes
the linker region between PHM and PAL, no change in the levels of intact PAM-1 or its
processed products was observed when PAM-1 cells were treated with 50 µM BCS overnight
(Figure 4.4A).
In order to evaluate PAM function in scramble vs. sh-µ1A PAM-1 cells, we took
advantage of the fact that proopiomelanocortin (POMC) synthesized in AtT-20 cells is
cleaved to produce amidated products along with adrenocorticotropic hormone (ACTH) and
β-lipotropin (βLPH) [260, 261] (Figure 4.4B). Following cleavage at the C-terminus of
ACTH, cleavage at its N-terminus reveals a potential amidation site (-Glu-Gly-Lys-Arg) at the
C-terminus of the 18 kDa fragment; PAM cannot act on this substrate until carboxypeptidase
E has removed the C-terminal basic amino acids, revealing a C-terminal glycine residue. An
additional prohormone convertase-mediated cleavage can generate amidated joining peptide
(JP) and 16 kDa fragment (Figure 4.4B). Amidated POMC products can first be detected in the
trans-Golgi network [192], but pulse/chase studies indicate that amidation occurs largely in
secretory granules [268]. An amide-specific antibody was generated by immunizing rabbits
with synthetic D-Tyr-Pro-Glu-Pro-Ser-Pro-Arg-Glu-NH2; affinity-purification yielded an
antibody specific for the amidated C-terminus shared by 18 kDa fragment and JP (Figure
4.4B). Based on an ELISA, the affinity-purified JP-NH2-specific antibody cross-reacted less
than 10,000 times as well with synthetic Pro-Glu-Pro-Ser-Pro-Arg-Glu-Gly (Figure 4.4C)
[269].
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Lysates prepared from wild-type AtT-20 cells depleted of copper by overnight incubation
in medium containing 50 µM BCS were used to test the JP-NH2-specific antibody (Figure
4.4D). An affinity-purified γ3MSH antibody (Figure 4.4B) was used to monitor levels of
POMC, ABI, 18 kDa fragment and 16 kDa fragment [226]. The JP-NH2-antibody detected
a single 18 kDa band in cell lysates while the γ3MSH-antibody detected 18 kDa fragment
along with much larger amounts of 16 kDa fragment, POMC and ABI. JP-NH2, which has
only 18 amino acids, does not bind to PVDF or nitrocellulose membranes and cannot be
assessed by Western blot analysis. BCS treatment eliminated the amidated 18 kDa band
without affecting levels of POMC, ABI or 16 kDa fragment. As expected, PAM function was
inhibited when AtT-20 cells were treated with 50 µM BCS for 16 hours.
4.3.5 PAM function is more sensitive to copper chelation in sh-µ1A PAM-1
cells
We reasoned that a significant alteration in copper homeostasis or protein trafficking caused
by decreasing µ1A levels in PAM-1 AtT-20 cells, might alter their sensitivity to BCS. This
cell impermeant Cu(I) chelator is generally applied to cells at a level of 50 to 200 µM for 4 to
48 hours [266, 267, 220, 270]. In addition to depleting cellular copper levels by removing
Cu(I) from the medium, BCS would be expected to remove copper from enzymes like PAM-1,
which reach the plasma membrane after exocytosis, enter the endocytic pathway and can be
returned to secretory granules or degraded [195].
We therefore asked whether the amidation of 18 kDa fragment in scramble and sh-µ1A
PAM-1 cells exhibited differential sensitivity to BCS (Figure 4.5A). Basal media and cell
extracts from both cell lines were examined for POMC processing using the γ3MSH antibody
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and for amidation using the JP-NH2 antibody; β-III tubulin served as a loading control for
cell lysates (Figure 4.5A). Neither the endoproteolytic cleavage of POMC nor secretion of its
major cleaved products was altered by BCS treatment in scramble or sh-µ1A PAM-1 cells. In
both scramble and sh-µ1A PAM-1 cells, BCS treatment produced a dose-dependent decrease
in the amount of 18 kDa fragment detected using the JP-NH2 antibody. Peptide amidation in
scramble PAM-1 cells was decreased to about 50% of control when cells were treated with
20 µM BCS while sh-µ1A PAM-1 cells saw their peptide amidation decrease to about 50%
when cells were treated with only 2 µM BCS (Figure 4.5A, graphs). Amidation of 18kDa
fragment secreted into the medium throughout the entire time of exposure to BCS showed a
similar difference between scramble and sh-µ1A cells. Using an antibody that recognizes the
exon 16 region between PHM and PAL, we observed that overnight treatment of both cell
lines with 50 µM BCS did not alter the level or processing of PAM-1 (Figure 4.5B). Taken
together, the AP-1 complex plays an important role in the ability of AtT-20 cells to provide
copper to PAM-1.
With no apparent change in cellular copper levels or in Atp7a levels, we explored the
possibility that altered PAM-1 trafficking contributed to its increased sensitivity to BCS in
sh-µ1A PAM-1 cells.
4.3.6 Levels of PAM-1 on the cell surface are increased in sh-µ1A PAM-1 cells
Since BCS is a cell-impermeant copper chelator, we hypothesized that PAM-1 reaches the
plasma membrane more frequently in sh-µ1A PAM-1 cells than in scramble PAM-1 cells,
exposing it to BCS and resulting in increased copper loss and inactivation. To quantify
cell surface levels of PAM-1 in scramble and sh-µ1A PAM-1 cells, surface biotinylation
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experiments were carried out [195]. Membrane trafficking was blocked by chilling the cells
on ice. Cell surface proteins were then biotinylated at 4◦C using the cell impermeable sulfo-
NHS-LC-biotin; biotinylated proteins were isolated by binding to streptavidin beads. PAM-1
proteins in total cell lysates (inputs) and biotinylated PAM-1 in eluates were compared by
Western blot analysis (Figure 4.6). A 75% increase in PAM-1 cell surface levels was observed
in sh-µ1A PAM-1 cells vs. scramble PAM-1 cells; the amount of PALm on the cell surface
was doubled in sh-µ1A PAM-1 cells. This increase in PAM-1 on the cell surface in sh-µ1A
PAM-1 cells would result in increased exposure to BCS, allowing faster removal of bound
Cu(I) and inactivation of the enzyme.
4.3.7 Atp7a trafficking differs in neuroendocrine cells and HeLa cells
When fibroblasts or HeLa cells are treated with elevated levels of copper, Atp7a shifts from
the Golgi region to the cell periphery; when these cells are treated with a copper chelator, such
as BCS, Atp7a exit from the Golgi is prevented [271, 219]. AtT-20 cells were treated with 20
µM or 200 µM of CuCl2 for 2 hours or with 50 µM of BCS overnight and endogenous Atp7a
was then localized by immunofluorescent staining (Figure 4.7A). Even after exposure to high
levels of CuCl2, Atp7a was largely localized in the Golgi area in AtT-20 cells; the effects of
20 µM and 200 µM CuCl2 were similar. Although a major shift of Atp7a towards the plasma
membrane was not observed, exposure to elevated levels of copper did affect the localization
of Atp7a. The ratio of average fluorescent intensity for Atp7a in the cytosol (any part of
the cell excluding the Golgi and nucleus) to average intensity in the Golgi area increased by
about 45% upon treatment with CuCl2; this ratio was not altered by BCS treatment (Figure
4.7A). Treatment with 200 µM CuCl2 resulted in a milder shift of Atp7a to the cell periphery
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than treatment with 20 µM CuCl2. This difference might be due to the toxicity of copper at
200 µM. Most Atp7a was still contained in the perinuclear region and colocalized with the
cis-Golgi marker, GM130.
Since Atp7a trafficking differed in AtT-20 cells and HeLa cells, we next turned to rat
primary anterior pituitary cultures to ask whether this difference in Atp7a trafficking was
specific to peptide-producing cells. Primary pituitary cells were cultured in vitro for 4 days
before being treated with either 50 µM BCS overnight, 20 µM CuCl2 for 2 hours or untreated
as a control. Treatment of primary pituitary cells with elevated levels of copper did not
produce a change in the localization of Atp7a (Figure 4.7B).
4.3.8 Copper-dependent Atp7a trafficking is not altered in sh-µ1A PAM-1
cells
Since Atp7a distribution shifted to peripheral regions of the cells under elevated copper
treatment in AtT-20 cells, we next asked whether this shift still occurred in sh-µ1A PAM-1
cells. Immunofluorescent staining was used to evaluate the effect of copper treatment on
Atp7a distribution in scramble and sh-µ1A PAM-1 cells. Both cell lines showed a very similar
distribution, with Atp7a accumulated in the perinuclear region, where it colocalized with
GM130 (cis-Golgi marker), and in vesicles distributed throughout the cells (Figure 4.8A).
Scramble and sh-µ1A PAM-1 cells treated with 20 µM CuCl2 for 2 hours showed a similar
slight, but reproducible, shift of Atp7a toward the cell periphery (Figure 4.8A, graph).
In order to confirm the immunofluorescent data, Western blot and surface biotinylation
were used to quantify the levels of Atp7a in the cell and at the cell surface after cells had
been treated with 20 µM CuCl2 for 2 hours (Figure 4.8B). SNAP25, an intracellular protein,
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was used as a negative control to ensure that copper treatment did not damage the cells. The
total cell lysate (input) shows increased Atp7a levels upon copper treatment. A 2 to 3 fold
increase in Atp7a levels was seen in both scramble and sh-µ1A PAM-1 cells in response to
elevated copper levels (Figure 4.8C). Only 0.1% of total Atp7a resides on the cell surface at
steady state. Atp7a cell surface levels increased 3-fold when cells were incubated with high
levels of copper in both scramble and sh-µ1A PAM-1 cells (Figure 4.8D). Taken together, the
copper-dependent trafficking of Atp7a was not altered in sh-µ1A PAM-1 cells.
4.3.9 Atp7a and PAM interact in AtT-20 cells
Unlike Cu/Zn superoxide dismutatase (SOD1) and cytochrome c oxidase, which receive
copper by interacting with their own specific cytosolic chaperones [216, 272], copper delivery
to PAM is not thought to involve a chaperone; Atox1 delivers copper to Atp7a for transport into
the lumen of the secretory pathway, but little is known about the status of copper in the luminal
compartment [255]. Biophysical studies indicated that copper could be transferred to PHM
from a scaffold that incorporated the His/Met-rich luminal loop connecting transmembrane
domains 1 and 2 of Atp7a [215]. We decided to use immunoprecipitation to see whether an
interaction between Atp7a and PAM could be detected in cells and whether this interaction
would be copper dependent. PAM-1 cells were treated with 50 µM BCS overnight or with 20
µM copper for 2 hours before extraction and solubilization for immunoprecipitation using an
Atp7a antibody and rabbit IgG as a negative control. In both, the BCS and copper treated
samples, Atp7a was successfully immunoprecipitated, with essentially no background. Co-
immunoprecipitation of PAM was evaluated using antibody to exon 16; a small percentage
of the total PAM-1 and PALm in the lysate was recovered in the Atp7a precipitate (Figure
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4.9). Both PAM-1 and PALm were detected at levels above background. Atp7a successfully
co-immunoprecipitated PAM-1 under BCS and copper overload conditions, indicating that
Atp7a and PAM-1 interact independent of copper levels.
4.4 Discussion
4.4.1 Copper handling is cell type specific
Neuroendocrine cells synthesize and store bioactive neuropeptides; many of these peptides
must be amidated before they are fully active [273]. Amidation cannot occur until after
a prohormone convertase has cleaved the precursor and carboxypeptidase E has removed
any basic amino acids from the C-terminus of the biosynthetic intermediates, revealing a
C-terminal glycine. As a result, amidation occurs late in the peptide biosynthetic pathway.
Based on pulse/chase metabolic labeling experiments, amidation generally occurs in secretory
granules. Quite strikingly, very little Atp7a is found in mature secretory granules. In contrast,
mature secretory granules contain both intact PAM-1, which can be recovered from the cell
surface after granule exocytosis, and soluble PHM.
Both PAM and Atp7a localize to the Golgi region in pituitary cells. Immature secretory
granules, which form from the trans-Golgi network, contain PAM-1 along with condensing
granule content proteins [234]. Much of the PAM-1 is recovered from the immature granules
in a process that involves AP-1 [88, 86, 82, 190]; it is not yet clear whether Atp7a also
enters immature secretory granules. If Atp7a delivers copper directly to PAM, the transfer
is likely to occur in the trans-Golgi network, immature secretory granules or an endocytic
compartment. If PAM-1 retrieved from the plasma membrane loses one or both of its copper
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ions, copper could again be provided as the protein is returned to secretory granules [195]. If
the transfer of copper to PHM is not direct, luminal copper levels would determine where
metallation of PAM occurs.
When treated with high amounts of copper, ATP7A was redistributed to the periphery
in HeLa cells [271, 220]. Excess of extracellular copper did not dramatically alter the
Golgi distribution of Atp7a in AtT-20 cells and primary pituitary cells presumably to ensure
that cuproproteins like PAM-1 acquire copper effectively. Upon exposure to high levels
of copper, Atp7a protein levels increased. Since Atp7a regulates the exit of copper from
the cells, this indicated that neuroendocrine cells respond to increasing levels of copper by
augmenting the protein expression level of Atp7a rather than moving Atp7a from the Golgi to
the cell periphery. In melanocytes, tyrosinase, a cuproenzyme required for melanin synthesis,
receives copper from ATP7A in melanosomes [274]. Lack of Biogenesis of Lysosome-related
Organelle Complex 1 resulted in accumulation of ATP7A in early endosomes instead of
melanosomes in the human melanoma cell line, MNT-1, indicating that ATP7A trafficking is
cell type specific [274].
Increased extracellular copper may also affect other cuproproteins differently in neuroen-
docrine cells. Ctr1 transports copper across the plasma membrane into the cytosol, where
it is rapidly transferred to chaperones [216]. In the small intestine and heart of mice fed a
copper-deficient diet, total and cell surface levels of Ctr1 were increased compared with mice
fed a normal diet, presumably due to increased stability [270]. Atox1, a copper chaperone,
delivers copper to Atp7a. Fibroblasts lacking Atox1 contained increased intracellular levels
of copper and had impaired Atp7a translocation to the cell periphery in response to high
copper levels [267]. Additional studies looking at Ctr1 and Atox1 expression and trafficking
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will help to shed light on how copper is handled in neuroendocrine cells.
4.4.2 Atp7a endocytic trafficking is altered in neuroendocrine cells with re-
duced AP-1 function
In HeLa cells, internalized transferrin concentrated in a perinuclear Golgi region when
expression of one AP-1 subunit was decreased [236]. A similar response was observed in
fibroblasts isolated from µ1A knockout mice, where early endosomes tend to group near
the nucleus [178]). Atp7a trafficking is strongly dependent on AP-1 in HeLa cells and
fibroblasts [220, 219]. Because the peri-nuclear Golgi region contains a complex mixture of
biosynthetic and endocytic organelles in AtT-20 cells, scramble and sh-µ1A PAM-1 cells
were treated with nocodazole to disperse endosomes. This allowed us to observe an increase
in the colocalization of Atp7a and internalized transferrin in sh-µ1A PAM-1 cells compared
to scramble PAM-1 cells. Retrieval of Atp7a from the endocytic pathway to the Golgi requires
AP-1.
Although cell surface levels of Atp7a were very low in AtT-20 cells (0.1%), surface
biotinylation did not show an increase in the amount of Atp7a on the cell surface at steady
state in sh-µ1A PAM-1 cells. In addition, treatment of sh-µ1A PAM-1 cells with elevated
levels of copper revealed that Atp7a trafficking in response to copper was not prevented.
These data indicated that Atp7a requires AP-1 for retrograde trafficking but that AP-1 was
not necessary for anterograde and copper-dependent trafficking.
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4.4.3 PAM-1 function is sensitive to copper levels and AP-1
Peptide amidation is an essential post-translational modification; neither flies nor mice
lacking this activity can complete development [260, 275]. Although PAM requires copper
for activity, the PHM/CuA dissociation constant is ~60 nM; in contrast, it is around 6 fM in
SOD1, indicating that copper bound to PAM-1 is easily exchangeable [276, 277]. In AtT-20
cells, reduced AP-1 function impairs the formation of immature secretory granules [234];
both PAM and ACTH accumulate in the non-condensing secretory granules that appear in
sh-µ1A PAM-1 cells. Basal secretion of PHM is elevated in sh-µ1A PAM-1 cells, suggesting
that the trafficking of PAM-1 along the regulated secretory pathway is perturbed when AP-1
function is reduced [234]. In this study, we observed an increase of PAM-1 cell surface
levels in sh-µ1A PAM-1 cells. Since PAM-1 does not bind copper very tightly, its increased
presence on the cell surface in sh-µ1A PAM-1 cells suggests that PHM loses its copper
more readily in the presence of BCS, resulting in reduction ability of these cells to produce
amidated product.
Reduced peptide amidation could also be due to changes in PAM-1 endocytic trafficking.
The phosphorylation status of the PAM-1 cytosolic domain has been shown to drive PAM-1
within the endocytic pathway [195]. A phosphomimetic mutant of PAM-1, PAM-1 TS/DD,
where Thr946 and Ser949 were mutated into Asp, showed that phosphorylation at these sites
prevented entry into intraluminal vesicles of multivesicular bodies and recycling from the
endocytic pathway. Levels of PAM-1 phosphorylated at Ser949 were reduced and biotinylation
experiments indicated that PAM-1 exhibited more recycling from the endocytic pathway to
the regulated secretory pathway in sh-µ1A PAM-1 cells (Bonnemaison M.L. et al. manuscript
in preparation). This is in contrast with Atp7a, which was trapped in endocytic compartments
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in shµ1A PAM-1 cells.
AtT-20 cells thus presented a similar phenotype of altered Atp7a trafficking to that
observed in fibroblasts and HeLa cells when AP-1 function was reduced. Patients with
MEDNIK lack the expression of σ1A, an AP-1 subunit, and had altered skin pigmentation
and organization. Because Atp7a trafficking is different in pituitary cells from HeLa cells, it
would be interesting to find out how the lack of AP-1 function can alter other cell types.
4.5 Materials and Methods
4.5.1 Antibodies
The antibodies used in this study are summarized in Table 4.1.
4.5.2 Cell culture and generation of scramble and sh-µ1A PAM-1 cells
AtT-20 cells were grown at 37◦C with 5% CO2 in Dulbecco’s modified Eagle’s medium/F-12
(DMEM/F-12) containing 25 mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin,
10% fetal bovine serum, 10% NuSerum. AtT-20 cells stably expressing PAM-1 were described
previously [188]. Generation of sh-µ1A and scramble PAM-1 AtT-20 cells using lentivirus
targeted to µ1A (Sigma; clone ID TRCN0000111549) and a non-target shRNA (Sigma #
SHC002V), respectively, was described previously [234].
4.5.3 Immunofluorescent staining
Cells were plated onto 0.16 to 0.19 mm thick, glass, 12-mm round coverslips (Fisher Scien-
tific) or 4-chamber glass slides. Both supports were coated with 0.1 mg/ml poly-L-lysine for
5 minutes followed by a rinse in NuSerum and two rinses in growth medium. Cells were fixed
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in 4% formaldehyde in PBS (50 mM NaH2PO4, 150 mM NaCl, pH 7.4) for 20 minutes at
room temperature. After rinsing in PBS, cells were permeabilized in 0.075% Triton X-100, 2
mg/ml BSA in PBS for 20 minutes at room temperature and then incubated in block (2 mg/ml
BSA in PBS) for 20 minutes at room temperature. Primary antibodies diluted in block were
incubated with the cells overnight at 4◦C. After three rinses in PBS, cells were incubated for
one hour at room temperature in block containing either fluorescein isothiocyanate (FITC,
1:500 dilution) or Cy3 (1:2000 dilution) conjugated donkey antibody to mouse or rabbit
immunoglobulin (Jackson ImmunoResearch). After three rinses in PBS, cells were incubated
with Hoechst (1:1000 dilution in PBS) for 10 minutes at room temperature. After three rinses
in PBS, cells were mounted using ProLong R© Gold (Invitrogen).
4.5.4 Quantification of images
Cells were visualized using a Nikon TE300 epifluorescence microscope with an oil immersion
63X Plan Apochromat objective (NA 1.4). Quantification of fluorescence images was done
using NIS Elements Software. Background values were determined by measuring the average
intensity in parts of the picture without cells for both green and red images. Background
was then subtracted for both green and red images using the average intensity measured as
a constant value for the entire image. Three regions were identified in each cell analyzed:
Golgi (based on staining for GM130), nucleus and cytosol (region distinct from nucleus and
Golgi). For each cell, two identical boxes were drawn: one box was placed over the Golgi
while the other box was placed over the cytosol. The average fluorescence signal intensity in
each region was measured for 8 to 41 cells. Cytosol/Golgi fluorescence intensity ratios are
shown. Statistical analyses were made using paired t-tests on the ratios calculated.
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For confocal analyses, cells were visualized using a Zeiss LSM 510-Meta with an oil
immersion 63X Plan Apochromat objective (NA 1.4). Colocalization of markers was assessed
using Metamorph. For each image, colors were first separated and the background was
subtracted as described above. For each color, the image was thresholded using an inclusive
threshold at least three times background. Colocalization of markers was measured based on
area. Statistical analyses were made using paired t-tests on the ratios calculated.
4.5.5 Inductively coupled plasma mass spectrometry (ICP-MS)
Tubes used for ICP-MS were incubated in 1% HNO3 (trace metal grade, Fisher Scientific) for
at least 24 hours. Scramble and sh-µ1A PAM-1 cells were plated onto a 6 well dish. When
confluent, cells were trypsinized and resuspended in HSG buffer (15 mM HEPES, 120 mM
NaCl, 2 mM CaCl2, 4 mM KCl, 25 mM glucose, pH 7.4). Resuspended cells were split into
three equal aliquots, which were used for cell counting, measurement of protein concentration
and ICP-MS. Cells for ICP-MS were spun and the supernatant was discarded. Samples were
digested with 200 µL 50% HNO3 (trace metal grade, Fisher Scientific) in Eppendorf tubes
at room temperature overnight. The digested samples were brought to a total volume of
1 mL with 1% HNO3, mixed by vortexing, and spun at 3500 rcf for 3 minutes to remove
debris. ICP-MS analysis was carried out in the Elemental Analysis Core at Oregon Health
and Science University using an Agilent 7700x equipped with an ASX 250 autosampler. The
system was operated at a radio frequency power of 1550 W, an argon plasma gas flow rate
of 15 L/min, and Ar carrier gas flow rate of 1.08 L/min. Elements were measured in kinetic
energy discrimination (KED) mode using He gas (4.2 mL/min). For measurement, samples
were transferred to acid-treated 15-mL conical tubes. Data were quantified using a 9-point
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calibration curve (0, 0.5, 1, 2, 5, 10, 50, 100, 1000 ppb (ng/g)) for Ca, Mn, Fe, Cu, and Zn
using an external standard (Common Elements Mix 2 Multi-Element Aqueous Standard,
VHG Labs) in 1% HNO3. For each sample, data were acquired in triplicate and averaged. A
Ge-72 internal standard (Internal Standard Multi-Element Mix 3, VHG Labs) introduced with
the sample was used to correct for plasma instabilities, and frequent measurements of a 10
ppb all-analyte solution as well as a blank (containing 1% HNO3 only) were used as quality
control and to determine the coefficient of variance. To access recovery rates of elements
and probe background contamination from containers a certified NIST standard reference
material (Trace Elements in Water, 1643e) was digested and analyzed by the same method as
the samples. HSG buffer was also analyzed to determine background contributions.
4.5.6 Primary anterior pituitary cell culture
Rat anterior pituitary cells were plated on 0.16 to 0.19 mm thick glass, 12-mm round
coverslips (Fisher Scientific) coated with 0.1 mg/ml poly-L-lysine for 5 minutes followed
by a rinse in NuSerum and two rinses in AtT-20 growth medium as described previously
[278]. Briefly, rat anterior pituitary was rinsed in CSFM-air medium (DMEM/F-12 air, 25
mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin, 1-2 mg/mL BSA, ITS, 50 µM
ascorbate) and diced. Pituitary pieces were incubated in 0.75 mL collagenase solution (4
mg/mL crude collagenase, 1 mg/mL hyaluronidase, 0.1 U/mL benzonase, 10 mg/mL BSA)
for 20 minutes at 37◦C without CO2 under agitation. Pituitary fragments were diluted with
14 mL of CSFM-air and spun down at room temperature for 5 minutes. Supernatant was
removed and cells were incubated with 0.75 mL of 3 mg/mL trypsin I-300 dissolved in
CSFM-air for 5 minutes at 37◦C without CO2 under agitation. Trypsin was blocked by adding
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0.75 mL of 0.2 mg/mL LBTI (Lima Bean Trypsin Inhibitor) dissolved in AtT-20 medium.
The dissociated cells were then filtered through a 70 µm filter. After centrifugation of the
flow through, the cell pellet was resuspended in 5 mL of 160 mM NH4Cl to lyse red blood
cells and then spun again for 5 minutes at room temperature. The cell pellet was resuspended
in 5 mL of AtT-20 growth medium. 1/25th of a rat anterior pituitary was plated per well of a
24-well dish. Cells remained in AtT-20 growth medium for 2 days and were then switched to
DMEM/F-12, 25 mM HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin, 1-2 mg/mL
BSA, Insulin-Transferrin-Selenium (ITS), 50 µM ascorbate. Cells were used on days 3 and 4.
4.5.7 Manipulation of cells
Cells were incubated in DMEM/F-12 air medium containing 25 mM HEPES, pH 7.4, 1 mg/ml
BSA for 30 minutes at 37◦C without CO2. For transferrin uptake experiments, cells were
then incubated in DMEM/F-12 air medium containing 25 mM HEPES, pH 7.4, 1 mg/ml BSA,
25 µg/mL Alexa fluor 546 transferrin (Life Technologies) for 10 minutes at 37◦C without
CO2. Cells were fixed using 4% formaldehyde in PBS for 20 minutes at room temperature.
For nocodazole treatment experiments, cells were treated as described above and treated with
DMEM/F-12 air medium containing 10 µM nocodazole (Sigma) or the equivalent volume of
DMSO for 20 minutes at 37◦C without CO2.
4.5.8 BCS and copper treatment of AtT-20 cells
Cells were first incubated for 30 minutes in DMEM/F-12 medium or DMEM/F-12 air medium
containing ITS, 25 mM HEPES, pH 7.4, 1 mg/ml BSA. Cells were equilibrated in air medium
during two consecutive 30 minute incubations at 37◦C with or without CO2. Cells were then
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treated with medium containing 50 µM bathocuproinedisulfonic acid (BCS, Sigma) overnight
or CuCl2 (20 µM or 200 µM, Sigma) for 2 hours or medium only as a control. Cells were
either fixed for immunostaining, lysed in detergent for biochemical analysis or chilled for
cell surface biotinylation.
4.5.9 Detection of joining peptide (JP) amidation
Antibody specific to the amidated C-terminus of JP was generated by linking D-Tyr-Pro-Glu-
Pro-Ser-Pro-Arg-Glu-NH2 [D-Tyr JP(12-18)NH2]] to BSA as described [269]. The addition
of a Gly residue to the C-terminus of this peptide [JP(12-19)] reduced its cross-reactivity
with this antiserum by 10,000-fold [269]. For Western blot analysis, a fraction enriched in
immunoglobulin by precipitation with ammonium sulfate (45% saturation) was dialyzed
into 100 mM NaPhosphate, pH7.4 and incubated with JP(12-19) bound to Affi-Gel15 (4mg
peptide/2ml resin) for 1h at 4◦C to remove any antibodies capable of recognizing this peptide.
The unbound fraction was applied to a column of JP(12-18)NH2 linked to AffiGel10 (5mg
peptide/2ml resin); bound antibodies were eluted with 0.2 M Glycine HCl, 0.1M NaCl,
0.1 % TX-100, pH 2.3; the eluate was rapidly neutralized with 3M Tris HCl, pH 8.0 and
BSA (final concentration in eluate = 0.2 mg/ml) was added before dialysis against 100 mM
NaPhosphate, pH7.4. Preparation of an antibody specific for γ3MSH [226] was described




Protein A Coated Plates (Pierce) were rinsed three times with 200 µl Tween-Tris-Buffered-
Saline (TTBS, 0.5% Tween 20, 50 mM Tris, 150 mM NaCl, pH 7.5). Affinity-purified JP-NH2
antibody (1:500,000 dilution), standard peptide (rat joining peptide; Phoenix Pharmaceuticals)
and sample diluted into TTBS was allowed to bind to the strips for two hours. Biotinylated
JP-NH2 (labeled using Pierce EZ-Link NHS-PEG4-Biotinylation Kit, per manufacturer’s
instructions; nominally 20 pg=11 fmol per well) was added for 1 h. After 4 rinses (200 µl
TTBS), wells were incubated in 100 µl 1:5000 Pierce High sensitivity Streptavidin-HRP for
1 h, followed by TTBS rinses. Color was developed using 100 µl TMB (Pierce 1-Step Ultra
TMB-ELISA, diluted 1:3 in 100 mM Na-acetate pH 5.0) for 5-10 min and stopped with 110
µl 2 M H2SO4; OD was determined at 450 nm.
4.5.11 Biotinylation
AtT-20 cells plated in a 12-well plate were first incubated for 30 minutes in DMEM/F-12 air
medium containing ITS, 25 mM HEPES, pH 7.4, 100 µg/ml BSA. Cells were equilibrated in
air medium during two consecutive 30 minute incubations at 37◦C without CO2. Cells were
then treated with air medium containing 20 µM CuCl2 or air medium only as a control. Dishes
were placed on ice and incubated 10 minutes at 4◦C. Cells were rinsed with ice cold HSG
buffer (15 mM HEPES, 120 mM NaCl, 2 mM CaCl2, 4 mM KCl, 25 mM glucose, pH 7.4).
A solution containing 1.25 mM sulfo-NHS-LC-biotin (Thermo Scientific) in HSG buffer was
made fresh and added to the cells for 10 minutes at 4◦C. After removing the biotin solution,
cells were rinsed twice for 5 minutes with CSFM-air containing 2 mg/ml BSA. Cell extracts
were collected using TMT [20 mM Na N-Tris[hydroxymethyl]methyl-2-aminoethanesulfonic
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acid (TES), 10 mM mannitol, 1% Triton X-100, pH 7.4] containing a cocktail of protease
inhibitors (final concentrations 0.34 mg/ml phenylmethylsulfonyl fluoride, 50 µg/ml lima
bean trypsin inhibitor, 2 µg/ml leupeptin, 16 µg/ml benzamidine, and 2 µg/ml pepstatin).
Cells were solubilized in TMT for 30 minutes at 4◦C. Cell extracts were collected into
microfuge tubes and centrifuged at 22,000 x g for 15 minutes at 4◦C. Solubilized cell extracts
were then incubated with Streptavidin-agarose beads for 1 hour at 4◦C. Beads were rinsed
twice with TMT and once with TM (no Triton X-100). The bound fraction was eluted into
Laemmli sample buffer by heating the samples for 5 minutes at 95◦C (PAM-1) or 55◦C
(Atp7a).
4.5.12 Co-immunoprecipitation
A confluent well of a 6-well dish of AtT-20 cells expressing PAM-1 was lysed in 500 µl
TMT, 1 mM EDTA and a cocktail of protease inhibitors (final concentrations 0.34 mg/ml
phenylmethylsulfonyl fluoride, 50 µg/ml lima bean trypsin inhibitor, 2 µg/ml leupeptin, 16
µg/ml benzamidine, and 2 µg/ml pepstatin) was added. After incubation at 4◦C for 30 min,
cell extracts were centrifuged at 22,000 x g for 15 minutes at 4◦C. Supernatants (220 µl)
were pre-cleared by incubation with 10 µl packed protein A (Repligen BioProcessing) for
30 minutes at 4◦C. After centrifugation at 1,000 x g for 5 minutes, 10 µl of supernatant was
collected as the input for the Western blot and the rest of supernatant was transferred into a
new tube containing 1 µg antibody (affinity-purified rabbit antibody to Atp7a or rabbit IgG
as control). Samples were tumbled overnight at 4◦C and then centrifuged at 22,000 x g for
15 minutes at 4◦C to remove insoluble material. The supernatants were added to protein A
beads (10 µl packed resin) and tumbled for 1 hour at 4◦C. Beads were washed twice in pH
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7.4 TMT containing 1 mM EDTA and protease inhibitors, and once in pH 7.4 TM containing
1 mM EDTA and protease inhibitors. The bound fraction was eluted by incubation for 30
minutes at 55◦C in Laemmli sample buffer, fractionated by SDS-PAGE on 4-15% gradient
gels (Bio-Rad) and subjected to Western blot analysis.
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4.6 Tables
Antigen Working dilution Identity, source
Atp7a 1:1000 CT77 [261]
APP (rabbit) 1:1000 ZEMED laboratories
rat PAM:
C-STOP, PAM-1(965-976) 1:1000 C-stop [223]
Exon 16, PAM-1(409-497) 1:1000 JH629 [224]
Secretory granule proteins:
POMC (γ3-MSH) 1:1000 JH189 [226]
JP-NH2 1:1000 [269]
ACTH 1:1000 ABCAM (clone # 56)
AP-1 components:
µ1A 1:500 ProteinTech Group
γ-adaptin 1:1000 BD Biosciences
Golgi markers:
GM130 1:1000 BD Biosciences
TGN38 (155-249) 1:1000 [189]
Table 4.1: Antibody list.
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4.7 Figures
Figure 4.1: Reduced µ1A levels in AtT-20 cells stably expressing PAM-1 do not alter
cuproprotein levels.
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Figure 4.1: (A) Western blot showing µ1A levels in non-infected (N.I.) PAM-1 cells
(N.I.), PAM-1 cells infected with a non-target shRNA expressing lentivirus (scramble,
scr.) and PAM-1 cells infected with the #549 lentivirus (sh-µ1A). GAPDH was used
as a loading control. The graph below indicates µ1A levels normalized to GAPDH
compared between N.I., scramble and sh-µ1A PAM-1 cells (***, p<0.001, n=5). (B)
Indirect immunofluorescent staining of γ-adaptin (FITC anti-mouse) and TGN38
(Cy3 anti-rabbit) in scramble and sh-µ1A PAM-1 cells. Nuclei were stained with
Hoechst (scale bar, 10 µm). (C) Copper levels in scramble and sh-µ1A PAM-1 cells
normalized to number of cells or amount of protein (N.S., not significant; n=3; error
bars represent SEM). (D) PAM-1 processing in secretory granules and endosomes is
shown. PC1/3 mediated cleavage produces PHM, PALm, PAL and intermediate 1 (Int.
1). In endosomes, α-secretase cleaves PAM-1 generating soluble PAM-1 (sPAM-1)
and intermediate 2 (Int. 2). Intermediates 1 and 2 undergo another cleavage catalyzed
by γ-secretase to provide a soluble fragment of the cytosolic domain (sf-CD), which
goes to the nucleus [223]. (E) Western blots showing Atp7a, PAM-1 and APP in N.I.,
scramble and sh-µ1A PAM-1 cells. GAPDH was used as a loading control for Atp7a
and APP. Graphs indicate normalized levels of Atp7a and APP over GAPDH and
PAM-1 processing (PHM/(PAM-1+PHM)) compared between N.I., scramble and
sh-µ1A PAM-1 cells (**, p<0.01, n=5).
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Figure 4.2: Atp7a concentrates in the Golgi region in pituitary cells. Indirect im-
munofluorescent staining of Atp7a (Cy3 anti-rabbit) and GM130 (cis-Golgi; FITC
anti-mouse), γ-adaptin (FITC anti-mouse), PAM (C-terminus, FITC anti-mouse) or
ACTH (secretory granule; FITC anti-mouse) in non-infected PAM-1 cells (A) and rat
anterior pituitary cells (B). Nuclei were stained with Hoechst. Non-infected PAM-1
cells also show Atp7a (FITC anti-rabbit) co-stained with internalized Alexa fluor
546 transferrin (early and recycling endosomes, iTf; white arrowheads point to the
Golgi; white arrows point to the tips, where secretory granules accumulate; blue
arrow points to a fibroblast; scale bar, 10 µm).
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Figure 4.3: Atp7a is shifted to endosomes in sh-µ1A PAM-1 cells. (A) Indirect
immunofluorescent staining of Atp7a (Cy3 anti-rabbit) and GM130 (cis-Golgi; FITC
anti-mouse) in scramble and sh-µ1A PAM-1 cells. (B) Indirect immunofluorescent
staining of Atp7a (FITC anti-rabbit) and internalized Alexa fluor 546 transferrin (iTf)
in scramble and sh-µ1A PAM-1 cells after treatment with DMSO or nocodazole. (C)
Confocal images of cells treated with nocodazole as described in B. Nuclei were
stained with Hoechst; white arrows indicate colocalization of internalized transferrin
and Atp7a; scale bar, 10 µm). Graph: % Atp7a area overlapping with internalized
transferrin was increased in sh-µ1A vs. scramble PAM-1 cells.
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Figure 4.4: Cell based assay for peptide amidation. (A) Western blot showing PAM-1
products in control and BCS-treated non-infected PAM-1 cells. The antibody used
targets exon 16, the region between PHM and PAL. Coomassie staining revealed
similar amounts of protein loaded in both lanes (*, non-specific band). (B) Diagram
of POMC processing in AtT-20 cells showing sites cleaved by prohormone convertase
1/3 (PC1/3) and amidated by PAM. The first cleavage generates ACTH biosynthetic
intermediate (ABI) and β-lipotropin (βLPH). ABI is further cleaved to produce
ACTH and 18 kDa fragment, which can be amidated by PAM only after CPE removes
any C-terminal basic amino acids. Amidated 18 kDa fragment is cleaved to generate
16 kDa fragment and amidated joining peptide (JP-NH2). Further cleavage of βLPH
produces γ-lipotropin (γLPH) and β-endorphin (βE). The epitopes recognized by the
γ3MSH and JP-NH2 antibodies are shown. (C) ELISA showing the specificity of the
JP-NH2 antibody for the amidated JP. JP-NH2 Std, AEEETAGGDGRPEPSPRE-NH2;
JP-NH2 small, PEPSPRE-NH2; JP-Gly, PEPSPREG. (D) Western blot of AtT-20 cells
treated or not with 50 µM BCS overnight. Antibodies against JP-NH2 and γ3MSH
were used. Amidated 18 kDa fragment levels were strongly reduced after treatment
with BCS (blot with JP-NH2); POMC products detected with the γ3MSH antibody
were not affected by BCS.
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Figure 4.5: Amidation is more sensitive to BCS in sh-µ1A PAM-1 cells than in scram-
ble PAM-1 cells. (A) Scramble and sh-µ1A PAM-1 cells were treated with increasing
amounts of BCS overnight. Media and cell extracts were collected and analyzed
using JP-NH2 and γ3MSH antibodies. βIII-tubulin was used as a loading control
for cell extracts. Amidated 18 kDa fragment levels decreased as the concentration
of BCS increased. Graphs: duplicate wells from three separate experiments were
analyzed; levels of amidated 18 kDa fragment were expressed as a percentage of the
levels observed in control samples. POMC cleavage and secretion were not altered
by BCS treatment. (B) Western blot showing PAM-1 processing of scramble and
sh-µ1A PAM-1 cells untreated or treated with 50 µM BCS overnight. The antibody
used targets exon 16, the region between PHM and PAL. Coomassie staining revealed
similar amounts of proteins loaded in all lanes (*, non-specific band).
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Figure 4.6: Cell surface levels of PAM are higher in sh-µ1A than in scramble PAM-1
cells. Western blot of cell surface biotinylation experiment carried out on cells chilled
to 4C. Streptavidin bound samples (B) represent 125-times more material than Input
(I) samples. The antibody used recognizes the region between PHM and PAL. The
graph shows the ratio of PAM-1 and PALm cell surface levels in sh-µ1A PAM-1 cells
over scramble PAM-1 cells (n = 3). (+, with biotin; -, without biotin; *, non-specific
band).
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Figure 4.7: Atp7a trafficking in pituitary cells is different from HeLa cells. (A)
Wild-type AtT-20 cells treated with 50 µM BCS overnight or with 20 or 200 µM
CuCl2 for 2 hours were fixed and stained for Atp7a (Cy3 anti-Rabbit). Graph shows
the ratio for mean Atp7a fluorescence intensity in the cytosol (any part of the cell
excluding nucleus and Golgi) and the Golgi region. A 50% increase in the ratio was
observed when cells were treated with copper. Treatment with BCS did not alter the
ratio (n = 8-25; ***, p<0.001; *, p<0.05). (B) Rat primary pituitary cells treated
with 50 µM BCS overnight, with 20 µM CuCl2 for 2 hours or untreated were fixed
and stained for Atp7a (Cy3 anti-Rabbit) and GM130 (cis-Golgi, FITC anti-mouse).
Atp7a distribution was not altered by BCS or copper treatment (Blue arrows point to
fibroblasts; scale bar, 10 µm).
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Figure 4.8: Copper-dependent trafficking of Atp7a in sh-µ1A PAM-1 cells. (A)
Scramble and sh-µ1A PAM-1 cells treated with 20 µM CuCl2 for 2 hours or untreated
were fixed and stained for Atp7a (Cy3 anti-Rabbit). Graph shows the ratio for mean
Atp7a fluorescence intensity in the cytosol over the Golgi region. A 20% increase in
the ratio was observed when either cell type was treated with copper (n = 35-44; *,
p<0.05; **, p<0.01). (B) Cell surface biotinylation after treatment of scramble and
sh-µ1A PAM-1 cells with 20 µM CuCl2 for 2 hours. Streptavidin bound samples (B)
represent 100-times more material than Input samples (I); Atp7a was visualized on
the upper part of the blot and SNAP25, an intracellular protein used as a negative
control, on the bottom part. (C) A two-to-three fold increase in total Atp7a levels
was observed in both scramble and sh-µ1A PAM-1 cells. (D) No difference between
scramble and sh-µ1A PAM-1 cells was seen (+ CuCl2, with 20 µM CuCl2 for 2 hours;
-CuCl2, no treatment; + biotin, with biotin; - biotin, without biotin).
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Figure 4.9: Atp7a and PAM interact in AtT-20 cells. PAM-1 cells treated with 50 µM
BCS overnight or 20 µM CuCl2 for 2 hours were extracted for immunoprecipitation
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5.1 Abstract
Copper is required for several biological processes such as peptide biogenesis. Because the
anterior pituitary gland produces large amounts of peptides, the distribution of copper in this
tissue was investigated. Subcellular fractionation of mouse and rat pituitary glands points to
an accumulation of copper in fractions enriched in secretory granules. These granules store
peptides along with processing enzymes, and secrete their content upon demand. The lumen
of the secretory pathway contains several cuproenzymes that receive copper from Atp7a, the P-
type ATPase that transports copper from the cytosol into the lumen. Lack of ATP7A function
results in Menkes disease, an X-linked, infantile onset, lethal condition characterized by the
inability to take up and utilize dietary copper. Peptidylglycine α-amidating monooxygenase
(PAM), a cuproenzyme that amidates many peptides to render them bioactive, functions in
the lumen of the secretory pathway. PAM receives copper from Atp7a, and loss of ATP7A
function results in impaired peptide amidation. Quantification of copper and PAM levels in
secretory granule enriched fractions indicated that copper levels exceeded PAM levels by
about 70-fold on a molar basis. This study provides the first quantitative description of copper
localization in the anterior pituitary gland.
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5.2 Introduction
Copper is an essential metal in human physiology as it is involved in a wide variety of cellular
processes, such as mitochondrial respiration, blood vessel formation and iron transport [279].
Formation of reactive oxygen species caused by copper is limited by the fact that copper is
bound to a variety of cuproproteins. A study done in yeast reported that less than one atom of
copper was free per yeast cell [277]. Copper enters the cell via copper transporter 1, Ctr1, and
is then rapidly transferred to specific chaperones that deliver the metal to mitochondria, the
secretory pathway or cytosolic proteins. Transport of copper from the cytosol into the lumen
of the secretory pathway is governed by two P-type ATPases, ATP7A and ATP7B. Lack of
ATP7A or ATP7B results in Menkes and Wilson disease, respectively. Menkes disease is
characterized by an overall lack of copper in most tissues resulting in neurodegeneration,
coarse hair, decreased bone density, and patients rarely survive past age 3 [279]. On the other
hand, the first signs of Wilson disease appear during the teenage years and are accompanied
by an overload of copper in most tissues, in particular the liver and the brain [280].
Copper is vital for neuropeptide and peptide hormone biogenesis, key chemical messen-
gers for cell communication. These peptides are first synthesized as larger, inactive precursors,
which undergo a sequence of post-translational modifications in order to gain bioactivity
[180]. The peptide precursors, biosynthetic intermediates and processing enzymes exit the
trans-Golgi network (TGN) in immature secretory granules. The luminal environment in the
TGN promotes aggregation of many secretory granule proteins, a process thought to promote
the sorting of granule proteins from cargo that is not stored in granules [180]. One of the last
steps in the sequence of post-translational modifications is amidation of glycine-extended
peptide intermediates, which is catalyzed by peptidylglycine α-amidating monooxygenase
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(PAM). This enzyme is composed of two catalytic core domains, PHM and PAL, which work
in sequence to complete the amidation reaction [238]. PAM is a demanding enzyme as PHM
requires copper, oxygen and ascorbate to catalyze the first reaction and PAL needs zinc and
calcium for structure and catalysis [276, 281, 282, 283]. Lack of PAM is embryonic lethal in
mice and Drosophila lacking PHM do not survive the larval stage, indicating that PAM is
required for development and that PAM is the sole protein to provide this function [260, 275].
In rodents, only the atrium of the heart expresses higher levels of PAM than the anterior
pituitary [284, 285]. This gland is composed of five major peptide-producing cell types,
somatotropes (50%), lactotropes (20%), corticotropes (15%), gonadotropes (10%) and thy-
rotropes (5%) [286]. Although none of the main anterior pituitary hormones is modified by
PAM, these same cells produce much lower levels of several amidated peptides (substance
P, neuropeptide Y, vasoactive intestinal peptide, galanin, GnRH, TRH, and pyroglutamyl-
glutamylprolineamide); these amidated peptides are thought to function more as autocrine
and paracrine agents [263].
The roles of copper in the brain and liver have been extensively explored to understand
Menkes and Wilson diseases. Although PAM is an essential cuproenzyme heavily expressed
in the pituitary gland, the distribution of copper in the pituitary has not been explored. Rat and
mouse pituitary glands were used to evaluate the concentration of copper and its distribution
using subcellular fractionation, X-ray fluorescence microscopy, and ICP-MS (Inductively
Coupled Plasma - Mass Spectometry).
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5.3 Results
5.3.1 The rat pituitary contains 40-50 µM copper
A rat pituitary was collected and frozen in cryoprotectant; 10 µm thick sections were cut and
the sections were stained with hematoxylin and eosin (Figure 5.1A). The anterior lobe can be
easily distinguished from the neural lobe in the center. The anterior pituitary is composed
primarily of peptide producing cells (chromophils; purple), while the neural lobe is composed
of the axons and terminals of neurosecretory neurons situated in the hypothalamus (light
pink).
X-ray fluorescence microscopy was used to determine the concentration of several ele-
ments, including copper. This technique can also generate a diffraction phase image as shown
in Figure 5.1A. Overall, sulfur, chloride, potassium, calcium, manganese and iron were more
concentrated in the neural lobe than in the anterior lobe, while phosphorus and copper were
present at similar concentrations in both regions (Figure 5.1B). Zinc is the only element
examined that was shown to be more concentrated in the anterior lobe. Somatotropes and
lactotropes, which represent about 70% of the anterior pituitary, produce growth hormone and
prolactin, respectively; the aggregation and storage of both hormones in secretory granules is
facilitated by the presence of zinc [287, 288]. Phosphorus, a key component of nucleic acids,
is the prevalent element with an average concentration of 75-80 mM (Figure 5.1C), followed
by sulfur and potassium with concentrations of 44 mM and 26 mM in the anterior lobe and
78 mM and 32 mM in the neural lobe. The concentrations of chloride, calcium, iron and zinc
in both the anterior and neural lobes were in the low mM range. The least prevalent metals
were manganese and copper, with both present at about 40 µM in the neural lobe and 30-45
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µM in the anterior lobe (Figure 5.1C). By comparison, brain copper levels were estimated to
be 100-250 µM at the synapse and up to 400 µM in senile plaques with Alzheimer’s disease
[216].
5.4 Copper is in secretory granule enriched pellets
Copper is required in the regulated secretory pathway, where the peptide amidating en-
zyme functions, in mitochondria for cytochrome c oxidase and in the cytosol, where the
Cu/Zn-dependent enzyme superoxide dismutase 1 and MEK reside. In order to evaluate the
distribution of copper in the pituitary gland, pituitaries were collected, homogenized and
subjected to differential centrifugation (Figure 5.2A). ICP-MS analysis of the resuspended
pellets and the cytosolic fraction (S4) indicated that S4 contained the largest amount of iron,
copper and zinc (Figure 5.2B). The P2 pellet, obtained after centrifuging samples at 4,000 g
for 17 minutes, contained more iron, copper and zinc than the other pellets combined (Figure
5.2B). Based on previous studies, we expected the P2 and P3 pellets to contain secretory
granules [289]. The peptide amidating enzyme, PAM, which spans the membrane of secretory
granules, endosomes and Golgi, has been identified in multiple subcellular fractions. Within
secretory granules, the isoform PAM-1 can be cleaved between PHM and PAL, generating
soluble PHM and PAL membrane (PALm). Soluble PHM has served as a useful marker for
secretory granules. Western blot analysis using an antibody specific for PAM exon 16, the
linker region between PHM and PAL, was used to characterize the subcellular fractions. P2
contained more PHM than the other fractions, indicating that it was enriched in secretory
granules (Figure 5.2C). Soluble PAL was also prevalent in P2, consistent with its presence in
secretory granules; PALm, which is retrieved through the endocytic pathway, was also found
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in P3 and P4, which contain endosomes and microsomes.
5.5 Copper is present in secretory granules
Because P2 contained most of the copper and protein and was enriched in secretory granules,
we next asked whether copper was present in secretory granules. The P2 pellet was gently
resuspended and loaded onto the top of a non-linear sucrose gradient to separate organelles
based on their density. Fractions of the sucrose gradient were collected from the top (low
sucrose) to bottom (high sucrose), fractionated by SDS-PAGE and western blotted for the
exon 16 region of PAM-1 (Figure 5.3A). Fractions 10-13 contained the highest amounts of
PHM and were thus identified as the secretory granule enriched fractions. Fractions 3-5
contained intact PAM-1 along with a significant amount of PALm, consistent with their
identification as an endosomal compartment. The small amount of PHM at the top of the
gradient represents secretory granules that were lysed during fractionation.
To determine the copper concentration in each sucrose fraction, ICP-MS was performed.
A peak of copper was observed between fractions 10-13, matching the secretory granule
enriched fractions (Figure 5.3B). The sucrose-containing buffer contained a significant amount
of copper (open symbols); the copper background contributed by the buffer was subtracted to
determine the level associated with the secretory granules. No peak of copper was associated
with the endosomal fractions containing PALm, but a substantial amount of copper was
recovered from the densest fraction, which would be expected to contain mitochondria.
Fractions 12 and 13 were combined and further analyzed by transmission electron mi-
croscopy after negative staining in order to verify the presence of secretory granules and to
assess purity. Secretory granules were identified as round structures filled with electron dense
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material (Figure 5.3C). On average, the secretory granules had a diameter of 283 +/- 34 nm.
Unlike other cuproenzymes, the PHM domain of PAM does not bind copper with ex-
tremely high affinity. We therefore wanted to compare the concentrations of copper and PAM
in the secretory granule enriched fractions. Using recombinant purified PAM 820s protein
as a standard, the total amount of PAM protein (intact + processed) in fractions #12 and
#13 was determined (Figure 5.3D). The concentration of copper in the same fractions was
determined using ICP-MS (Figure 5.3B). The ratio of the molar concentration of copper to
the molar concentration of PAM protein was about 70 for both fractions. Similar results were
obtained when whole mouse pituitaries were used; a copper to PAM ratio of 60 was observed
(data not shown). If most of the copper and most of the PAM protein in these fractions is
contained in secretory granules, copper is present in a significant molar excess. Assumptions
about the number and volume of the secretory granules must be made in order to use the
concentrations measured in fractions #12 and #13 to calculate the molarity of copper and
PAM in the secretory granule lumen.
5.6 Discussion
Copper is essential for the generation of many bioactive peptides, notably because PAM
is a cuproenzyme that catalyzes the α-amidation of most peptide hormones. The anterior
pituitary contains five major cell types producing peptide hormones, and copper is present in
secretory granules of the anterior pituitary. Each peptide producing cell can be distinguished
from the other types by their morphology and the size of their secretory granules, ranging
from 100 nm diameter in thyrotropes to 900 nm diameter in lactotropes [290]. The amount
and concentration of copper in anterior pituitary secretory granules may be cell type specific.
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In addition, heterogeneity in secretory granule content protein from the same cell has been
observed in corticotrope and somatotrope tumor cell lines, suggesting that copper amounts
within secretory granules of the same cell may also vary [187].
In an earlier study, metabolic labeling was used to estimate secretory granule content
of peptide hormone vs. processing enzyme; the conclusion reached was that each secretory
granule contained only about one PAM molecule [291]. Our data demonstrated the presence
of a substantially higher concentration of copper than PAM in fractions enriched in secretory
granules. The dissociation constant for copper binding to the CuH site of PHM is about 0.06
µM and copper must be bound to both the CuH and CuM site for the enzyme to function
[276]. With one PAM protein per 300 nm diameter secretory granule, the concentration
of PAM would be about 0.12 µM, making the concentration of copper in the secretory
granule lumen about 8 µM. Our data suggest that copper levels in secretory granules are
high enough to prevent PAM from becoming inactive in secretory granules due to a lack of
copper. Interestingly, no luminal copper chaperone has been identified, leaving it unclear
how secretory granules remain protected from copper toxicity [255]. Our data indicate that
secretory granule copper concentrations are not higher than the average copper concentration
in the pituitary. With no copper chaperones in the lumen of the secretory pathway, delivering
the correct amount of copper to the granule lumen may be the key step. Cytosolic copper
binding proteins would serve as a reservoir of copper that could be delivered by Atp7a when
needed.
Defining and understanding the distribution of metals such as copper is becoming impor-
tant for comprehending and possibly treating multiple diseases. Menkes and Wilson disease
are the most well described pathologies linked with impaired copper homeostasis. Other
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pathologies have been associated with mutations in ATP7A. Occipital horn syndrome is
caused by a change in splicing events and a reduction of functional ATP7A [292]. A more
recently described form of ATP7A mutation has been associated with distal motor neuropa-
thy; in these cases, ATP7A is functional, but its trafficking is altered [293, 294]. MEDNIK
(Mental Retardation Enteropathy Deafness Peripheral Neuropathy Ichtyosis Keratodermia)
is a disorder caused by lack of the small subunit of adaptor protein 1, a cytosolic protein
complex involved in post-Golgi trafficking [217]. This syndrome combines characteristics of
both Menkes and Wilson disease, presumably because ATP7A trafficking has been shown to
be perturbed in cells with reduced AP-1 function [220, 219]. Alzheimer’s disease, the most
common form of dementia, may involve an interaction of copper with amyloid β peptides,
promoting their aggregation and generating a cytotoxic environment that triggers neuronal
cell death [216]. On the contrary, when copper binds islet amyloid polypeptide, it prevents
this 37-residue peptide from forming amyloid fibrils and thus protects β-cells from apoptosis
[295]. Since aggregation of amyloid polypeptide has been observed in about 95% of patients
with type 2 diabetes, mild dietary copper augmentation might help prevent the development
of this disorder.
5.7 Material and Methods
5.7.1 X-ray fluorescence microscopy
Rat pituitaries were collected and frozen in cryoprotectant and stored at -80◦C until sectioning.
10 µm thick sections were obtained and imaged using X-ray fluorescence microscopy as
described previously [296]. In parallel, a section was cut and stained with hematoxylin and
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eosin to compare regions of interest.
5.7.2 Inductively coupled plasma mass spectrometry (ICP-MS)
Tubes used for ICP-MS were incubated in 1% HNO3 (trace metal grade, Fisher Scientific) for
at least 24 hours. Samples were digested with 50% HNO3 (trace metal grade, Fisher Scientific)
in Eppendorf tubes at room temperature overnight. The digested samples were brought to a
total volume of 1 mL with 1% HNO3, mixed by vortexing, and centrifuged at 3500 rcf for 3
minutes to remove debris. ICP-MS analysis was carried out as described previously [297].
Homogenization buffer and sucrose solutions were also analyzed to determine background
contributions.
5.7.3 Differential centrifugation and subcellular fractionation
Anterior pituitaries from adult male Sprague-Dawley rats or mouse pituitaries were homog-
enized at 4◦C in 10 volumes (w/v) of homogenization buffer: 0.32 M sucrose in 10 mM
Tris-HCl, pH 7.4, containing 34 mg/ml phenylmethylsulfonyl fluoride, 16 mg/ml benzami-
dine, 2 mg/ml leupeptin, and 10 mg/ml lima bean trypsin inhibitor (inhibitor mix) using
six strokes of a motor-driven glass Potter-Elvehjem homogenizer with a Teflon pestle. The
homogenate was subjected to differential centrifugation at 4◦C. The homogenate was first
centrifuged for 5 minutes at 800 g yielding a pellet (P1) containing nuclei and cell debris.
The supernatant (S1) was centrifuged at 4,000 g for 17 minutes to obtain a pellet (P2) and a
supernatant (S2), which was then centrifuged at 10,000 g for 15 minutes generating a pellet
(P3), and a supernatant (S3). Lastly, S3 was centrifuged at 350,000 g for 15 minutes and
provided another pellet (P4) and a cytosolic fraction (S4). Each pellet was resuspended in
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225 µL of homogenization buffer and either kept at -80◦C for further analysis or loaded on
top of a non-linear sucrose gradient. Sucrose solutions were always made fresh in 10 mM
Tris-HCl, pH 7.4, containing inhibitor mix. P2 was resuspended in homogenization buffer
and loaded onto a discontinuous sucrose density gradient composed (bottom to top) of: 200
µL 2M sucrose, 350 µL of 1.6M sucrose, 350 µL 1.4M sucrose, 350 µL 1.2M sucrose, 200
µL 1M sucrose, 200 µL 0.8M sucrose, 200 µL 0.4M sucrose, all in homogenization buffer.
After centrifugation at 120,000 x g in a TLS-55 rotor for two hours at 4◦C, aliquots of 150
µL were collected from top to bottom and kept at -80◦C for further analysis.
5.7.4 Negative staining and transmission electron microscopy
Fractions 12 and 13 (100 µL) from the subcellular fractionation were combined and 200
µL of 10 mM HEPES, pH 7.4 containing protease inhibitors. The sample was centrifuged
at 10,000 g for 15 minutes at 4◦C. The supernatant was discarded and 200 µL of 2.5%
glutaraldehyde in 10 mM HEPES, pH 7.4 was added on top of the pellet. The sample was
then centrifuged at 10,000 g for 10 minutes at 4◦C. The pellet was resuspended in 100 µL of
10 mM HEPES, pH 7.4 and used for negative staining. 4-5 µL of sample were added on top
of a copper mesh grid. After waiting for 1 minute for the sample to diffuse across the grid,
excess sample was removed using a filter paper. Uranyl acetate solution (4-5 µL of 1% to
3% uranyl acetate dissolved in water) was added on top. After allowing the uranyl acetate to
diffuse for 1 minute, excess salt was removed with filter paper. The sample was then imaged
using a Hitachi H-7650 Transmission Electron Microscope.
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5.7.5 Purification of PAM 820s
A CHO-DG44 cell line stably expressing pCIS-PAM3-∆Pro-∆Gly 820s was grown in serum-
free medium in CellMax artificial capillary cartridges (Spectrum laboratories, CA, USA;
Cartridge #400-023) [298]. Spent medium was collected (three times per week or daily,
depending on density) and stored frozen after addition of PMSF. Secreted proteins were
concentrated by addition of solid (NH4)2SO4. PAM 820s was purified on a DEAE-Sepharose
FF column (20 mm x 150 mm) equilibrated with 20 mM NaTES (pH 7.0) and eluted with a
150 ml gradient to 0.5M NaCl in the same buffer followed by gel filtration on a Superose 6
10/300GL column (25 x 350 mm) equilibrated with 20 mM NaTES, 150 mM NaCl (pH 7.0).
The purity and homogeneity of the protein was evaluated by SDS-PAGE (Bio-Rad Criterion
TGX gels, 4-15% gradient) followed by staining with Coomassie Brilliant Blue R250.
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Figure 5.1: The pituitary gland contains 40-50 µM copper. (A) Left, Hematoxylin
and eosin staining (H&E) showing the anterior and neural lobes of a 10 µm thick of
a transverse section. Right, Phase image of another 10 µm thick transverse section
observed by X-ray fluorescence microscopy. (B) X-ray fluorescence microscopy
scans of a rat pituitary showing the distribution of P, S, Cl, K, Ca, Fe, Cu and Zn.
The max and min values for each metal are indicated in µg/cm2. (C) Two boxes were
drawn either in the anterior or neural lobe to determine the concentration of each
element measured. The concentration is expressed in micromolar. Samples were 10
µm thick and the density used was 1.025 g/cm3.
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Figure 5.2: Copper is enriched in P2. (A) Differential centrifugation followed by
subcellular fractionation protocol. After separation on a sucrose gradient, 150 µL
fractions were collected from top (#1) to bottom (#15). (B) Percentage of iron,
copper and zinc in P2, P3 and P4 pellets from the differential centrifugation after
measurement by atomic absorption. P2 contains all 3 metals. (C) Western blots show
the distribution of PAM-1 and its processed products after differential centrifugation.
P2 is enriched in PHM, a PAM-1 processed product generated in secretory granules
[12].
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Figure 5.3: Copper is in secretory granules. (A) Western Blot of fractions #2 to #15
collected after separation of P2 on sucrose gradient. Fraction #15 corresponds to the
bottom of the gradient. PHM, the marker for secretory granules, accumulates in frac-
tions #10 to #13. Fractions #12 and #13 were collected for analysis by transmission
electron microscopy. (B) Copper concentration was measured for the fractions of
the sucrose gradient by atomic absorption. A peak of copper was seen in fractions
#10 to #13. Sucrose solutions were used to define the background signal shown in
blue. This experiment was repeated with mouse pituitaries with a similar result. (C)
Two representative images of secretory granules taken at different magnifications are
shown. Secretory granules are round and darker than the background. The average
diameter of 13 secretory granules measured using negative staining was 283 nm. (D)
Western Blot of fractions #12 and #13 along with known amounts of purified PAM
820s, which is truncated at residue 820, is shown. 820s* corresponds to degraded
PAM 820s and was included in the quantification.
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6.1 Abstract
Neuropeptides, which are expressed along with a classical neurotransmitter by most neurons,
play an essential role in physiological responses such as satiety and pain perception. For one
third of the neuropeptides, the presence of an α-amidated amino acid at the C-terminus is
essential for bioactivity. This post-translational modification requires a bifunctional integral
membrane enzyme, peptidylglycine α-amidating monooxygenase (PAM). PAM is composed
of two catalytic core domains, peptidylglycine α-hydroxylating monooxygenase (PHM) and
peptidyl-α-hydroxyglycine α-amidating lyase (PAL), which work in sequence to convert a
peptidylglycine substrate into an amidated product plus glyoxylate. Deletion of the gene
encoding PAM results in larval lethality in Drosophila melanogaster and embryonic lethality
in the mouse, demonstrating its importance. The expression of PAM protein was followed
during postnatal development (P0, 7, 14, 21, 28 and adult) in the rat hippocampus and cortex.
The PAM protein is subject to endoproteolytic cleavage, creating soluble, catalytically active
fragments that can be secreted along with their amidated peptide products. Western blot
analyses revealed a substantial increase in the expression of PAM-1, a major PAM splice
variant, from birth until a peak at P21 in both brain regions. At P0, intact PAM-1 was a
major product; soluble 45 kDa PHM accumulated in both tissues as development progressed.
The subcellular distribution of PAM-1 was determined by immunofluorescent staining of
cultured E18.5 rat hippocampal neurons maintained in vitro for 7, 10 or 14 days: PAM
was concentrated in perinuclear tubuloreticular structures in the cell soma and in vesicular
structures distributed throughout both dendrites and axons. Neuropeptide Y (NPY), one of
the most prevalent amidated neuropeptides, is concentrated in secretory granules located in
dendrites and axons of hippocampal neurons. Co-staining for PAM-1 indicated that NPY and
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PAM-1 partially colocalized in vesicles distributed in processes.
6.2 Introduction
Most neurons produce both small molecule neurotransmitters and neuropeptides to communi-
cate with other cells. Conventional or small molecule neurotransmitters accumulate in small
synaptic vesicles at presynaptic terminals whose release is regulated by action potentials
that depolarize the membrane at the presynaptic terminal. Released neurotransmitters bind
to their receptors on the postsynaptic side to generate an action potential or alter signaling
and are either degraded or recaptured in the presynaptic neuron [299]. Neuropeptides act as
neurotransmitters, autocrine or paracrine agents, or as hormones acting over long distances
[300]. After transiting through the endoplasmic reticulum and the Golgi, newly synthesized
neuropeptides are targeted into secretory granules located in the cell soma, dendrites and
axons [299, 300]. In contrast with small molecule neurotransmitters, which are secreted at
presynaptic terminals, neuropeptide exocytosis was observed from the perikaryon, along the
dendrites and axons near synapses [299]. Once secreted, neuropeptides are degraded and not
recaptured.
Neuropeptides are synthesized as inactive precursors that must undergo several modifi-
cation steps in order to become bioactive [187]. Many peptides contain an α-amide moiety
at their C-terminus that is required for binding to their receptor [273]. This modification is
catalyzed by peptidylglycine α-amidating monooxygenase (PAM), composed of two catalytic
core domains, peptidylglycine α-hydroxylating monooxygenase (PHM) and peptidyl-α-
hydroxyglycine-α-amidating lyase (PAL), which work in sequence in the amidation reaction
[238]. Although only one gene encodes PAM, at least seven splice variants have been identi-
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fied in rodents (Figure 6.1) [301]. PAM-1, PAM-2 and PAM-3 are the three major isoforms
expressed with PAM-3, the only major isoform that is not a membrane protein. PAM-1 and
PAM-4 are the only isoforms containing exon 16, which can be endoproteolytically cleaved
in secretory granules. PAM-4 does not encode PAL and PAM-5 encodes a truncated version
of PHM that is inactive. Because peptide amidation is a two-step reaction catalyzed by
PHM and then PAL, PAM-4 cannot catalyze the full reaction rendering its function unclear.
After transiting though the endoplasmic reticulum and the Golgi en route to the regulated
secretory pathway, PAM exits the Golgi in secretory granules with neuropeptides [12]. The
environment of secretory granules is ideal for PAM activity. Upon exocytosis, soluble PAM
isoforms are secreted along with the neuropeptides, while the membrane isoforms of PAM
that reach the plasma membrane are subsequently internalized into the endocytic pathway
[12]. Studies done on pituitary cells indicated that membrane PAM isoforms found in the
endocytic compartments can be degraded in lysosomes or recycled to the Golgi for re-entry
into secretory granules [195, 189].
High levels of PAM mRNA were identified in the heart atrium, anterior and neuroint-
ermediate lobes of the pituitary gland, sublingual and submandibular salivary glands and
specific regions of the central nervous system in rodents [302, 303, 304]. PAM is an enzyme
essential for development in mice and flies [260, 275]. A previous study indicated that PAM
mRNA levels and PAM activity in rat heart atrium and ventricle are developmentally regulated
[305]. Since PAM is highly expressed in the central nervous system, we investigated PAM
mRNA and protein levels in the rat cortex and hippocampus during postnatal development.
In addition, cultures of E18.5 rat hippocampal neurons were maintained for 7 to 14 days in
vitro to allow determination of the distribution of PAM.
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6.3 Results
6.3.1 PAM-1 mRNA is the major isoform expressed in cortex and hippocam-
pus during development
PAM mRNA expression in adult rat brain was detected in every brain region except the
cerebellum. The hippocampus, the supraoptic nucleus and the anterior olfactory nucleus
were the brain regions where PAM mRNA was the most prevalent [304]. Investigation of
which PAM mRNA isoforms are predominantly expressed during cortical and hippocampal
development was done using PCR. A set of primers were first designed to distinguish
between membrane and soluble PAM isoforms (membrane primers) (Figure 6.2A). Using the
membrane primers, the membrane isoforms of PAM were prevalent at P2, P16 and P30 in
both tissues suggesting that PAM-1, PAM-2 or PAM-3b were the most expressed isoforms
(Figures 6.1 and 6.2B). One difference between the three membrane isoforms of PAM is the
presence of exon 16 in PAM-1 only. To find out if PAM-1 is the major isoform expressed in
cortex and hippocampus of rats during postnatal development, a second set of primers was
generated to differentiate PAM-1 from PAM isoforms lacking exon 16 (Figure 6.2A). In the
cortex and hippocampus, PAM-1 mRNA levels increased during development while mRNA
from PAM isoforms lacking exon 16 did not (Figure 6.2C). In the cortex at P2, PAM-1 mRNA
levels were similar to PAM isoforms lacking exon 16 suggesting the presence of PAM-2 while
PAM-1 mRNA is already the main isoform in the hippocampus. PAM-1 mRNA at P16 in the
cortex migrated faster compared with the other samples. This sample was analyzed a second
time using less material and no difference with the other samples was seen, suggesting that
this difference was due to the high amount of material and not a change in mRNA processing
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of PAM (data not shown).
6.3.2 PAM-1 is developmentally regulated in rat cortex and hippocampus
The protein levels of PAM-1 during development in the hippocampus and the cortex were
investigated. Cortices and hippocampi from rats were collected at P0, P7, P14, P21, P28
and during adulthood, and Western blots using an antibody targeting the exon 16 region of
PAM-1 was performed (Figure 6.3A). Based on PCR data, we expected PAM-1 protein levels
to increase during development in the cortex while it would be constant in the hippocampus.
In the cortex, intact PAM-1 protein levels increase after the first week of birth until P21,
where PAM-1 levels were about 7 times higher than at birth. Intact PAM-1 protein levels then
reach the PAM-1 levels seen in adults, corresponding to about 3 times the amount observed
at birth. Interestingly, intact PAM-1 levels only slightly increase during development in the
hippocampus and were about 60% lower in adults than at birth. Based on studies in AtT-20
cells, when PAM-1 reaches secretory granules, it is endoproteolytically cleaved between the
two catalytic core domains producing membrane associated PAL (PALm) and soluble PHM
[12]. PHM and PALm expression profiles were similar in both tissues. In the cortex, PALm
and PHM expression levels resemble PAM-1 profile during development, while hippocampal
PHM and PALm levels were very low at birth, augmented very strongly until P21-P28 and
declining toward adult levels. Although PHM levels in the cortex were about 20 times higher
at P21 than at birth, hippocampal PHM levels were more than 70 times higher at P21 than at
birth.
The expression profile of PAM-1 was compared with another marker of secretory granules,
prohormone convertase 2 (PC2) (Figure 6.3B). PC2 is first synthesized as an inactive precursor
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that undergoes an endoproteolytic cleavage in secretory granules to generate the mature active
form [199]. In both tissues, PC2 precursor levels increased until P7 and then remained stable
throughout development. The expression profile of the mature form of PC2 matched that of
PHM and PALm in both tissues.
6.3.3 PAM-1 is localized in soma and processes of hippocampal neurons
In order to find out where PAM is localized in neurons, E18.5 rat hippocampal neurons
were maintained in vitro for 7, 8, 10 or 14 days (Figure 6.4). Immunofluorescent staining
of PAM-1 was performed using an antibody recognizing exon 16. Co-staining with βIII
tubulin, a marker that identifies the cell soma and all processes of neurons, showed that
PAM-1 was in the cell soma, where it concentrated in a perinuclear region and in puncta
observed in processes (Figure 6.4A). A strong colocalization between PAM-1 and γ-adaptin,
a Golgi region marker, was observed at the perinuclear region where PAM-1 accumulates,
indicating that PAM-1 concentrates at the Golgi of the perikaryon (Figure 6.4B). Transferrin
and transferrin receptor were reported to be excluded from the axon in hippocampal neurons
[185]. DIV8 hippocampal neurons were thus incubated with Alexa fluor 546 transferrin for
10 minutes, fixed and stained for PAM-1. Alexa fluor 546 transferrin puncta were easily
identified in processes and near the nucleus in the cell soma. One process lacking internalized
transferrin but containing PAM-1 suggested that PAM-1 goes to the dendrites and axons of
hippocampal neurons (Figure 6.4C). Co-labeling of neurons for PAM-1 and ankyrin G, a
marker of the axon initial segment, in DIV10 hippocampal neurons, indicated the presence of
PAM-1 in axons (Figure 6.4D). Lastly, PAM-1 staining of DIV14 hippocampal neurons with
MAP2 (Microtubule Associated Protein 2), a dendritic marker, revealed the presence of one
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process per cell that contained PAM-1 but was devoid of MAP2 (Figure 6.4E). Altogether,
these data indicated that PAM-1 concentrates in the Golgi region of the cell soma, in dendrites
and axons of hippocampal neurons at different days in vitro.
6.3.4 PAM-1 and neuropeptide Y colocalize in hippocampal neurons
Neuropeptide Y is an amidated peptide expressed in a subset of hippocampal neurons. Studies
on mice and human hippocampi indicated that neuropeptide Y acts as an essential anti-
epileptic agent [306, 307, 308]. Before PAM catalyzes the final modification of neuropeptide
Y, this peptide undergoes an endoproteolytic cleavage, catalyzed by prohormone convertase
2, followed by trimming of basic residues at the C-terminus by carboxypeptidase E (Figure
6.5A). Prohormone convertase 2, carboxypeptidase E and PAM-1 are more active at acidic
pH found in secretory granules. Although peptide amidation was observed at the trans-
Golgi network (TGN), this modification occurs mainly in secretory granules suggesting that
neuropeptide Y and PAM must leave the (TGN) to go to secretory granules together. In
order to compare neuropeptide Y distribution with that of PAM-1, hippocampal neurons
maintained in vitro for 10 days were stained with an antibody that recognizes all forms of
neuropeptide Y and an antibody that targets the exon 16 region of PAM-1. Both markers
strongly colocalized at the perinuclear region and in vesicles located in processes (Figure
6.5B). PAM-1 is a membrane protein known to span the membrane of secretory granules
and endosomes. PAM-1 positive vesicles lacking neuropeptide Y are likely to represent
endosomes. Interestingly, the ratio of neuroepeptide Y over PAM-1 in vesicles was not
the same within the same neuron suggesting that secretory granules are not all identical as
previously observed in a corticotrope and a somatotrope tumor cell lines [187].
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6.4 Discussion
Small molecule neurotransmitters from the synaptic cleft can be re-captured at the presynaptic
terminal and re-used. This is in contrast with neuropeptides which are degraded or diffuse
away once secreted in the extracellular compartment. After secretion of peptides, neurons
have to synthesize neuropeptides and processing enzymes to replenish their pool of secretory
granules. Because neurons can extend over long distances and the perikaryon is the only place
to generate secretory granules, it is not entirely clear how the cell soma senses the status of
the secretory granule pool in processes. PAM amidates many neuropeptides, rendering them
bioactive, and is essential during development [260, 275]. The membrane isoform, PAM-1, is
subject to regulated intramembrane proteolysis generating a soluble fragment of the cytosolic
domain capable of entering nuclei and altering gene expression in neuroendocrine cells and
neurons [223].
This study provides an overview of the PAM expression profile in the cortex and hip-
pocampus. The cortex is involved in perception and movement while the hippocampus
controls learning and memory. Although seven PAM isoforms were detected in rodents,
PAM-1 was the major PAM isoform expressed in the developing cortex and hippocampus. In
the cortex, glia develop the most after birth while the number of neurons is mostly defined
before birth. This is in contrast with the hippocampus, where the dentate gyrus can generate
new neurons postnatally [309]. Although the PAM-1 protein and PC2 detected could come
from neurons and glia, the level of these secretory granule markers increased during postnatal
development until P21 and then reached adult levels. Even though peptides can be secreted
from the cell soma, along the processes and at synapse, P21 marks the peak of synaptogenesis
in rodents. This suggested that secretory granules and synapses form at a similar moment in
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the cortex and hippocampus. Interestingly, the expression pattern of proopiomelanocortin and
the formation of its cleavage products (β-endorphin and adrenocorticotropin) in the pituitary
gland resembles that of PAM-1 [310].
The adaptor protein 1 complex (AP-1) is a heterotetrameric complex involved in the trans-
port of cargo between the trans-Golgi network and endosomes and mediates the biogenesis
and maturation of secretory granules. A previous study in hippocampal neurons indicated
that AP-1 interacts with transferrin receptor to prevent its entry into the axon [185]. Mutation
of the AP-1 binding site on the cytosolic domain of the transferrin receptor resulted in equal
distribution of the membrane protein between axons and dendrites [185]. Interestingly, the
cytosolic domain of PAM was shown to interact with AP-1 in neuroendocrine cells and in a
yeast two-hybrid screen [234]. Cultured hippocampal neurons indicated that PAM-1 concen-
trated at the Golgi region and was distributed in both axons and dendrites. This suggested
that AP-1 function in PAM trafficking is different from AP-1 function in transferrin receptor
trafficking. Since AP-1 is required for retrograde trafficking, it would be interesting to find
out whether AP-1 is required for PAM-1 retrograde trafficking into the Golgi in neurons
[220, 178].
Regulated secretion prevails in neurons and diseases like autism are associated with
diminished neuronal connectivity [311]. During development, neurons secrete peptides to
promote neuron survival, growth, differentiation and synapse formation. Impairment in
providing the right peptide during a specific time window and at a defined location can thus
alter brain development severely. Understanding PAM trafficking in neurons will thus provide
insight in the roles of peptide synthesis in brain development.
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6.5 Material and methods
6.5.1 Polymerase Chain Reaction (PCR)
For time course studies, cortices and hippocampi were collected in TRIzol and homogenized
using a Polytron. Each sample received 0.2 ml of chloroform per ml of TRIzol, and was
shaken by hand for 15 seconds. After sitting for 2-3 minutes, samples were spun at 10,000
g for 15 minutes at 4◦C. The aqueous phase was collected, received 0.65 ml of isopropyl
alcohol per ml of TRIzol reagent used and kept at -20◦C overnight. After centrifuging at
10,000 g for 10 minutes at 4◦C, the supernatant was discarded and the RNA pellet was washed
using 75% ethanol twice. 20 µL of DEPC treated water was added to the dried pellet. The
cDNA samples were prepared from 1 µg RNA using Superscript II (Invitrogen) and iScript
(BioRad) with random primers. Samples were kept at 65◦C for 5 minutes before chilling and
adding the iScript reverse transcriptase. Samples were then incubated at room temperature
for 5 minutes followed by an incubation at 42◦C for 45 minutes and 65◦C incubation for 5
minutes. Samples were kept at -80◦C until analysis. PCR was performed using a BioRad MJ
Mini Personal Thermal Cycler (#PTC-1148) and Sybr-Green (BioRad), with the following
parameters: 95◦C 3 min; 95◦C 30 sec, 58◦C 1 min, 72◦C 1 min; repeat 40x. The last
parameter was hold at 72◦C for 5 minutes. The primers used are shown in Table 6.1.
6.5.2 Western Blot Analysis
For time course studies, cortices and hippocampi collected from rats of different ages were
sonicated into the SDS lysis buffer used for half-life studies, heated for 5 min at 95 ◦C, and
centrifuged to remove insoluble debris as described [312]. 20 µg of total protein was loaded
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onto each lane for analysis of PAM and PC2.
6.5.3 Cell culture
Cultures of rat hippocampal neurons were described previously [312]. Briefly, hippocampi
from embryonic day 18 Sprague-Dawley rats were collected and digested using 0.28% trypsin
for 15 min at 37◦C with gentle shaking. Cells were dissociated with a fire-polished glass
pipette and plated at about 2-4 x 104 cells/mL onto 12 mm coverslips coated with poly-L-
lysine (1 mg/mL). At plating, cells were incubated in Dulbecco’s Modified Eagle Medium/F-
12 (DMEM/F-12) containing 10% fetal calf serum, 5% heat-inactivated horse serum, 0.5 mM
glutamine, 50 U/mL of penicillin, and 50 µg/mL of streptomycin and maintained at 37◦C in
a 5% CO2 atmosphere (all reagents were from Life Technologies). Twenty-four hours later,
plating medium was replaced with Neurobasal medium containing 3% horse serum, 0.5 mM
glutamine, 50 U/mL of penicillin, and 50 µg/mL of streptomycin. Thereafter, 50% of the
culture medium was exchanged with Neurobasal medium containing 2% B27 supplement,
0.5 mM glutamine, 50 U/mL of penicillin, and 50 µg/mL of streptomycin twice a week. For
transferrin uptake, neurons were directly incubated in neurobasal medium containing 25
µg/mL of Alexa fluor 546 transferrin for 10 minutes and then fixed using 4% formaldehyde
in PBS for 20 minutes at room temperature.
6.5.4 Immunofluorescent staining
Hippocampal neurons were fixed at DIV7, DIV8, DIV10 and DIV14 using 4% formaldehyde
in phosphate buffer saline (PBS, 50 mM NaH2PO4, 150 mM NaCl, pH 7.4). After rinsing
in PBS once, cells were permeabilized in 0.2% Triton X-100, 2 mg/ml BSA in PBS for 20
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minutes at room temperature and then incubated in block (2 mg/ml BSA in PBS) for an
hour at room temperature. Primary antibodies diluted in block buffer were incubated with
the cells overnight at 4◦C. After three rinses in PBS, cells were incubated for one hour at
room temperature in block containing either fluorescein isothiocyanate (FITC, 1:500 dilution)
or Cy3 (1:2000 dilution) conjugated donkey antibody to mouse or rabbit immunoglobulin
(Jackson ImmunoResearch). After three rinses in PBS, cells were incubated with Hoechst
(1:1000 dilution in PBS) for 10 minutes at room temperature. After three rinses in PBS, cells
were mounted using ProLong R© Gold (Invitrogen). Neurons were visualized using either a
Nikon TE300 epifluorescence microscope or a Zeiss LSM 510-Meta with an oil immersion
63X Plan Apochromat objective (NA 1.4).
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6.6 Tables
Name Sequence Tm (◦C)
Membrane For CACCGTGTGGAAGTTCACCCTGAC 62
Membrane Rev GAAATTTCCCAGATTTAAGCCGCCGC 61
Exon 16 For GCACGGGCATCACAAAGAAGCAGAAAAC 62.5
Exon 16 Rev CAGGCCAGTCCAGTTCTTCTTCCA 61.5
Table 6.1: List of primers used for PCR.
Antigen Working dilution Identity, source
Exon-16, PAM-1(409-497) 1:500 JH629 [224]
βIII tubulin 1:1000 Covance (Tuj1)
γ-adaptin 1:1000 BD Biosciences
Ankyrin G 1:500 NeuroMAb (Clone N106/36)
MAP2 1:500 Sigma (Clone AP-20)
PC2 (626-638) 1:500 JH1159 [199]
Neuropeptide Y 1:500 Abnova (Clone 2C10)
Table 6.2: List of antibodies used.
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6.7 Figures
Figure 6.1: PAM isoforms produced by alternative splicing. In all tissues studied so
far, PAM-1, PAM-2 and PAM-3b are the membrane isoforms while PAM-3, PAM-3a,
PAM-4 and PAM-5 are the soluble isoforms. PAM-1, PAM-2 and PAM-3 are the
three major PAM isoforms. PAM-1 is the only major isoform containing exon 16
while PAM-3 is the only major isoform lacking a transmembrane domain. TMD,
transmembrane domain; CD, cytosolic domain.
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Figure 6.2: PAM-1 mRNA predominates during development of cortex and hip-
pocampus. (A) Two sets of primers were used: membrane primers (blue) and exon
16 primers (red). The membrane primers were designed to amplify exons 24-27
encoding the transmembrane domain. Expected band size after amplification for each
primer pair is noted on top of each PAM isoform. (B) PCR results after using the
membrane primers (blue). Membrane forms of PAM (PAM-1, PAM-2 and PAM-3b)
predominate throughout development in both cortex and hippocampus. (C) PCR
results after using exon 16 primers (red). Similar amounts of PAM mRNA with and
without exon 16 are detected at P2 in cortex suggesting presence of PAM-2. At P30,
PAM-1 mRNA is the predominant isoform in both the cortex and the hippocampus.
TMD, transmembrane domain; CD, cytosolic domain.
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Figure 6.3: PAM and PC2 are developmentally regulated. Western blot using an
antibody specific for Exon 16 identifies intact PAM-1 at all ages (A) and an antibody
specific for PC2 (B). On the right of each blot is shown the endoproteolytic cleavage
of PAM-1 and PC2. The cleavage generating PHM occurs primarily in secretory
granules (SG). PC2 is first synthesized as pre-proPC2. The signal sequence (shown in
black) is cleaved in the endoplasmic reticulum (ER) while the pro-sequence (shown
in yellow) is cleaved in secretory granule (SG) to generate the mature form of PC2
(shown in red). In both cortex and hippocampus, the most dramatic change during
development is an increase in the amount of soluble PHM and the mature form of
PC2, markers of secretory granule. In B, Coomassie staining reveals equal amounts
of protein per lane. Graphs show the levels of PAM-1, PALm, PHM and PC2 in the
cortex and hippocampus normalized to the levels in adulthood.
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Figure 6.4: PAM-1 is located in the cell soma, dendrites and axons of hippocampal
neurons. Immunofluorescent staining of cultured E18.5 rat hippocampal neurons
maintained in vitro for 7 days (A), 8 days (B), 10 days (C and D),14 days (E)
revealed PAM-1 in the cell soma, dendrites and axon. Immunostaining for PAM-1
used an antibody specific for exon 16 (Cy3 anti-rabbit in A, C and D and FITC
anti-rabbit in B). (A) PAM-1 accumulates in the perinuclear region of the cell soma
corresponding to the region occupied by the Golgi complex and is evenly distributed
in processes. βIII tubulin (FITC anti-mouse) reveals the cell soma and all processes.
(B) Alexa fluor 546 transferrin was incubated with DIV8 hippocampal neurons for
10 minutes. Transferrin is not taken up by the axon [185]. (C) PAM (Cy3 anti-rabbit)
and an antibody that recognizes γ-adaptin, a subunit of AP-1. Both markers strongly
colocalized in the perinuclear region which corresponds to the Golgi region. (D)
Ankyrin G (FITC anti-mouse) shows the axon initial segment [312]. (E) MAP2 stains
the dendrites and cell soma. White arrowheads delineate the axon, where PAM is
present. In (A), (B) and (C), the nuclei were stained with Hoechst. Scale bar, 10 µm.
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Figure 6.5: Neuropeptide Y and PAM share a similar distribution. (A) Neuropeptide
Y processing is characterized by four modifications. The last step is catalyzed by
PAM, generating the bioactive peptide. (B) Immunostaining of DIV10 hippocampal
neurons used an antibody that recognizes exon 16 of PAM (Cy3 anti-rabbit) and
an antibody that recognizes all forms of neuropeptide Y (NPY, FITC anti-mouse).
Strong colocalization in the cell soma and processes was observed. On the right, the
same image is shown but the signal was greatly enhanced to observe the processes.
Surrounding neurons express PAM at a different level but they do not express NPY.
Nuclei were stained with Hoechst in blue. Scale bar, 10 µm.
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Chapter 7
Conclusions and future directions
Mathilde L. Bonnemaison.
Acquisition of data
Yan Yan and Richard E. Mains prepared the neurons; Mathilde L. Bonnemaison did the
remaining experiments under the supervision and guidance of Ann E. Cowan, Richard E.
Mains and Betty A. Eipper.
7.1 Introduction
The adaptor protein 1 complex (AP-1), a cytosolic complex composed of two large subunits
(γ and β1), a medium subunit (µ1) and a small subunit (σ1), plays a central role in both
the regulated secretory pathway and endocytic pathway. Reduced AP-1 function in AtT-20
cells had profound effects on the architecture of the trans-Golgi network (Chapter 2), the
formation of secretory granules (Chapter 2), the regulated secretion of peptides (Chapter 2),
the maturation of endosomes (Chapter 3), the trafficking of vital proteins and cholesterol
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(Chapters 2-4) and copper homeostasis (Chapter 4).
AP-1 is part of a family of adaptor protein complexes where each member has a similar
structural organization. Lack of any one AP subunit is sufficient to alter the stability and the
function of the remaining complex. Although yeast that lack expression of AP-1 subunits do
not show any phenotype, mice lacking the expression of γ or µ1A die during the prenidation
period and at embryonic day E13.5, respectively, indicating that AP-1 is essential for devel-
opment of multicellular organisms [92, 178, 183]. In humans, MEDNIK (Mental retardation,
Enteropathy, Deafness, peripheral Neuropathy, Ichthyosis, Keratodermia) syndrome and a
type of X-linked mental retardation have been associated with mutations in σ1A and σ1B
respectively, [254, 217, 218]. Both subunits are ubiquitously expressed isoforms of the
small subunit of AP-1 [92]. Both pathologies identified as mutations of an AP-1 subunit
are associated with mental retardation. Patients with X-linked mental retardation also have
hypotonia early in life, delay in walking and basal ganglia calcification, underlining that AP-1
containing σ1B is important for motor neuron function [313, 218]. MEDNIK patients have
hypotonia, growth and psychomotor delay, alternating diarrhea and constipation episodes,
and red patches on the skin [219].
7.2 Which AP-1 subunit is expressed in the brain?
Several subunit isoforms of AP-1 have been observed: AP-1 has two γ subunits (γ1, γ2), two
medium subunits (µ1A, µ1B) and three small subunits (σ1A, σ1B, σ1C). Although most AP
subunit isoforms are ubiquitously expressed, µ1B is expressed only in polarized epithelial
cells [92]. It is currently not known which AP-1 subunit isoforms form the AP-1 complex
in the various brain regions and, more specifically, in neurons and glia. Establishing a map
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of the AP-1 subunits expressed per brain region or cell type would be very informative and
helpful to decipher symptoms of MEDNIK and X-linked mental retardation. An overview of
AP-1 subunits mRNA was determined via in situ hybridization and is available on the Allen
Brain Atlas (http://mouse.brain-map.org). Focusing on the mRNA distribution of the three
small subunit isoforms (σ1A, gene ID: 11769; σ1B, gene ID: 108012; σ1C, gene ID: 252903)
in the cortex and hippocampus, no striking difference was observed. The subunit composition
of AP-1 complex in the brain can be investigated by Western blot and immunofluorescence in
brain slices or cultured neurons.
7.3 How does AP-1 regulate the release of neurotransmitters and
neuropeptides in neurons?
Since the regulated secretory pathway is necessary for the brain to function properly, studying
the role of AP-1 in regulated secretion in neurons will help understand the phenotypes
observed in patients with MEDNIK and X-linked mental retardation. Since AP-1 is required
for secretory granule biogenesis in neuroendocrine cells (Chapter 2), and in the formation of
other types of secretory granules, such as glue granules in Drosophila, rhoptries in Toxoplasma
gondii, and Weibel Palade bodies in endothelial cells, we hypothesized that AP-1 is necessary
for generating secretory granules in neurons. In addition, AP-1 interacts with synaptophysin, a
synaptic vesicle protein important for neurotransmitter release, suggesting that AP-1 function
may also be required in synaptic vesicle biogenesis and function [314]. One approach would
be to use mouse embryonic fibroblasts from µ1A deficient mice, reprogram the cells into
neurons and investigate AP-1 function in secretory granule biogenesis and neurotransmitter
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release.
7.4 Is PAM-1 trafficking altered in neurons from MEDNIK and
X-linked mental retardation?
Neuroendocrine cells and neurons produce large amounts of peptides many of which re-
quire the presence of an α-amide group at the C-terminus to be functional. This modifi-
cation is catalyzed by peptidylglycine α-amidating monooxygenase (PAM), a bifunctional
enzyme composed of peptidylglycine α-hydroxylating monooxygenase (PHM) and peptidyl-
α-hydroxyglycine-α-amidating lyase (PAL) catalytic core domains working sequentially.
Although PAM-1 is the main isoform expressed in developing hippocampus and cortex, very
little is known about PAM-1 trafficking in neurons (Chapter 6). In hippocampal neurons,
PAM-1 is concentrated at the Golgi and scattered in vesicles of dendrites and axons (Chapter
6). Investigating PAM-1 distribution in hippocampal neurons after reduction of AP-1 function
would provide information on the efficiency of PAM activity and insights into understanding
MEDNIK and X-linked mental retardation. In addition, transfection of a plasmid encoding
PAM-1 or PAM-2 linked to GFP into hippocampal neurons was performed, suggesting that
investigating PAM trafficking in live neurons is also possible (Figure 7.1). Since endogenous
PAM is PAM-1 (containing Exon 16), this creates the opportunity to examine whether en-
dogenous PAM-1 (stained with JH629) is trafficked differentially from PAM-2-GFP. Previous
work focused only on soluble PHM-GFP transfected into sensory neurons and indicated what
the dynamics of secretory granules containing PHM-GFP were under basal and stimulated
conditions [300].
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7.5 What are the dynamics of PAM-1 trafficking in neuroen-
docrine cells?
Although biochemical studies of PAM-1 trafficking have provided extensive amounts of
information on this protein in neuroendocrine cells, the dynamics of PAM-1 movement in live
cells is lacking (Figure 7.2). According to previous studies done in AtT-20 cells, about 5% of
PAM-1 is in the endoplasmic reticulum and Golgi, 30% at the TGN, 5% in immature secretory
granules, about a third in mature secretory granules, less than 5% at the cell surface and 25%
in endosomes. Exit of PAM-1 from the TGN into secretory granules was evidenced by the
formation of PHM after PAM-1 endoproteolytic cleavage. Because holding the temperature
at 20◦C blocks the exit of proteins from the TGN, it was possible to control the trafficking
of newly synthesized PAM-1 at this stage. Calculating PHM formation after release of
temperature blockade, Milgram and Mains were able to estimate that about 15%/hour PAM-1
exited the TGN to go into immature secretory granules [12]. The constitutive-like secretory
pathway is well developed in cancer cell lines, such as AtT-20 cells. The secreted material
from this type of secretory pathway consists of proteins that were removed from immature
secretory granules. It was proposed that material that is retrieved from immature secretory
granules is transported to endosomes before being released constitutively as shown in figure
7.2. Measuring the rate of secretion of newly synthesized PHM under basal condition was
synonym of measuring constitutive-like secretion rate of PAM-1. About 2/3 of PAM-1 that
exited the TGN for immature secretory granules, exited immature secretory granules for
constitutive like secretion. Work done by De et al. and Bäck et al. demonstrated that a
lot of PAM-1 cycled between plasma membrane and endosomes and only 2-3% of PAM-1
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was present on the cell surface at steady state [195, 266]. We generated a plasmid encoding
PAM-1 linked to photoactivatable GFP (PAGFP) at its C-terminus 3.1A). PAGFP contains
a few crucial point mutations when compared with wild-type GFP, making it behave like
a GFP only after UV excitation. Thus, only the PAGFP which has been irradiated at the
proper wavelength will be seen under a fluorescence microscope 3.1B). Photoactivation
at a perinuclear region corresponding to the Golgi revealed that PAM vesicular transport
across the cell is mediated by microtubules (Figure 7.3C). This technique would also enable
visualization of PAM trafficking from the tips, where mature secretory granules accumulate.
A complete study on PAM-1 trafficking in AtT-20 cells can then be compared with the
information obtained using biochemical studies (Figure 7.3C).
7.6 What is the distribution of copper in pituitary cells?
Even though very few proteins require copper for activity, copper is an essential metal.
Copper in the brain and liver has been investigated in detail, but data remain limited on how
copper is handled in other tissues. PAM-1 requires copper to amidate neuropeptides and
the pituitary gland expresses high levels of PAM, suggesting that copper must be handled
appropriately in order to synthesize bioactive peptides. X-ray fluorescence microscopy (XFM)
allowed the visualization of copper content in the pituitary gland (Chapter 5). In addition,
determination of cellular distribution and concentration of metals is now possible [315].
Using XFM, it is possible to identify copper distribution in pituitary cells, to see whether a
difference is observed between pituitary cell types and to compare with other cell types. A
clear identification of copper distribution is needed to understand copper associated diseases.
AP-1 is at the heart of post-Golgi trafficking. This work provided a view of AP-1 function
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in neuroendocrine cells and how its function impacted directly or indirectly the trafficking of
many proteins, as seen for PAM, POMC, carboxypeptidase D, Atp7a and transferrin. During
HIV infection, AP-1 is sequestered from its biological function to interact with the viral
protein Nef. Together, they promote the down-regulation of the Major Histocompatibility
Complex (MHC) class I [316]. Insight into AP-1 trafficking in different cell types would help
prevent the re-routing of MHC class I and possibly increase resistance to viral infection.
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7.7 Figures
Figure 7.1: PAM-1 and PAM-2 GFP expression in hippocampal neurons. Hippocam-
pal neurons were maintained for 7 days in vitro before being transfected with pCI-neo
PAM-1 GFP (A) or pEGFP Kr PAM-2 (B) using lipofectamine (0.5 µg DNA/well
of a 4 well dish; see Chapters 2 or 3 for methods about lipofectamine). A day after
transfection, neurons were fixed and immunostained for βIII-tubulin (Tuj1, Covance,
1:1000 dilution, Cy3 anti-mouse) to visualize processes. To enhance PAM signal,
neurons transfected with PAM-1 GFP were immunostained with Exon 16 antibody
(JH629, 1:1000 dilution, FITC anti-rabbit) and neurons transfected with PAM-2 GFP
were co-stained with a PHM antibody (JH1761, 1:1000, dilution, FITC anti-rabbit)
[224, 225]. Merge+ images show the same neuron for which FITC/GFP signal was
greatly enhanced in order to visualize processes. Scale bar, 10 µm.
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Figure 7.2: Summary of PAM trafficking in AtT-20 cells. Cell diagram representing
the number of PAM proteins in a pool of 1000 PAM molecules (yellow boxes)
and the rate at which PAM navigates from an organelle to another (green boxes).
These numbers were based on previous studies looking at PAM trafficking using
biochemical techniques [317, 318, 195, 190, 188, 189, 12, 37, 176]. ISG, Immature
Secretory Granule; MSG, Mature Secretory Granule; TGN, trans-Golgi network;
Endo, endosome; Lyso, lysosome; ER, endoplasmic reticulum.
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Figure 7.3: PAM PAGFP in an AtT-20 cell. (A) Diagram of PAGFP vector. (B) Princi-
ple of photoactivatable GFP (PA-GFP); once PAM-1 PA-GFP has been synthesized, it
is not fluorescent. Only after imaging the protein at 405 nm, a conformational change
in PA-GFP occurs rendering it fluorescent with similar properties of GFP. (C) AtT-20
cells were transfected with pCI-neo PAM-1 PAGFP using nucleofection. A few
weeks after transfection, cells were imaged to examine the dynamics of PAM-PAGFP.
Panels representing an AtT-20 cells transfected with PAM-PAGFP. The region that
was photoactivated is delineated in red on the brightfield image. Several images taken
after photoactivation are shown.
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